Wednesday, 18 October 2017

Industry Exhibition

MIS01, OPENING CEREMONY Welcome to Country – Nunukul Yuggera Aboriginal Dancers

Chairs:
Dunn, Jeff (Brisbane, Australia)
Smithers, B. Mark (Brisbane, Australia)
Soyer, H. Peter (Brisbane, Australia)
Flaherty, Keith T. (Boston, United States)

P20, Others

An 18-year study of Paediatric Malignant Melanoma at Morriston Hospital
Al-Himdani, Sarah (Swansea, United Kingdom)

Detailed FACS, migration, and invasion assay analyses of MeLiM melanoma model
Amrichova, Jana (Brno, Czech Republic)

Phenotypic and molecular characterisation of Circulating Tumour Cells isolated from metastatic melanoma patients using a microfluidic device
Aya-Bonilla, Carlos (Perth, Australia)

Epidemiological profile of cutaneous malignant melanoma in Tlemcen (west Algeria): January 2011 to December 2015
Boudghene Stambouli, Omar (Tiemcen, Algeria)

Malignant melanoma and psoriasis association: about a case
Boudghene Stambouli, Omar (Tiemcen, Algeria)

Metastatic malignant melanoma and vitiligo
Boudghene Stambouli, Omar (Tiemcen, Algeria)

Malignant melanoma and psoriasis acrolentigineux
Boudghene Stambouli, Omar (Tiemcen, Algeria)

Malignant Melanoma, is dominant at the ends: about a new observation acral
Boudghene Stambouli, Omar (Tiemcen, Algeria)
Concordance of Mutations in Circulating Tumour DNA (ctDNA) and Tissue Biopsy in Melanoma
Calapre, Leslie (Perth, Australia)

Teledermatology and teledermoscopy as tools to help general practitioners in effective e-triage of suspicious skin lesions prior to dermatology evaluation
Claveau, Joel (Québec City, Canada)

Generation and characterization of 90 melanoma patient-derived xenograft models
Couts, Kasey (Aurora, United States)

Preferences for advanced melanoma Immuno-Oncology treatments
Del Cuore, Mark (Sydney, Australia)

Evaluation of commercial kits for extraction of circulating free DNA
Diefenbach, Russell (Sydney, Australia)

Targeted therapy or immunotherapy..."this is the question" in frontline approach to BRAF-mutant melanoma: the challenge of combination immunotherapy.
Franchina, Tindara (Messina, Italy)

Precision medicine for melanoma patients: Development of a Melanoma-specific gene panel for integrative molecular tumor boards
Freiberger, Sandra (Zurich, Switzerland)

Electric field mediated drug and gene delivery provides effective treatment protocols for melanoma
Gilbert, Richard (Tampa, United States)

Refining risk models for distant and CNS metastasis in Stage III melanoma
Haydu, Lauren (Houston, United States)

Preclinical validation of a new anti-melanoma compound in B-Raf inhibitors sensitive and resistant cells.
Jaune, Emilie (Brussels, Belgium)

Randomized Phase (ph) II study of Paclitaxel (P), Carboplatin (C), Bevacizumab (B) +/- Everolimus (E) in Metastatic Melanoma (MM): Secondary analysis of outcomes in patients (pts) who harbor NRAS mutation NCCTG N0879 (Alliance).
Kottschade, Lisa (Rochester, United States)

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
Lee, Rebecca (Manchester, United Kingdom)

A preclinical platform for evaluating targeted therapy and immunotherapy combinations in BRAFV600E melanoma
Lelliott, Emily (Melbourne, Australia)

Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China
Li, Siming (Beijing, United States)

Clinical application of various flaps in repair of soft tissue defect in weight-bearing region of foot caused by wide excision of melanoma: our experience after 31 cases
Li, Tao (Hangzhou, China)
Multifactorial Analysis of Prognostic Factors And Survival Rates Among 706 Mucosal Melanoma Patients  
Liu, Frank Xiaoqing (Beijing, China)

Evolution of treatment patterns for advanced melanoma in US oncology clinical practices: an observational study  
Liu, Frank Xiaoqing (Beijing, China)

A significant interaction between sex and UV index in melanoma risk  
Liu-Smith, Feng (Irvine, United States)

Long-term survival outcome of patients with thin (T1) cutaneous melanomas: a naturally-occurring, biologically-relevant Breslow thickness cutpoint of 0.8mm separates higher risk from lower risk tumors  
Lo, Serigne (Sydney, Australia)

Optimization of spiral microfluidics for melanoma cell isolation  
Marsavela, Gabriela (Perth, Australia)

Clinical and molecular associations of body mass index (BMI) in regional melanoma metastases  
McQuade, Jennifer (Houston, United States)

Fortune Cookie Flap: New option to cover the defect  
Park, Tae Hwan (Seoul, Korea, Republic of)

The burden of Non-Melanoma skin cancers in Auckland, New Zealand  
Pondicherry, Ashwini (Auckland, New Zealand)

Psychosocial outcome, neurocognitive functioning (NCF) and quality of life (QoL) in advanced melanoma survivor  
Rogiers, Anne (Brussels, Belgium)

US guided wire localization of malignant melanoma subcutaneous metastases  
Rostom, Mai (Edinburgh, United Kingdom)

Sentinel node biopsy status is strongly predictive of survival in cutaneous melanoma: Extended follow-up of 1,527 Oxford patients from 1998-2014.  
Rughani, Milap (Oxford, United Kingdom)

Predicting the development and timing of subsequent primary melanomas in a population-based Australian cohort  
Smith, Juliet (Sydney, Australia)

Iris freckling as a marker of cutaneous melanoma risk: a case-control study  
Sturm, Richard (Brisbane, Australia)

Classifying dermoscopic patterns of naevi in a case-control study of melanoma  
Sturm, Richard (Brisbane, Australia)

Dermoscopic features of Vulvar Intraepithelial Neoplasia  
Tosti, Giulio (Milano, Italy)

Modelling terahertz radiation absorption and reflection with computational phantoms of skin to aid melanoma diagnosis and management  
Vilagosh, Zoltan (Melbourne, Australia)
The neutrophil-lymphocyte and platelet-lymphocyte ratios for surveillance in cutaneous melanoma
Wade, Ryckie George (Leeds, United Kingdom)

Acral melanoma (AM) demonstrates distinct clinical pattern and worse prognosis compared with non-acral cutaneous melanoma (NACM): a prospective analysis of 1461 cases
Yan, Xieqiao (Beijing, China)

A multicentre EADO study assessing the epidemiological, clinical and histological characteristics of thin nodular melanomas
Stratigos, Alexandros (Athens, Greece)

Poster
12:00 - 20:00
Poster Exhibition

P19, Tumour Microenvironment

Paracrine Activin-A signaling promotes melanoma growth and mediates tumour immune evasion
Constam, Daniel (Lausanne, Switzerland)

Composition or lack of exogenous growth factors do not influence viability and phenotype of drug naïve V600EBRAF melanoma cells but it might be crucial for drug-resistant cells
Czyz, Małgorzata (Lodz, Poland)

Combined loss of epidermal AMBRA1 and Loricrin is a prognostic biomarker for AJCC stage I melanoma and a companion biomarker for novel targeted therapy
Ellis, Robert (Darlington, United Kingdom)

Diversity of fibroblastic populations in the microenvironment of human melanomas
Eom, Jennifer (Auckland, New Zealand)

Multiplex immunohistochemistry and flow cytometry provide divergent but complementary insights into the immune context in metastatic melanoma
Gyorki, David (Melbourne, Australia)

Immune Cell Profiles in Neoadjuvant Therapy of Advanced Stage III Melanoma
Hieken, Tina (Rochester, United States)

Fucosylation and Immune Surveillance in Melanoma
Lester, Daniel (Tampa, United States)

Tumour-derived exosomes promote the bone tropism of melanoma cells by CXCR7 upregulation
Mannavola, Francesco (Bari, Italy)

Development of a 3D human metastatic melanoma model for in vitro evaluation of targeted therapy efficiency
Morales, Delphine (Compiègne, France)

Origin of vascular progenitors driving melanoma angiogenesis in vivo
Patel, Sapna (Houston, United States)

Pittelkow, Mark (Scottsdale, United States)
Nanoparticle-based immunotherapy in a humanized mouse melanoma model targeting macrophages in the tumor microenvironment
Schupp, Jonathan (Mainz, Germany)

Metastatic melanoma cells commandeer p53 activity to promote the survival of a therapy resistant subpopulation.
Webster, Marie (Philadelphia, United States)

GARP expressing platelets are capable of regulatory T cell induction
Zimmer, Niklas (Mainz, Germany)

Poster
12:00 - 20:00
Poster Exhibition

P18, Tumour Heterogeneity and Plasticity

Spatial analysis of gene expression in Stage III cutaneous malignant melanoma
Eriksson, Hanna (Stockholm, Sweden)

Highly multiplexed single-cell protein analysis of melanoma FFPE samples
Izar, Benjamin (Boston, United States)

Convergent evolution in therapy naïve human melanoma.
Peng, Angela (Melbourne, Australia)

In-depth molecular and immune characterization of melanoma with heterogeneous PTEN expression
Petaccia de Macedo, Mariana (São Paulo, Brazil)

Role of JARID1B expression in radiation resistance in melanoma cells
Roesch, Alexander (Essen, Germany)

Metastatic growth after melanoma dissemination requires MITF and BRN2
Simmons, Jacinta (Brisbane, Australia)

BRN2 co-ordinates switching of melanoma cells to an invasive phenotype to promote metastasis and metabolic adaptation to micro-environmental cues
Smith, Aaron (Brisbane, Australia)

MITF regulates dynamic heterogeneity and structural integrity in melanoma
Spoerri, Loredana (Brisbane, Australia)

Melanin pigment and melanoma heterogeneity
Szeto, Pacman (Melbourne, Australia)

Poster
12:00 - 20:00
Poster Exhibition

P17, Targeted Therapy

Incidental Perineural Invasion in Keratinocyte cancer (KC): A prospective analysis of the incidental Perineural Invasion (PNI) registry with a five year follow up in Queensland
Adams, Agnieszka (Brisbane, Australia)
Real life targeted therapies alone or in combination in brain metastases patients: French experience within MelBase
Allayous, Clara (Paris, France)

Possible immune adverse-events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma
Ben-Betzalel, Guy (Ramat Gan, Israel)

Preclinical efficacy of the DLL3-targeted antibody drug conjugate Rovalpituzumab tessirine in metastatic melanoma
Bishop, Evan (San Francisco, United States)
Williams, Sam (San Francisco, United States)

Role of miR-193a as therapeutic agent and biomarker in cutaneous melanoma
Carpi, Sara (Pisa, Italy)

Identification of Molecular Signatures Associated with Response to MAPK Inhibitors in Metastatic Melanoma
Stagni, Camilla (Padova, Italy)

A Prospective Observational Safety Study of Patients (pts) With BRAFV600-Mutated Unresectable or Metastatic Melanoma (mM) Treated With Vemurafenib (VEM) (Zelboraf Safety Study (ZeSS)): Final Results
Colburn, Dawn

Induction of ER stress augments apoptotic and immunogenic responses in melanoma cells
Daignault, Sheena (Queensland, Australia)

Combination of EGFRi and METi - a new targeted therapeutic strategy for melanoma
Das, Ishani (Stockholm, Sweden)

Extended follow-up results of a phase 1b study (BRIM7) of cobimetinib (C) combined with vemurafenib (V) in BRAFV600-mutated melanoma
McArthur, Grant (Melbourne, Australia)

Combination BRAF/MEK inhibitors for melanoma with active brain metastases: A real-world multi-center experience
Drago, Joshua (Boston, United States)

HDAC inhibition reverses adaptation to MEK inhibitor therapy in uveal melanoma: a systems level proteomic study
Faia-Flores, Fernanda (Tampa, United States)

Investigating the sensitivity of RAC1 mutated melanomas to PI3K pathway inhibition
Foth, Mona (Salt Lake City, United States)

V600EBRAF melanoma cell response to vemurafenib and trametinib is not affected by exogenous growth factors bFGF, EGF and HGF in vitro
Hartman, Mariusz (Lodz, Poland)

A phase I/II study of pembrolizumab and imatinib in patients with locally advanced/metastatic melanoma with c-KIT mutation or amplification
Jeter, Joanne (Columbus, United States)

BRAF inhibitor treatment in the oldest old metastatic melanoma patients
Kohtamäki, Laura (Vantaa, Finland)
Deciphering the role of PREX and PI3K signalling in melanoma
Koludrovic, Dana (Glasgow, United Kingdom)

Differential effects on immune activity after Neoadjuvant MAPK pathway inhibition in stage III melanoma patients
Lim, Su Yin (Sydney, Australia)

Efficacy and Safety Analysis of Imatinib in 78 Advanced Melanoma Patients Harboring KIT Aberrations
Mao, Lili (Beijing, China)

CDK4 inhibition synergizes with BRAF and MEK inhibition in treatment naïve melanoma cells but not after the development of BRAF inhibitor resistance
Martin, Claire (Melbourne, Australia)

Clinical and biologic associations of body mass index (BMI) with survival in patients (pts) with BRAFV600-mutated metastatic melanoma (MM) treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib + vemurafenib (C+V)
McQuade, Jennifer (Houston, United States)

Identification of actionable survival pathways in BRAF/NRAS wild type melanomas
Ming, Zizhen (Sydney, Australia)

Rose Bengal melanoma therapy - phototoxicity versus intrinsic cytotoxicity
Nierfeld, Mathias (Brisbane, Australia)

Real-world data in a new-era of targeted and immuno-oncology treatment (Tx) of Metastatic Melanoma (MM) patients (pts)
Ortiz, Carolina (Barcelona, Spain)

Cobimetinib + atezolizumab versus pembrolizumab in patients with previously untreated, advanced, BRAFV600 wild-type melanoma: phase 3 IMspire 170 study
Gogas, Helen

ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment.
Recio, Juan (Barcelona, Spain)

A Phase Ib study of AEB071, a PKC inhibitor, and BYL719, a PI3Kα inhibitor, in Patients with Metastatic Uveal Melanoma (UM)
Shoustari, Alexander (New York City, United States)

Activity of the ERK1/2 inhibitor Ulixertinib in patients with BRAF and NRAS mutant melanoma
Sullivan, Ryan (Boston, United States)

BRAF mutant metastatic melanoma - stopping treatment after complete response?
Warburton, Lydia (Perth, Australia)

Elevated BRAFV600 mutant circulating tumor DNA (ctDNA) and circulating hepatocyte growth factor (cHGF) are associated with poor prognosis in patients with metastatic melanoma
Yan, Yibing (United States)

A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma
Yan, Xieqiao (Beijing, China)
**Scientific Programme**

*In vitro study in exploring the critical mediator involved in Vemurafenib resistance*
Yang, Muyi (Stockholm, Sweden)

*Inhibition of mitochondrial oxidative phosphorylation overcomes de novo and acquired resistance to MAPK pathway inhibitors*
Yennu Nanda, Vashisht (Houston, United States)

---

**P16, Melanoma and Melanocyte Biology**

*Performance comparison of PD-L1 antibody clones 28-8 and 22C3 in stage III and IV metastatic melanoma samples: A tissue microarray study*
Carapeto, Fernando (Houston, United States)

*Genetic variation in IRF4 expression modulates growth characteristics, pigmentation and interferon-gamma response in melanocytic cells*
Chhabra, Yash (Brisbane, Australia)

*Frequency of BRAF V600 mutation in 354 locally advanced or metastatic melanoma patients from an academic center in Argentina. The apple does not fall very far from the tree.*
Cinat, Gabriela (Buenos Aires, Argentina)

*MiR-149 Function as a Tumor Suppressor in Mucosal Melanoma*
Dai, jie

*Focal perinuclear cytoplasmic BAP1 is associated with high impact mutations in uveal melanoma*
Farquhar, Neil (Liverpool, United Kingdom)

*Natural genetic variation controlling propensity for an individual’s melanocytes to transform after UVR exposure*
Ferguson, Peter (Sydney, Australia)

*Detection, molecular profiling and culture of CSF-CTCs in leptomeningeal disease (LMDz) in melanoma*
Forsyth, Peter (Tampa, United States)

*The ATM Ser49Cys variant is defective for DNA damage and senescence signalling*
Gabrielli, Brian (Brisbane, Australia)

*COMBI-i: A phase 3 study of the anti-PD1 antibody PDR001 in combination with dabrafenib (D) and trametinib (T) in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma*
Gasal, Eduard (East Hanover, United States)

*A novel signalling pathway ACTN4-RIPK1-NF-κB in regulating melanoma cell proliferation*
Jin, Lei (Newcastle, Australia)

*Dissecting molecular and genetic determinants of UV response using iPSC based melanocyte models*
Juraleviciute, Marina (Oslo, Norway)
Site-specific phosphorylation of the EMT-inducing molecule Y-box binding protein 1 regulates tumourigenicity and invasiveness of human melanoma cells
Kosnopfel, Corinna (Tübingen, Germany)

BRIM8: a randomized, double-blind, placebo-controlled phase 3 study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600 mutation-positive melanoma at high risk for recurrence
Lewis, Karl (Denver, United States)

Pigment-producing melanocytes as the cells of origin of cutaneous melanoma
Marine, Jean-Christophe (Leuven, Belgium)

Identification of TERT, Braf and NRAS hotspot mutations from formalin fixed and circulating tumour DNA of melanoma samples through highly sensitive ddPCR assay in melanoma
McEvoy, Ashleigh (Perth, Australia)

Growth factor activation of melanoma cell signalling pathways
Piva, Terrence (Melbourne, Australia)

In-depth Proteomic Profiling of Uveal Melanoma Exosomes
Predergast, Samuel (Liverpool, United Kingdom)

Evaluation of the transcriptome of large/giant congenital melanocytic nevi
Puig Butille, Joan Anton (Barcelona, Spain)

Notch signaling in mouse melanoma tumor development and drug resistance of human metastatic melanoma cells
Setaluri, Vijay (Madison, United States)

Wnt-dependent regulation of Sox10 expression in melanoma development
Shakhova, Olga (Zurich, Switzerland)

Functional testing of MTAP haplotypes demonstrates differential expression, signalling and pigmentation effects in primary melanocytic cells
Sturm, Richard (Brisbane, Australia)

RPS3 fucosylation in melanoma cell biology
Watson, Gregory (Tampa, United States)

Subcutaneous Cellular Nodule and Pigmented Epithelioid Melanocytoma on the Ipsilateral Upper Arm associated with Plaque-type Blue Nevus on the Hand
Yun, Sook Jung (Gwangju, Korea, Republic of)

Roles of Wnt signaling in melanoma pathogenesis
Zhang, Yudong (Zurich, Switzerland)

Poster
12:00 - 20:00
Poster Exhibition

P15, Immunotherapy

Preliminary results of a Phase 1b/2 study of PV-10 and pembrolizumab in Stage IV melanoma
Agarwala, Sanjiv (Easton, United States)
Response of melanoma cells to immune activity  
Alavi, Sara (Sydney, Australia)

The oncolytic effect of ECHO-7 virus on cell viability in vitro  
Alberts, Peteris (Riga, Latvia)

Does time to switch in immunotherapy sequential strategy impact immunotherapy efficacy: results from the French cohort MelBase  
Allayous, Clara (Paris, France)

Biodistribution and Shedding of Talimogene Laherparepvec (T-VEC) in Patients (Pts) With Unresectable Stage IIIB/IV Melanoma  
Andtbacka, Robert (Salt Lake City, United States)

Anti PD-1 therapy induced pancreatic atrophy and its clinical significance  
Baruch, Erez (Rishon Le Zion, Israel)

Older age may predict a higher response rate to anti PD-1 therapy in metastatic melanoma patients  
Ben-Betzalel, Guy (Ramat Gan, Israel)

Improving adoptive T cell therapy by selection of 4-1BB expressing TIL  
Besser, Michal (Ramat Gan, Israel)

Dissecting and deactivating immunosuppressive signals at metastatic lymphovascular sites  
Cerezo Wallis, Daniela (Madrid, Spain)

Phase Ic Trial of Intralesional OriensX010 Oncolytic Viral Therapy Into Liver Metastases Among Melanoma Patients  
Cui, Chuanliang (Beijing, China)

Antibody profiling of melanoma patients undergoing immunotherapy with checkpoint inhibitors  
Duarte, Jessica (Melbourne, Australia)

Generic strategy to model tumour antigens and T-cell based immunotherapies in melanoma  
Effern, Maike (Bonn, Germany)

Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma  
Ferrucci, Pier Francesco (Milan, Italy)

Quantitative analysis of immune profiles of metastatic melanoma patients reveals biomarkers of response and resistance to combined anti-CTLA-4 and anti-PD-1 immunotherapy  
Gide, Tuba (Sydney, Australia)

c-MET dependent neutrophil responses limit ACT immunotherapy of melanoma  
Glodde, Nicole (Bonn, Germany)

Monitoring patient response to Pembrolizumab with peripheral blood immune profiles  
Graves, Moira (Newcastle, Australia)

Effective Immuno Gene Therapy via the Delivery of Plasmids Encoding Cytokines as a Potential Treatment of Melanoma  
Heller, Richard (Norfolk, United States)
DNA pattern recognition receptor activation after plasmid gene therapy in melanoma and other tumor cell types
Heller, Loree (Norfolk, United States)

Using Mass Cytometry to assess CD8 T cell phenotype during melanoma relapse on anti-PD1 treatment
Hersey, Peter (Sydney, Australia)

Identification of Gene Signatures Predicting Response to PD1 Immunotherapy in 54 Metastatic Melanoma Patients
Hintzsche, Jennifer (Denver, United States)

Inhibitors of the renin-angiotensin system could negatively impact survival benefit from ipilimumab/nivolumab combination but not from ipilimumab monotherapy
Homicsko, Krisztian (Lausanne, Switzerland)

Clinical activity and safety of ipilimumab for metastatic uveal melanoma: the St Bartholomew’s Hospital experience
Hussain, Rohan (London, United Kingdom)

Real life outcome of patients with advanced melanoma after discontinuation of a PD-1 inhibitor in the absence of disease progression or treatment limiting toxicity
Jansen, Yanina (Jette, Belgium)

The efficacy of concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): Protocol for a multicenter phase II open label study
Jespersen, Henrik (Goteborg, Belgium)

Distinct genomic alterations in patients with advanced melanoma treated with anti-PD-1 therapy
Kong, Yan (Beijing, China)

A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosomeb in Patients with Unresectable Stage III and IV Melanoma: Trial in Progress
Lau, Peter (Melbourne, Australia)

Immune phenotypic analysis of NK cells in predicting anti-PD-1 therapy
Lee, Hansol (Sydney, Australia)

Pembrolizumab (PEM) utilization and overall survival (OS) for patients with advanced melanoma: the real world US experience
Liu, Frank Xiaoqing (North Whales, United States)

Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis
Lomax, Anna (Waurn Ponds, Australia)

BRAF ± MEK inhibition following pembrolizumab (pembro) in KEYNOTE-006
Long, Georgina (Sydney, Australia)

Pre-clinical evaluation of vectorized therapies combined with an anti-CTLA4 antibody in murine xenografted-models in melanoma
Ludovic, Martin (Angers, France)

Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia.
Mason, Robert (Nambour, Australia)
Widely Metastatic Uveal Melanoma Responding to Combination Immune Therapy and Focal Radiotherapy after Pembrolizumab Failure
McNulty, Meabh (Perth, Australia)

SALVO: Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for McWilliams, Robert (Rochester, United States)

Management of Rheumatological Immune Related Adverse Events in Melanoma Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies
Mitchell, Emma (Victoria, Australia)

An immunogenic personalized neoantigen vaccine in patients with high risk melanoma Ott, Patrick (Boston, United States)

Exploring Lenalidomide in both inhibiting proliferation and blocking PDL1 signals in melanoma cells: a preclinical study Passarelli, Anna (Bari, Italy)

A Time and Motion Study of Patients Treated with Pembrolizumab and Nivolumab in Australia.
Pivneva, Irina (Canada)

Real World data on the Safety and Efficacy of anti-PD-1 antibodies in the Elderly Population with Metastatic Melanoma Randhawa, Manreet (Garran, Australia)

Real world Efficacy and Toxicity of Combined Nivolumab and Ipilimumab in patients with Metastatic Melanoma Randhawa, Manreet (Garran, Australia)

Autophagy Drives Resistance to PD-1 Blockade in Melanoma
Rebecca, Vito (Philadelphia, United States)

Combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in melanoma pts Saiag, Philippe (Boulogne, France)

The peripheral blood TCR repertoire might facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma Schindler, Sabrina (Zurich, Switzerland)

A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic melanoma Sheng, Xinan (Beijing, China)

A case of anti-PD1 induced hepatitis associated with corticosteroid resistant T cells Shklovskaya, Elena (Sydney, Australia)

Inhibition of melanoma cell derived prostaglandin E2 amplifies T cell receptor signaling and shows clinical efficacy in combination with anti-PD1 therapy Sinnberg, Tobias (Tuebingen, Germany)

A Phase II study of JS001, a Humanized IgG4 mAb Against Programmed Death-1 (PD-1) in Patients with Advanced Acral and Mucosal Melanoma Tang, Bixia (Beijing, China)

Quantifying the treatment-free interval after first-line immuno-oncology (IO) treatment of advanced melanoma Tarhini, Ahmad (Pittsburgh, United States)
Benefit of the Nivolumab and Ipilimumab combination in pretreated advanced melanoma
Tetu, Pauline (France)

Paradoxical reduced response to combined PD-1/CTLA-4 blockade in low tumor burden melanoma
Tsai, Katy (San Francisco, United States)

Access to immunotherapy for treatment of metastatic melanoma in the Netherland and Australia: a tale of two countries
van Akkooi, Alexander (Amsterdam, Netherlands)

High-dose corticosteroids do not prevent lymphocyte proliferation or IL-2 production after stimulation with pembrolizumab
Walker, John (Edmonton, Canada)

The role of chemotherapy after immunotherapy resistance in melanoma
Wang, Xuan (Beijing, China)

Durable complete responses after cessation of anti-PD-1 monotherapy are associated with undetectable circulating tumour DNA
Warburton, Lydia (Perth, Australia)

PD-L1 expression and density of CD8+ T cells in matched brain and extracerebral metastases are highly concordant
Westphal, Dana (Dresden, Germany)

Profound inflammation-mediated change to the immunopeptidome of melanoma
Woods, Katherine (Melbourne, Australia)

The incidence of basal cell carcinoma is reduced in patients on anti-Programmed cell death-1 therapy for metastatic melanoma
Zhao, Cathy (New South Wales, Australia)

Poster
12:00 - 20:00

P14, Genetics and Genomics

The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
Aoude, Lauren (Brisbane, Australia)

Melanoma cases demonstrate double the expected carrier frequency of phenylketonuria/hyperphenylalanemia mutations
Arbesman, Joshua (Cleveland, United States)

Melanoma mutational burden and copy number alteration levels do not differ between adolescent and young adult and older patients
Arbesman, Joshua (Cleveland, United States)

Genome-wide association study in 185,000 Europeans elucidates the genetic architecture of skin sensitivity to sun
Bataille, Veronique (Hemel Hempstead, United Kingdom)

Association between gut microbiome and naevus count in the TwinsUK registry
Bataille, Veronique (Hemel Hempstead, United Kingdom)
**Scientific Programme**

**Low-Pass Whole Genome Sequencing of Single Uveal Melanoma Cells**  
Beasley, Aaron (Perth, Australia)

**Prognostic value of non-sentinel lymph node (non-SLN) status and a prognostic 31-gene expression profile (GEP) in stage III cutaneous melanoma patients**  
Cook, Robert (Friendswood, United States)

**Actionable kinase fusions are frequent in pan-negative melanomas**  
Couts, Kasey (Aurora, United States)

**The association between polygenic score and melanoma risk by biological pathways and examination of effect modification of sun exposure-melanoma risk associations**  
Cust, Anne (Sydney, Australia)

**Incremental contribution of common genomic variants to melanoma risk, and overlap with phenotypic risk in Australia and the UK**  
Cust, Anne (Sydney, Australia)

**NRAS mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy and clinical outcome**  
Duggan, Megan (Columbus, United States)

**Molecular profiling of resected melanoma and its role in predicting patient outcome**  
Essner, Richard (Los Angeles, United States)

**Genomic characterisation of lethal melanoma from thin primaries**  
Ferguson, Peter (Sydney, Australia)

**First-Line Immunotherapy in BRAF V600R Mutant Melanoma**  
François, Rony (Gainsville, United States)

**The Cancer Survival Transcriptome Links Annotated Gene Signatures to Melanoma Patient Survival**  
Harari, Daniel (Rehovot, Israel)

**TERT promoter mutations in melanoma**  
Kumar, Rajiv (Heidelberg, Germany)

**TERT promoter mutations, telomere length and melanoma risk**  
Kumar, Rajiv (Heidelberg, Germany)

**Characterising melanoma risk genetics through gene-based tests**  
Law, Matthew (Brisbane, Australia)

**Performance of a 31-gene expression profile test for melanoma prognosis in a combined validation cohort of 690 patients**  
Leachman, Sancy (Portland, United States)

**Clinical impact of a 31-gene expression profile test on physician recommendations for management of melanoma patients in a prospectively tested cohort**  
Johnson, Clare (Friendswood, United States)

**Mutational and transcriptional profiling of clinical specimens of melanoma brain metastases: investigation of alterations and molecular signatures of potential clinical significance**  
Nygaard, Vigdis (Oslo, Norway)
**Scientific Programme**

A case-control analysis of POT1 variants in melanoma  
Robles-Espinoza, Carla (Queretaro, Mexico)

Clinical use of targeted DNA, RNA, and protein analysis in cutaneous and unknown primary melanomas identifies treatment targets and frequent Co-Occurring driver alterations  
Shoushtari, Alexander (New York, United States)

Cell Free DNA BRAF (cfBRAF) Mutation V600 Plasma Detection in Melanoma: NCCTG N0879 (Alliance)  
Slostad, Jessica (Rochester, United States)

Family History of Cancer in Patients Diagnosed with Melanoma  
Sussman, Tamara (Cleveland, United States)

The prevalence of somatic BRAF and NRAS mutations in dermoscopic subtypes of acquired naevi  
Tan, Jean-Marie (Brisbane, Australia)

Prediction of malignant potential of naevi using miRNA biomarkers  
Tom, Lisa (Brisbane, Australia)

Whole-Genome Sequencing in Dutch Melanoma Families  
Visser, Mijke (Den Haag, Netherlands)

BAP1 mutations prevalence and associated tumour spectrum in a cohort of Australian uveal melanoma cases  
Walpole, Sebastian (Brisbane, Australia)

The landscape of driver mutations in over 1,000 melanoma exomes  
Watson, Ian (Montreal, Canada)

Somatic and Germline TERT Events are Frequent in Acral Melanoma  
Zismann, Victoria (Phoenix, United States)

**Poster**  
12:00 - 20:00

**Poster Exhibition**

**P12, Drug Resistance**

Mechanisms of Resistance in anti-PD1 Treated Patients with Metastatic Melanoma  
Amato, Carol (Denver, United States)

Targeting TOP1 gene in melanoma as a novel mechanism of resistance and combinational therapies  
Aparecida de Oliveira, Erica (São Paulo, Brazil)

Repurposing chemotherapy to target methylation and induce DNA repair to overcome treatment resistance in melanoma.  
Bowden, Nikola (Newcastle, Australia)

Uncovering novel resistance mechanisms to BRAF and MEK inhibition by integrative RNAseq and targeted panel sequencing  
Cheng, Phil (Zurich, Switzerland)
Scientific Programme

Targeting the JNK-JUN pathway to reduce phenotypic plasticity and overcome therapy resistance in metastatic melanoma
Ferrao, Petranel (Melbourne, Australia)

Detection of BRAF splicing variants in plasma of patients developing resistance to combined BRAF/MEK inhibition
Gray, Elin (Perth, Australia)

Amino acid transporter ASCT2 as a potential therapeutic target for BRAF inhibitor resistant melanoma
Guan, Yi Fang (Sydney, Australia)

OGT and TET1 mediated H3K4me3 remodelling drives acquired BRAF inhibitor resistance in melanoma
Hammerlindl, Heinz (Brisbane, Australia)

Targeting Apoptosis to Enhance BRAF/MEK Directed Therapy
Mehnert, Janice (New Brunswick, United States)

A Phase Ib/II randomised study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib in patients with advanced melanoma
Straume, Oddbjørn (Bergen, Norway)

ABCB5 Transporter: Mediator of Intrinsic Resistance to Vemurafenib in Melanoma
Tangella, Lokeswari (Perth, Australia)

SETDB2-mediated drug tolerance in melanoma
Torrano, Joachim (Brisbane, Australia)

Preclinical efficacy and sensitivity determinants of statins in molecularly-defined models of melanoma
Tran, Khanh (Auckland, New Zealand)

Use of primary melanoma cells for testing novel combination therapies
Tuominen, Rainer (Stockholm, Sweden)

Response and Resistance of MEKi Treated Melanomas with BRAF Fusions
Turner, Jacqueline (Denver, United States)

Resistance to BRAF inhibition in a somatic mouse model of melanoma
Yang, Hana (Austin, United States)

P11, Treatment & Follow-up

Pregnancy associated multiple melanoma: A case study of nine primary melanomas in a young female patient
Adams, Agnieszka (Brisbane, Australia)

Sweet's syndrome associated with ipilimumab in a patient with metastatic melanoma
Adler, Nikki R (Melbourne, Australia)

10 key moments in melanoma history
Scientific Programme

Clinical trial recruitment and management of melanoma patients who live a long-distance from a tertiary referral centre
Cruzado, Maria (Sydney, Australia)

Kissing naevus of the penis: report of two cases
Cheng, Suzanne Wei Na (Singapore, Singapore)

Neutrophilus - lymphocytes reason in the survey prognosis in patients with maligno cutaneo melanomanational institute of neoplastic diseases 2005-2012
Pinto, Mirian (Lima, Peru)

Primary melanoma of lacrimal sac-- Report of a rare case
Ramakrishnan, Vijayabhaskar (Madurai, India)

Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti PD-1
Thomas, Stephen (Brisbane, Australia)

Laser treated aminated melanocytic nevi and the potential for malignant transformation
Yap, Megan (Murdoch, Australia)

Poster
12:00 - 20:00
Poster Exhibition

P10, Surgical Issues

Total lymph node yield as a marker of quality assurance in axillary lymphadenectomy for metastatic melanoma
Anderson, William (Auckland, New Zealand)

Interval sentinel node drainage as a predictor factor in melanoma patients
Bertolli, Eduardo (São Paulo, Brazil)

Clinical behavior and prognostic in patients with head and neck cutaneous melanoma who underwent sentinel node biopsy
Bertolli, Eduardo (São Paulo, Brazil)

Invasive melanoma with preoperative diagnosis of melanoma in situ
Gonzalez, Virginia (Buenos Aires,, Argentina)

Subungual Melanoma of the Hand
Chakera, Annette Hougaard (Sydney, Australia)

A protocol for the safe use of patent blue V dye in sentinel node biopsy
Crampton, Nicholas (Coolangatta, Australia)

Management of primary cutaneous melanoma: A retrospective audit of 887 cases and review of current clinical guidelines
Doolan, Brent J (Melbourne, Australia)

Sentinel lymph node biopsy for cutaneous melanoma in elderly patients: the Cambridge experience
Durrani, Amer (Cambridge, United Kingdom)
Initial experience in the UK with use of (99mTc) Tilmanocept (a novel radiopharmaceutical) for sentinel lymph node biopsy (SLNB) for malignant melanoma  
Durrani, Amer (Cambridge, United Kingdom)

Patterns of care for regional biopsies and nodal surgery for melanoma treatment in Queensland  
Forristal, Catherine E (Brisbane, Australia)

Mini-invasive subcutaneous lymphangiection in patients with skin melanoma  
Galaychuk, Igor (Ternopil, Ukraine)

Sentinel lymph node biopsy for cutaneous versus mucosal melanoma in the anorectal region: two case reports  
Hausien, Omar (Cambridge, United Kingdom)  
Durrani, Amer (Cambridge, United Kingdom)

Giant melanoma of the scalp without metastases: a case report  
Heald, Alicia (Herston, Australia)

Shave versus elliptical biopsy for melanoma substantially increases re-excision area and scar length  
Hishon, Matt (Brisbane, Australia)

Importance of ulceration and mitoses in the selection of patients for sentinel lymph node biopsy in thin cutaneous melanoma? A study based on the Swedish Melanoma Register and the Melanoma Institute Australia Research Database  
Isaksson, Karolin (Lund, Sweden)

Venous free flap reconstruction of fingers and toes in subungual melanoma  
Kim, Byung Jun (Seoul, Korea, Republic of)

A safe way to reduce length of hospital stay following lymph node dissection for cutaneous malignancy nodal metastasis  
Peach, A. Howard (Leeds, United Kingdom)

Treatment of melanoma in situ with erbium: YAG laser  
Pizinger, Karel (Pilsen, Czech Republic)

Results of sentinel lymph node biopsy in thin (Breslow < 1mm) cutaneous melanoma of trunk and extremities  
Quildrian, Sergio (Buenos Aires, Argentina)

Video-assisted inguinal lymphadenectomy in melanoma  
Quildrian, Sergio (Buenos Aires, Argentina)

The Circumferential Aligned Lateral Advancement with Fasciotomy (CALF) flap: A straightforward reconstruction technique for melanoma of the leg following wide local excision  
Royal, Richard E. (Houston, United States)

Surgical treatment of acral melanoma  
Roh, Mi Ryung (Seoul, Korea, Republic of)

Surgical management of cutaneous malignant melanoma - current status  
Sabol, Martin (Bratislava, Slovakia)

Lymph node dissection guided by indocyanine green fluorescence for cutaneous melanoma  
Tsutsumida, Arata (Tokyo, Japan)
Scientific Programme

Adherence to surgical melanoma guidelines in New South Wales of all newly diagnosed melanomas over a one-year period
Varey, Alexander (North Sydney, Australia)

Management of dysplastic vaevi: An international perspective (withdrawn)

The keystone perforator island flap in the management of large melanoma defects including groin dissections
Behan, Felix (Melbourne, Australia)

P09, Prevention & Health Economics

How does skin cancer risk perception influence sun-exposure behaviours in Australian adults?
Abbott, Lisa (Darlinghurst, Australia)

At a glance: The role of vitamin D in melanoma
Al-kutubi, Huda (Cardiff, United Kingdom)

Connecting design and health professionals for skin cancer prevention: a novel, sustainable approach in Queensland, Australia
Baldwin, Louise (Brisbane, Australia)

Photoaging smartphone apps for skin cancer prevention in German adolescents: the Sunface randomized trial
Brinker, Titus (Essen, Germany)

The sunscreen and young children (SAY) pilot study
Ford, Helen (Kelvin Grove, Australia)

New technologies in skin cancer prevention
Hacker, Elke (Kelvin Grove, Australia)

Teledermoscopy for skin cancer - what do dermatologists want to be paid to perform a simple consultation?
Snoswell, Centaine (Brisbane, Australia)

Utility-based quality of life in melanoma patients: Preliminary findings from the Whole Brain Radiotherapy (WBRT) trial
Tran, Anh (Sydney, Australia)

P08, Pathology

Anorectal melanoma, a case series of patients from the Melanoma Institute of Australia (MIA)
Dodds, Tristan (Sydney, Australia)
Scientific Programme

Review article: Role of beta catenin in melanoma
Hosseini Gharalari, Farzaneh (Urmia, Iran, Islamic Republic of)

A case of Spitz nevus: differential diagnosis from melanoma
Hosseini Gharalari, Farzaneh (Urmia, Iran, Islamic Republic of)

Poster
12:00 - 20:00
Poster Exhibition

P07, Oncology

Real world data on intensive follow-up for stage IV metastatic melanoma patients receiving combination ipilimumab and nivolumab: a safer model of care?
Archer, Christine (Canberry, Australia)

Case report: vemurafenib-induced facial edema
Peris, Ketty (Rome, Italy)

Effective in vivo targeting of neo-antigens to Clec9A+ cross-presenting dendritic cells to improve personalized immunotherapy of melanoma
Dolcetti, Riccardo (Woolloongabba, Australia)

Ipilimumab is not active in Japanese patients with nivolumab-refractory melanoma
Fujisawa, Yasuhiro (Tsukuba, Japan)

Topical diphencyprone for the treatment of in transit melanoma metastases of the skin: Long-term outcomes & management suggestions
Garioch, Jennifer (Norwich, United Kingdom)

Incidence of hypophysitis in patients with melanoma undergoing adjuvant ipilimumab 10mg/kg - a single center experience
Jang, Sekwon (Fairfax, United States)

If you are going to pay for it, do it on time
Llanos, Anabella (Buenos Aires, Argentina)

Real world PD-1 immunotherapy related side effects in metastatic melanoma, an Australian regional cancer centre experience
Lui, Andrew KH (Coffs Harbour, Australia)

Outcomes on Central Nervous System irradiation for melanoma brain metastasis: 10-year experience in a developing country institution
Mauro, Geovanne Pedro (Sao Paulo, Brazil)

The combination of BRAFi and MEKi: a treatment option for BRAF WT patients?
Niessner, Heike (Tuebingen, Germany)

Park, Jun Hong (Daegu, Korea, Republic of)

Toxic epidermal necrolysis associated with combination immunotherapy with nivolumab and Ipilimumab for advanced metastatic melanoma
Shah, Farida (Birmingham, United Kingdom)
Scientific Programme

Patient derived organotypic slice cultures for preclinical profiling of human BRAF wildtype melanomas

Two cases of trametinib-induced rhabdomyolysis of Japanese melanoma patients treated by dabrafenib and trametinib combination therapy
Yamazaki, Naoya (Tokyo, Japan)

Successful neoadjuvant therapy of BRAF and MEK inhibition for inoperable stage 3 metastatic Melanoma (Withdrawn)

P06, Keratinocyte Cancers & Merkel Cell Carcinoma

Squamous cell carcinoma in the caruncle during Vemurafenib treatment - case report
Cozzani, Romina Paula (Buenos Aires, Argentina)

Proposal for randomised controlled trial (RCT) of immunotherapy combined with wide field radiotherapy versus wide field radiotherapy alone in stage IA-IIIC Merkel Cell Carcinoma (MCC)
Fogarty, Gerald (Sydney, Australia)

Recurrence rates of lesions treated with curettage and cautery in a busy multi-practitioner dermatology practice in Brisbane, Australia.
Hishon, Matt (Brisbane, Australia)

Sentinel lymph node biopsy in clinically node negative Merkel cell carcinoma - Westmead Hospital, Sydney experience
Jenkins, Lillian (Westmead, Australia)

Primary Merkel cell carcinoma of the earlobe in a young, healthy adult male
Kim, Sue Kyung (Seoul, Korea, Republic of)

Basal Cell Carcinoma detection through transfer learning in dermoscopy images using a convolutional neural network
Lee, Tim K. (Vancouver, Canada)

Squamous cell carcinoma of the nail unit: A retrospective review of 14 cases and our proposal for surgical management
Lee, Tae Min (Seoul, Korea, Republic of)

Omega-3 fatty acid intake and cutaneous squamous cell carcinoma in organ transplant recipients
Miura, Kyoko (Herston, Australia)

A retrospective analysis of wide local excision for Merkel cell carcinoma: a single-center series of 11 patients
Park, Seong Oh (Seoul, Korea, Republic of)

Epidermal clonal proliferative response upon UVB irradiation is bimodal
Roy, Edwige (Brisbane, Australia)

Case report of a patient with metastatic basal cell carcinoma: mixed response to vismodegib therapy
Seeber, Arno (Vienna, Austria)
**Scientific Programme**

**Comparison of primary Merkel cell carcinoma (MCC) and melanoma T-cell immuno-profile and PD-L1 expression by multi-spectral immunohistochemistry (mIHC)**
Wong, Annie N.M. (Melbourne, Australia)

**Poster**
12:00 - 20:00

**P05, Immunology**

*Enhancing Immunotherapy with radiotherapy and topical treatments - Case report*
Bertolli, Eduardo (São Paulo, Brazil)

*Regulation of the cytotoxic immune response by the presence of normal and melanoma-associated fibroblasts*
Érsek, Barbara (Budapest, Hungary)

*Understanding the impact of immunotherapy side effects on quality of life of patients with stage IV melanoma not on clinical trial: ‘Real world’ data to inform supportive care interventions*
Milne, Donna (Melbourne, Australia)

*Successful reinstitution of nivolumab in combination with corticosteroids for metastatic malignant melanoma with diverse immune-related adverse events including severe hemolytic anemia*
Tanaka, RYO (Kurashiki, Japan)

**P04, Genetics & Genomics**

*Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and secondary cutaneous melanomas*
Hugdahl, Emilia

*Genotypic frequency of EGF+61 A>G polymorphism associated with risk of cutaneous melanoma in a mixed population*
Crivelari, Bruna Aparecida (Barretos, Brazil)

*Pilot study to evaluate the intratumor heterogeneity in melanoma by next generation sequencing*
Jang, Sekwon (Fairfax, United States)

*Efficient protocol for melanin purification: impact on melanoma molecular diagnosis of highly pigmented lesions*
Laus, Ana Carolina (Barretos, Brazil)

*Genetic ancestry in Brazilian melanoma patients*
Laus, Ana Carolina (Barretos, Brazil)

*Whole exome sequencing reveals that nail apparatus melanoma and acral melanoma are distinct entities*
Lee, Young Bok (Seoul, Korea, Republic of)
Gene expression profiling test is useful to predict the risk of relapses. A multicenter retrospective cohort study
Carrera, Cristina (Barcelona, Spain)

Candidate BAP1 phenocopy variants in a cohort of high case density Queensland melanoma families
Read, Jazlyn (Brisbane, Australia)

Novel segregating variants in a cohort of high case density Queensland melanoma families
Read, Jazlyn (Brisbane, Australia)

Polygenic landscape and possible pleiotropy in individuals with melanoma and other cancers
Read, Jazlyn (Brisbane, Australia)

Characteristics of mesenchymal transition of melanoma
Wenzina, Judith (Vienna, Austria)

---

Survival of cutaneous melanoma patients with MC1R and CDKN2A mutations in Southern Brazil
Bakos, Renato (Porto Alegre, Brazil)

1,848 Brazilian melanoma patient characteristics: From Demographic to clinical and related to treatment and survival from a single institution from Brazil
Bonato, Flávia (Barretos, Brazil)

Endogenous and exogenous hormonal factors associated with the presence and number of naevi in women
Cervenka, Iris (Villejuif, France)

Recent trends in cutaneous melanoma incidence and mortality: a 10-year nationwide cohort study
Choi, Jee-Woong (Suwon, Korea, Republic of)

Diverging in situ and invasive melanoma incidences - Trends from Victoria, Australia, 1985-2015
Curchin, David (St Leonards, Australia)

Incidence of invasive cutaneous melanoma in the island of Gran Canaria (Spain) in the period 2011 - 2015
Grau Pérez, Mercè (Las Palmas de Gran Canaria, Spain)

Descriptive epidemiology of malignant skin melanoma in Morocco
Hami, Hinde (Kenitra, Morocco)

Hydrochlorothiazide use and risk of malignant melanoma
Hölmich, Lisbet Rosenkrantz (Herlev, Denmark)

Acral lentiginous melanoma - Does it confer a poorer prognosis? An analysis of cases from 2009 to 2017 at University College Hospital Galway
Keyes, Alan (Galway, Ireland)
Heterogeneous spectrum of acral melanoma: A clinicoprognostic study of 213 acral melanomas according to tumor site
Lee, Ye Jin (Seoul, Korea, Republic of)

Acral lentiginous melanoma - is chronic microtrauma the missing link?
Peach, Howard (West Yorkshire, United Kingdom)

Increased incidence of cutaneous melanoma in organ transplant recipients in a single-center longitudinal study in Rome, Italy
Peris, Ketty (Rome, Italy)

Prevalence of common melanocytic naevi in the general population in South East Queensland and a systematic review of the evidence
Plasmeijer, Elsemieke (Brisbane, Australia)

The natural history of common melanocytic naevi in the general population: systematic review and pilot results from the Mind Your Moles study
Plasmeijer, Elsemieke (Brisbane, Australia)

High mortality of cutaneous melanoma in Norway: a population-based study of prognostic factors
Robsahm, Trude Eid (Oslo, Norway)

Melanoma and sunscreen use - A systematic review and meta-analysis
Rueegg, Corina S. (Oslo, Norway)

Is vitamin D status at time of melanoma diagnosis associated with stage of tumour? Study protocol and recruitment
Rye, Sheree (Maroochydore, Australia)

Exposure in early adulthood and subsequent risk of malignant melanoma: a review
Salna, Ingrid (Woodville South, Australia)

Comparison of histopathological features and clinical outcomes of primary invasive amelanotic and pigmented melanomas
Santos Filho, Ivan (São Paulo, Brazil)

The utilization of the National Dermatology Radiation Oncology Registry: A human research registry to collect information from patients referred to radiation oncologists for the management of melanoma and non-melanoma skin cancer through radiotherapy.
Spelman, Lynda (Brisbane, Australia)

Measured anthropometric factors and cutaneous melanoma risk: Data from the population-based Janus cohort
Stenehjem, Jo S (Oslo, Norway)

Measurement error in Breslow thickness and misclassification of T-stage: terminal digit preference in a national melanoma register 2008-2015
Veierød, Marit B. (Oslo, Norway)

Associations of statins and diabetes with diagnosis of ulcerated cutaneous melanoma
von Schuckmann, Lena (Brisbane, Australia)

Impact of associated naevus on survival for nodular and superficial spreading melanomas
Vu, Mi (Melbourne, Australia)

Melanoma excisions by specialty in Australia
Wu, Albert (Adelaide, Australia)
Scientific Programme

P02, Early Diagnosis & Dermoscopy

Diagnostic melanoma smartphone applications - what are the legal implications for dermatologists, patients and regulators?
Abbott, Lisa (Darlinghurst, Australia)

An unusual onset of agminated Spitz naevi in an adult patient
Adler, Nikki R (Melbourne, Australia)

The unregulated use of Melanotan-II may induce change and obscure the assessment of melanocytic lesions
Adler, Nikki R (Melbourne, Australia)

Relationship between melanocytic naevi (MN) acquired during childhood and adult MN count and melanoma risk
Barsoum, Ramez (Brisbane, Australia)

Confocal features of Sutton nevi can simulate melanoma: A reminder of the role of clinical-dermoscopic and confocal correlation to avoid overestimation of confocal features
Carrera, Cristina (Barcelona, Spain)

A case report of Lentigo Maligna of the nose treated with topical Imiquimod & followed-up with reflective confocal microscopy
Chio, Martin (Singapore, Singapore)

Teledermatology: an effective aid in diagnosing melanoma

Cancer systems biology of therapy-resistant melanoma
Filipp, Fabian (Merced, United States)

Photometric spectral analysis of digital images can improve telediagnosis of skin melanoma
Galaychuk, Igor (Ternopil, Ukraine)

Head and neck sentinel lymph node biopsy for cutaneous melanoma at a tertiary referral centre
Durrani, Amer (Cambridge, United Kingdom)

A guideline for the assessment of adult patients with suspected melanoma of unknown primary (MUP)
Durrani, Amer (Cambridge, United Kingdom)

Frequency and clinical features of synchronous multiple primary melanomas at an Australian tertiary referral centre
Kanzaki, Akiko (Melbourne, Australia)

Self-assessed sunbed use is not associated with melanoma diagnosis in patients attending a teledermatoscropy clinic in New Zealand
Oakley, Amanda (Hamilton, New Zealand)

Referrals of skin lesions from primary care do not meet quality standards for teledermatology
Lee, Gerald (Auckland, New Zealand)

Case report: Upstaging of melanoma in-situ following shave biopsy
Lim, Kathleen (Launceston, Australia)
Scientific Programme

Naevi in chronic graft versus host disease patients, a clinical challenge for dermatologist. Dermoscopic evaluation
Malvehy, Josep (Barcelona, Spain)

Melanoma in a cohort of organ transplant recipients: Experience from a dedicated transplant dermatology clinic in Victoria
Goh, Michelle (Melbourne, Australia)

The role of teledermoscopy in prompt diagnosis of melanoma
Oakley, Amanda (Hamilton, New Zealand)

Dermoscopy in Asian Skin
Oh, Choon Chiat (Singapore, Singapore)

Fluorescent and reflective spectroscopy at diagnosis of melanoma malignum and dysplastic nevi
Pavlova, Elmira (Sofia, Bulgaria)

Dermoscopic “Chaos and Clues” in the diagnosis of melanoma in situ
Ramji, Rajan (Auckland, New Zealand)

Digital imaging in melanoma diagnosis
Ryder, Emily (Oxford, United Kingdom)

Triple assessment of early melanoma - a new gold standard?
Ryder, Emily (Oxford, United Kingdom)

Mapping the unexpected: Delineating the margins of complex Lentigo Maligna with In vivo reflectance confocal microscopy
Star, Phoebe (Sydney, Australia)

Surveillance of patients with high-risk resected melanoma: What are we doing with these patients?
Roberts-Thomson, Rachel (Adelaide, Australia)

Development of a low-cost, liquid-biopsy microRNA assay for melanoma diagnosis, staging and treatment response monitoring
Van Laar, Ryan (Balaclava, Australia)

Identification and validation of a diagnostic autoantibody signature for primary cutaneous melanoma
Zaenker, Pauline (Joondalup, Australia)

Poster
12:00 - 20:00
Poster Exhibition

P01, Biology & Biomarkers

Nortriptyline can induce cytotoxic effect and autophagy on human melanoma cells (A2058)
Chuo, Wen-Ho (Pingtung County, Taiwan, Republic of China)

The role of neuronal nitric oxide synthase (nNOS) in interferon-gamma-induced melanoma progression
Fong, Shirley (Irvine, United States)
A gene-signature based risk score significantly improves melanoma relapse prediction in synergy with sentinel lymph node status
Gambichler, Thilo (Bochum, Germany)

Targeting cell cycle phase-specific drug sensitivity for melanoma therapy
Haass, Nikolas K. (Brisbane, Australia)

Serum doublecortin like kinase 1 (DCLK1) levels measured by ELISA correlate with disease status, and pre-treatment levels predict for therapeutic response in patients with malignant melanoma
Ikeguchi, Alexandra (Oklahoma City, United States)

Cooperativity of HOXA5 and STAT3 is essential for transcriptional activation of PD-L1
Jiang, Chench (Callaghan, Australia)

Analysis of the statistic data of melanogenesis disregulation
Karafieb, Elkh (Tashkent, Uzbekistan)

Diversity of circulating melanoma cells; detection of heterogenetic BRAF mutations by single-cell analysis
Kiniwa, Yukiko (Matsumoto, Japan)

MAPK inhibitor resistant melanoma cells can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
Kosnopflel, Corinna (Tübingen, Germany)

Immune profiles of responders and non-responders to topical imiquimod for the treatment of lentigo maligna
Mar, Victoria (Melbourne, Australia)

Peripheral blood Th9 cells can be an efficacy biomarker of anti-PD-1 antibody treatment in metastatic melanoma patients
Otsuka, Atsushi (Kyoto-shi, Japan)

Melanoma - What’s hair got to do with it?
Paul, Sharad (Auckland, New Zealand)

Isolation of cytotoxic compounds against melanoma cells from Epicoccum nigrum, an endophyte isolated from Ferula sumbul plant
Perveen, Irum (Islamabad, Pakistan)

Establishment of a clinical resource to evaluate biomarkers to systemic therapies in melanoma patients
Raleigh, Jeanette (Melbourne, Australia)

Body-Mass-Index as a predictive marker for response in patients with metastatic melanoma treated with ipilimumab
Richtig, Erika (Graz, Austria)

Acetylsalicylic acid governs the effect of Sorafenib in NRAS- mutant melanoma
Schaider, Helmut (Brisbane, Australia)

The serial measurements of S100B protein serum concentrations predict independently disease outcome in advanced melanoma stage
Tsoutsos, Dimosthenis (Athens, Greece)
The baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios as biomarkers of survival in cutaneous melanoma
Wade, Ryckie George (Leeds, United Kingdom)

The baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios are associated with microscopic metastases of cutaneous melanoma to the sentinel lymph node
Wade, Ryckie George (Leeds, United Kingdom)

The co-evolution of tumour and host immunity in metastatic melanoma through BRAF inhibition and checkpoint blockade
Wong, Stephen Q. (Melbourne, Australia)

2-Deoxy-D-glucose can abolish the cisplatin-induced melanoma giant cell formation and enhance the cytotoxic effect of cisplatin on melanoma cells
Wu, Chieh-Shan (Kaohsiung, Taiwan, Republic of China)

P13, Epigenetics and Metabolism

The Mitochondrial Pyruvate Carrier 1 regulates differentiation and proliferation in melanoma
Antunes, Ana (Zurich, Switzerland)

A-to-I miR-378a-3p editing prevents melanoma progression via regulation of PARVA expression
Bar-Eli, Menashe (Houston, United States)

Epigenome-wide association scan in healthy human skin tissue in relation to naevus counts
Bataille, Veronique (Hemel Hempstead, United Kingdom)

ROS production induced by BRAF inhibitor treatment rewire metabolic processes affecting cell growth of melanoma cells
Cesi, Giulia (Belvaux, Luxembourg)

Genome-wide base-resolution DNA methylation analysis of invasive and non-invasive melanoma cell lines
Eccles, Michael (Dunedin, New Zealand)

Distinct histone remodelling defines early stress-induced drug tolerance in melanoma
Emran, Abdullah Al (Brisbane, Australia)

Crosstalk between metabolism and epigenetics
Filipp, Fabian (Merced, United States)

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
Gallagher, Stuart (Sydney, Australia)

PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival
Micevic, Goran (New Haven, Switzerland)
Elevated miR-146a-5p levels in melanoma versus melanoma microenvironment in NRAS-negative tumors
Ruksha, Tatiana (Kray, Russian Federation)

Histone Acetyltransferase p300 critically controls proliferation and survival of melanoma cells by transcriptionally regulating MITF
Ryu, Byungwoo (Boston, United States)

Targeting metabolic reprogramming in BRAFV600E melanoma
Smith, Lorey (Melbourne, Australia)

Untargeted Metabolomics of Melanoma and Adjacent Skin
Taylor, Nicholas (College Station, United States)

Epigenetic silencing of anti-tumour immunity in melanoma.
Tiffen, Jessamy (Sydney, United States)

Targeting the CoREST Complex as a Novel Therapeutic Strategy for Melanoma
Wu, Muzhou (Boston, United States)

Plenary Lecture
12:20 - 13:50
Great Hall

PL01, Melanoma Epidemiology and Early Diagnosis
Chairs:
Smithers, B. Mark (Brisbane, Australia)
Thompson, John (Sydney, Australia)

Keynote Address: Neville Davis and Gerald Milton Lecture The changing epidemiology of cutaneous melanoma: 1967-2017
Green, Adèle (Brisbane, Australia)

Delays have dangerous rnds! Who benefits from early detection?
Kittler, Harald (Vienna, Austria)

No one should die from melanoma: vision or impossible mission?
Zalaudek, Iris (Graz, Austria)

The changing landscape of melanoma detection
Halpern, Allan C. (New York, United States)

Symposium
14:40 - 15:40
Great Hall

SY01, Medical Oncology: Intra-lesional Therapy for Recurrent Melanoma
Chairs:
Andtbacka, Robert (Salt Lake City, United States)
Weide, Benjamin (Tuebingen, Germany)

Introduction

Page 29 / 122
Is there a role for monotherapy intralesional immunotherapy in regionally advanced melanoma?

**Presentation of “no” case**
Ross, Merrick (Houston, United States) 14:42 - 14:50

**Presentation of “yes” case**
Agarwala, Sanjiv (Easton, United States) 14:50 - 14:58

**Immunological effects and efficacy of monotherapy intralesional immunotherapies in regionally advanced melanoma**
Weide, Benjamin (Tuebingen, Germany) 14:58 - 15:07

**Intralesional immunotherapies - modifiers of the tumour microenvironment**
Algazi, Alain (San Francisco, United States) 15:07 - 15:16

**Combination intralesional immunotherapy - the path forward**
Andtbacka, Robert (Salt Lake City, United States) 15:16 - 15:25

**Panel discussion**
15:25 - 15:40

**SMR Session**
14:40 - 17:00  Room M4

**SMR01, Tumour Microenvironment and Drug Resistance**

**Chairs:**
Marais, Richard (Manchester, United Kingdom)

**At a crossroad: how mechanical changes in the aging ECM affect routes of metastatic dissemination in melanoma**
Weeraratna, Ashani (Philadelphia, United States) 14:40 - 15:00

**HAPLN1 mediates collagen remodeling during aging to influence melanoma and immune cell motility**
Kaur, Amanpreet (Philadelphia, United States) 15:00 - 15:15

**Evidence for a causal relationship between Vitamin D and melanoma progression**
Newton-Bishop, Julia (Leeds, United Kingdom) 15:15 - 15:30

**Adipocyte-derived lipids mediate melanoma progression via FATP proteins**
Zhang, Maomao (New York City, United States) 15:30 - 15:45

**c-MET+ neutrophils limit cancer immunotherapy by inducing senescence in anti-tumoral T cells**
Bald, Tobias (Brisbane, Australia) 15:45 - 16:00

**The Cdon-Shh-Edn1 axis is a therapeutic target for patients with giant congenital naevi**
Chitsazan, Arash (Brisbane, Australia) 16:00 - 16:15

**FGF2 provides protection against BET inhibitors in metastatic uveal melanoma**
Chua, Vivian (Philadelphia, United States) 16:15 - 16:30
Scientific Programme

Aging Induces Rewiring of Key Metabolic Pathways in Fibroblasts and Melanoma Cells
Alicea, Gretchen (Philadelphia, United States)

16:30 - 16:45

Inhibition of the protein arginine methyltransferase PRMT5 overcomes resistance to CDK4-inhibition in melanoma
AbuHammad, Shatha (Melbourne, Australia)

16:45 - 17:00

Symposium
14:40 - 15:40 Room M3

SY02, Clinical Diagnosis: Nail and Acral Dermoscopy

Chairs:
Tanaka, Masaru (Tokyo, Japan)
Thomas, Luc (Lyon, France)

Nail plate dermoscopy: a help in the diagnosis of melanonychia striata
Thomas, Luc (Lyon, France)
14:40 - 14:50

Nail matrix dermoscopy
Hirata, Sérgio (Sao Paulo, Brazil)
14:50 - 15:00

Nail matrix confocal dermoscopy
Thomas, Luc (Lyon, France)
15:00 - 15:10

Acral dermoscopy
Tanaka, Masaru (Tokyo, Japan)
15:10 - 15:20

Acral naevi
Koga, Hiroshi (Matsumoto, Japan)
15:20 - 15:30

Acral melanomas
Mun, Je-Ho (Seoul, Korea, Republic of)
15:30 - 15:40

Symposium
14:40 - 15:40 Room M2

SY03, Public Health, Prevention and Epidemiology: Global Patterns and Causes of Melanoma

Chairs:
Berwick, Marianne (Albuquerque, United States)
Whiteman, David (Brisbane, Australia)

Melanoma in Central and South America
de Vries, Esther (Bogota, Colombia)
14:40 - 14:55

Recent global trends in incidence and mortality from melanoma
Whiteman, David (Brisbane, Australia)
14:55 - 15:10

Over-diagnosis and under registration of melanoma in the United States - trends in incidence and mortality
Berwick, Marianne (Albuquerque, United States)
15:10 - 15:25
9th World Congress of Melanoma – a Joint Meeting with the Society for Melanoma Research

Scientific Programme

Free Communication
14:40 - 15:40
Room M1

**FC01, Keratinocyte Cancers and Merkel Cell Carcinoma**

**Chairs:**
Saunders, Nicholas (Brisbane, Australia)
Lewandowski, Richard (Brisbane, Australia)

14:40 - 14:50
**Dualities of germline and somatic mutations leading to basal cell carcinoma**
Khosrotehrani, Kiarash (Brisbane, Australia)

14:50 - 15:00
**Hydrochlorothiazide use and risk of non-melanoma skin cancer**
Hølmich, Lisbet Rosenkrantz (Herlev, Denmark)

15:00 - 15:10
**Declining risk of cutaneous squamous cell carcinoma after organ transplantation. A population-based, nation-wide cohort study**
Gjersvik, Petter (Oslo, Norway)

15:10 - 15:20
**Circulating free miR-375 is a surrogate marker of tumor burden in Merkel cell carcinoma**
Becker, Jürgen (Essen, Germany)

15:20 - 15:30
**Merkel cell polyomavirus T-antigen regulated microRNAs suppress autophagy in Merkel cell carcinoma**
(Under review)

15:30 - 15:40
**1-year follow-up analysis from the JAVELIN Merkel 200, a phase 2 clinical trial of avelumab in patients with metastatic Merkel cell carcinoma**
Sandhu, Shahneen (Melbourne, Australia)

Symposium
15:50 - 16:50
Great Hall

**SY04, Clinical Diagnosis: What’s New in Dermoscopy**

**Chairs:**
Argenziano, Giuseppe (Caserta, Italy)
Puig, Susana (Barcelona, Spain)

15:50 - 16:00
**A new method to diagnose facial melanoma**
Argenziano, Giuseppe (Caserta, Italy)

16:00 - 16:10
**Scalp tumours**
Zalaudek, Iris (Graz, Austria)

16:10 - 16:20
**What’s new in non-melanoma skin cancer**
Lallas, Aimilios (Thessaloniki, Greece)

16:20 - 16:30
**Polarised total body photography: a new way of monitoring patients with multiple naevi**
Malvehy, Josep (Barcelona, Spain)
Scientific Programme

Dermoscopy and melanoma prognosis  16:30 - 16:40
Puig, Susana (Barcelona, Spain)

Dermoscopy in different skin types  16:40 - 16:50
Bakos, Renato (Porto Alegre, Brazil)

Satellite Symposium
15:50 - 16:50  Room M3

SAT01, Incyte Corporation: Melanoma: Future Approaches to Therapy and Trials
Chairs:
Long, Georgina (Sydney, Australia)

Welcome and introductions  15:50 - 15:55
Long, Georgina (Sydney, Australia)

State-of-the-art treatments for melanoma - what is the current situation?  15:55 - 16:20
Long, Georgina (Sydney, Australia)

Combination therapy - what does the future hold?  16:20 - 16:45
Weber, Jeffrey (New York, United States)

Panel discussions and closing remarks  16:45 - 16:50
Long, Georgina (Sydney, Australia)

Symposium
15:50 - 16:50  Room M2

SY05, Public Health, Prevention and Epidemiology: Global Patterns and Causes of Keratinocyte Cancers
Chairs:
Nijsten, Tamar (Rotterdam, Netherlands)
Olsen, Catherine (Brisbane, Australia)

Impact of skin cancer on the health care system  15:50 - 16:05
Nijsten, Tamar (Rotterdam, Netherlands)

The incidence rates and multiplicity of keratinocyte cancers in Australia  16:05 - 16:20
Olsen, Catherine (Brisbane, Australia)

Emerging evidence on keratinocyte cancer aetiology in the USA  16:20 - 16:35
Karagas, Margaret (New Hampshire, United States)

Discussion  16:35 - 16:50
Scientific Programme

Satellite Symposium
15:50 - 16:50  Room M1

**SAT02, MEDSCAPE: New Paradigms in BRAFm Metastatic Melanoma: State-of-the-Art**

*The educational activity is provided by Medscape Education with an Independent Educational Grant from Pierre Fabre*

**Chairs:**
Atkinson, Victoria (Brisbane, Australia)

**Key challenges and unmet needs**
Atkinson, Victoria (Brisbane, Australia) 15:50 - 16:10

**New treatment paradigms: the evidence**
Dummer, Reinhard (Zurich, Switzerland) 16:10 - 16:30

**Optimising treatment and outcomes in the real world**
Ascierto, Paolo (Napoli, Italy) 16:30 - 16:50

Symposium
17:00 - 18:00  Great Hall

**SY06, Medical Oncology: Advances in Immune Therapy**

**Chairs:**
Michielin, Olivier (Lausanne, Switzerland)
Weber, Jeffrey (New York, United States)

**New checkpoint-based therapies**
Weber, Jeffrey (New York, United States) 17:00 - 17:15

**Biomarkers for patient selection**
Michielin, Olivier (Lausanne, Switzerland) 17:15 - 17:30

**Combinations of checkpoints and TKI**
Ribas, Antoni (Los Angeles, United States) 17:30 - 17:45

**Discussion**
17:45 - 18:00

Symposium
17:00 - 18:00  Room M2

**SY07, Public Health, Prevention and Epidemiology: Genetics of Melanoma**

**Chairs:**
Hayward, Nick (Brisbane, Australia)
Landi, Maria Teresa (Bethesda, United States)

**Genome-wide association study and polygenic risk score for melanoma in multiple populations**
Landi, Maria Teresa (Bethesda, United States) 17:00 - 17:20
Scientific Programme

Combined genetic associations of melanoma and naevi
Law, Matthew (Brisbane, Australia)  17:20 - 17:35

Analysis of melanoma prone families by whole-genome sequencing
Adams, David (Hinxton, United Kingdom)  17:35 - 17:50

Melanoma predisposition genes
Hayward, Nick (Brisbane, Australia)  17:50 - 18:00

Free Communication
17:00 - 18:00  Room M1

FC02, Early Diagnosis & Dermoscopy

Chairs:
Lallas, Aimilios (Thessaloniki, Greece)
Mar, Victoria (Melbourne, Australia)

Artificial intelligence offers improved availability and standardisation for melanoma screening of populations
Bowling, Adrian (Auckland, New Zealand)  17:00 - 17:10

Survey of primary care referrers to teledermatology service reveals mixed teledermatoscopy capability
Sykes, AJ (Hamilton, New Zealand)  17:10 - 17:20

MoleMap lesion distribution analysis
Vu, Mi (Melbourne, Australia)  17:20 - 17:30

The High Risk Clinic Study: A single institution analysis: Melanoma Institute Australia
Star, Phoebe (Sydney, Australia)  17:30 - 17:40

A national budget impact analysis of a specialised surveillance program for individuals at high risk of melanoma in Australia
Cust, Anne (Sydney, Australia)  17:40 - 17:50

In vivo dermoscopic and confocal microscopy multi-step algorithm to detect in situ melanomas
Borsari, Stefania (Reggio Emilia, Italy)  17:50 - 18:00

SMR Session
17:00 - 18:00  Poster Exhibition

SMR Poster Viewing
Thursday, 19 October 2017

**SY08, Clinical Diagnosis: Reflectance Confocal Microscopy**

**Chairs:**
Guitera, Pascale (Sydney, Australia)
Pellacani, Giovanni (Modena, Italy)

- The different patterns of melanocytic naevi and their dynamics 08:00 - 08:12
  Scope, Alon (Tel Aviv, Israel)
- Implementing confocal for sequential imaging 08:12 - 08:24
  Malvehy, Josep (Barcelona, Spain)
- Melanoma: different patterns for different types 08:24 - 08:36
  Pellacani, Giovanni (Modena, Italy)
- Tips and tricks how to not miss a melanoma 08:36 - 08:48
  Longo, Caterina (Reggio Emilia, Italy)
- Can we define lentigo maligna margins? 08:48 - 09:00
  Guitera, Pascale (Sydney, Australia)
- Mucosal melanocytic proliferations 09:00 - 09:12
  Collgros, Helena (Sydney, Australia)
- Difficult cases: where confocal helps and where not! 09:12 - 09:24
  Hofmann-Wellenhof, Rainer (Graz, Austria)

**SMR Session**

**SMR02, Immune Therapy I**

**Chairs:**
Ribas, Antoni (Los Angeles, United States)
Teng, Michele (Brisbane, Australia)

- Melanoma cell plasticity in cancer immunotherapy 08:00 - 08:20
  Hoelzel, Michael (Bonn, Germany)
- Targeting Adenosine in Melanoma 08:20 - 08:35
  Smyth, Mark (Brisbane, Australia)
- Molecular, Immune and Microbial Predictors of Response and Toxicity to Combination Immune Checkpoint Blockade (CICB) in Melanoma (MEL) Patients 08:35 - 08:50
  Andrews, Miles (Houston, United States)
**Scientific Programme**

**08:50 - 09:05**

**eIF4F regulates PDL1 expression and response to anti-PD1 immunotherapy**

Cerezo, Michael (Villejuif, France)

**09:05 - 09:20**

**High dimensional single-cell analysis identifies classical monocyte frequencies to be predictive of progression free survival to anti-PD-1 immunotherapy**

Levesque, Mitch (Zürich, Switzerland)

**Discussion**

---

**SY09, Surgical Oncology: Primary Melanoma Management**

**Chairs:**
Henderson, Michael (Melbourne, Australia)
Kaufmann, Roland (Frankfurt/Main, Germany)

**Margins of excision, current recommendations and controversies**
Henderson, Michael (Melbourne, Australia)

**Management of melanomas in difficult locations**
Kaufmann, Roland (Frankfurt/Main, Germany)

**Margins of excision - special situations**
Gyorki, David (Melbourne, Australia)

**Follow-up surveillance after wide excision for melanoma**
Saw, Robyn (Sydney, Australia)

**Discussion with presentation of cases**
Henderson, Michael (Melbourne, Australia)
Kaufmann, Roland (Frankfurt/Main, Germany)

---

**SY10, Public Health, Prevention and Epidemiology: Primary Prevention and Health Promotion**

**Chairs:**
Janda, Monika (Brisbane, Australia)
Lazovich, DeAnn (Minneapolis, United States)

**The role of digital and social media in skin cancer prevention**
Janda, Monika (Brisbane, Australia)

**Countering indoor tanning industry arguments against under age 18 bans with epidemiologic data**
Lazovich, DeAnn (Minneapolis, United States)
### Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:36 - 08:54</td>
<td>The economics of skin cancer prevention</td>
<td>Gordon, Louisa (Brisbane, Australia)</td>
</tr>
<tr>
<td>08:54 - 09:12</td>
<td>Insights into nicotinamide chemoprevention</td>
<td>Damian, Diona (Sydney, Australia)</td>
</tr>
<tr>
<td>09:12 - 09:30</td>
<td>Primary prevention of skin cancer in Europe</td>
<td>de Vries, Esther (Bogota, Colombia)</td>
</tr>
</tbody>
</table>

### Free Communication

08:00 - 09:30

**Room M1**

**FC03, Treatment and Follow-up**

**Chairs:**
Barbour, Andrew (Brisbane, Australia)
Coventry, Brendon (Adelaide, Australia)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:10</td>
<td>Immunologic reshaping and therapy of cancer by stimulation of innate</td>
<td>Mathy, Jon A. (Auckland, New Zealand)</td>
</tr>
<tr>
<td></td>
<td>nucleic acid sensor RIG-I (withdrawn)</td>
<td></td>
</tr>
<tr>
<td>08:10 - 08:20</td>
<td>Developing evidenced-based guidelines for prevention of surgical site</td>
<td>Mathy, Jon A. (Auckland, New Zealand)</td>
</tr>
<tr>
<td></td>
<td>infections in skin cancer surgery using prophylactic incisional antibiotics: PICASSO trial</td>
<td></td>
</tr>
<tr>
<td>08:20 - 08:30</td>
<td>Whole-body MRI including diffusion weighted imaging for the surveillance of melanoma patients at high risk for recurrence following surgery or systemic therapy</td>
<td>Jansen, Yanina (Jette, Belgium)</td>
</tr>
<tr>
<td>08:30 - 08:40</td>
<td>Radiation risk from computed tomography surveillance imaging in asymptomatic adults treated for stage III melanoma: a simulation modelling study</td>
<td>Martin, Anna L. (Sydney, Australia)</td>
</tr>
<tr>
<td>08:40 - 08:50</td>
<td>Patients with cutaneous melanoma in the head and neck region benefit from initial CT staging prior to sentinel lymph node biopsy</td>
<td>Hafstrom, Anna (Lund, Sweden)</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td>BRAF mutation is associated with sentinel lymph node positivity and central nervous system metastasis in patients with primary cutaneous melanoma</td>
<td>Adler, Nikki R (Melbourne, Australia)</td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td>Clinical impact of non-sentinel node positivity in recurrence and melanoma death. A single-center retrospective analysis</td>
<td>Bertolli, Eduardo (São Paulo, Brazil)</td>
</tr>
<tr>
<td>09:10 - 09:20</td>
<td>The introduction of electrochemotherapy (ECT) to a specialist skin cancer service - why, what went right, what went wrong, and how to do it better</td>
<td>MacKenzie Ross, Alastair (London, United Kingdom)</td>
</tr>
<tr>
<td>09:20 - 09:30</td>
<td>Managing melanoma patient by multidisciplinary cancer service (Skin Cancer Unit): a model from Italy</td>
<td>Raucci, Margherita (Reggio Emilia, Italy)</td>
</tr>
</tbody>
</table>
Scientific Programme

Miscellaneous
08:00 - 18:00

Industry Exhibition

Poster
08:00 - 18:30

Poster Exhibition

P01, Biology & Biomarkers

- The role of neuronal nitric oxide synthase (nNOS) in interferon-gamma-induced melanoma progression
- A gene-signature based risk score significantly improves melanoma relapse prediction in synergy with sentinel lymph node status
- Targeting cell cycle phase-specific drug sensitivity for melanoma therapy
- Serum doublecortin like kinase 1 (DCLK1) levels measured by ELISA correlate with disease status, and pre-treatment levels predict for therapeutic response in patients with malignant melanoma
- Cooperativity of HOXA5 and STAT3 is essential for transcriptional activation of PD-L1
- Diversity of circulating melanoma cells; detection of heterogenous BRAF mutations by single-cell analysis
- MAPK inhibitor resistant melanoma cells can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
- Immune profiles of responders and non-responders to topical imiquimod for the treatment of lentigo maligna
- Peripheral blood Th9 cells can be an efficacy biomarker of anti-PD-1 antibody treatment in metastatic melanoma patients
- Melanoma - What’s hair got to do with it?
- Establishment of a clinical resource to evaluate biomarkers to systemic therapies in melanoma patients
- Body-Mass-Index as a predictive marker for response in patients with metastatic melanoma treated with ipilimumab
- Acetylsalicylic acid governs the effect of Sorafenib in NRAS- mutant melanoma
- The serial measurements of S100B protein serum concentrations predict independently disease outcome in advanced melanoma stage
- The baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios as biomarkers of survival in cutaneous melanoma
- The baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios are associated with microscopic metastases of cutaneous melanoma to the sentinel lymph node
- The co-evolution of tumour and host immunity in metastatic melanoma through BRAF inhibition and checkpoint blockade
- 2-Deoxy-D-glucose can abolish the cisplatin-induced melanoma giant cell formation and enhance the cytotoxic effect of cisplatin on melanoma cells
Scientific Programme

Poster
08:00 - 18:30
Poster Exhibition

**P12, Drug Resistance**

- **Mechanisms of Resistance in anti-PD1 Treated Patients with Metastatic Melanoma**
- **Targeting TOP1 gene in melanoma as a novel mechanism of resistance and combinational therapies**
- **Repurposing chemotherapy to target methylation and induce DNA repair to overcome treatment resistance in melanoma.**
- **Uncovering novel resistance mechanisms to BRAF and MEK inhibition by integrative RNAseq and targeted panel sequencing**
- **Targeting the JNK-JUN pathway to reduce phenotypic plasticity and overcome therapy resistance in metastatic melanoma**
- **Detection of BRAF splicing variants in plasma of patients developing resistance to combined BRAF/MEK inhibition**
- **Amino acid transporter ASCT2 as a potential therapeutic target for BRAF inhibitor resistant melanoma**
- **OGT and TET1 mediated H3K4me3 remodelling drives acquired BRAF inhibitor resistance in melanoma**
- **Targeting Apoptosis to Enhance BRAF/MEK Directed Therapy**
- **A Phase Ib/II randomised study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib in patients with advanced melanoma**
- **ABCB5 Transporter: Mediator of Intrinsic Resistance to Vemurafenib in Melanoma**
- **SETDB2-mediated drug tolerance in melanoma**
- **Preclinical efficacy and sensitivity determinants of statins in molecularly-defined models of melanoma**
- **Use of primary melanoma cells for testing novel combination therapies**
- **Response and Resistance of MEKi Treated Melanomas with BRAF Fusions**
- **Resistance to BRAF inhibition in a somatic mouse model of melanoma**

**P02, Early Diagnosis & Dermoscopy**

- **Diagnostic melanoma smartphone applications - what are the legal implications for dermatologists, patients and regulators?**
- **An unusual onset of agminated Spitz naevi in an adult patient**
- **The unregulated use of Melanotan-II may induce change and obscure the assessment of melanocytic lesions**
- **Relationship between melanocytic naevi (MN) acquired during childhood and adult MN count and melanoma risk**
Confocal features of Sutton nevi can simulate melanoma: A reminder of the role of clinical-dermoscopic and confocal correlation to avoid overestimation of confocal features

A case report of Lentigo Maligna of the nose treated with topical Imiquimod & followed-up with reflective confocal microscopy

Teledermatology: an effective aid in diagnosing melanoma

Photometric spectral analysis of digital images can improves telediagnóstics of skin melanoma

Head and neck sentinel lymph node biopsy for cutaneous melanoma at a tertiary referral centre

A guideline for the assessment of adult patients with suspected melanoma of unknown primary (MUP)

Frequency and clinical features of synchronous multiple primary melanomas at an Australian tertiary referral centre

Self-assessed sunbed use is not associated with melanoma diagnosis in patients attending a teledermatoscopy clinic in New Zealand

Referrals of skin lesions from primary care do not meet quality standards for teledermatology

Case report: Upstaging of melanoma in-situ following shave biopsy

Naevi in chronic graft versus host disease patients, a clinical challenge for dermatologist. Dermoscopic evaluation

Melanoma in a cohort of organ transplant recipients: Experience from a dedicated transplant dermatology clinic in Victoria

The role of teledermoscopy in prompt diagnosis of melanoma

Dermoscopy in Asian Skin

Fluorescent and reflective spectroscopy at diagnosis of melanoma malignum and dysplastic nevi

Dermatoscopic “Chaos and Clues” in the diagnosis of melanoma in situ

Digital imaging in melanoma diagnosis

Triple assessment of early melanoma - a new gold standard?

Mapping the unexpected: Delineating the margins of complex Lentigo Maligna with In vivo reflectance confocal microscopy

Surveillance of patients with high-risk resected melanoma: What are we doing with these patients?

Development of a low-cost, liquid-biopsy microRNA assay for melanoma diagnosis, staging and treatment response monitoring

Identification and validation of a diagnostic autoantibody signature for primary cutaneous melanoma
Scientific Programme

Poster
08:00 - 18:30
Poster Exhibition

P03, Epidemiology

Survival of cutaneous melanoma patients with MC1R and CDKN2A mutations in Southern Brazil

1,848 Brazilian melanoma patient characteristics: From Demographic to clinical and related to treatment and survival from a single institution from Brazil

Endogenous and exogenous hormonal factors associated with the presence and number of naevi in women

Recent trends in cutaneous melanoma incidence and mortality: a 10-year nationwide cohort study

Diverging in situ and invasive melanoma incidences - Trends from Victoria, Australia, 1985-2015

Incidence of invasive cutaneous melanoma in the island of Gran Canaria (Spain) in the period 2011 - 2015

Descriptive epidemiology of malignant skin melanoma in Morocco

Hydrochlorothiazide use and risk of malignant melanoma

Acral lentiginous melanoma - Does it confer a poorer prognosis? An analysis of cases from 2009 to 2017 at University College Hospital Galway

Melanoma skin cancer: epidemiology study about 85 cases in Casablanca morocco

Heterogeneous spectrum of acral melanoma: A clinicoprognostic study of 213 acral melanomas according to tumor site

Acral lentiginous melanoma – is chronic microtrauma the missing link?

Increased incidence of cutaneous melanoma in organ transplant recipients in a single-center longitudinal study in Rome, Italy

Prevalence of common melanocytic naevi in the general population in South East Queensland and a systematic review of the evidence

The natural history of common melanocytic naevi in the general population: systematic review and pilot results from the Mind Your Moles study

High mortality of cutaneous melanoma in Norway: a population-based study of prognostic factors

Melanoma and sunscreen use - A systematic review and meta-analysis

Is vitamin D status at time of melanoma diagnosis associated with stage of tumour? Study protocol and recruitment

Exposure in early adulthood and subsequent risk of malignant melanoma: a review

Comparison of histopathological features and clinical outcomes of primary invasive amelanotic and pigmented melanomas

Primary cutaneous melanoma: clinical characteristics and demographic features of 200 cases: A single center experience from the south east marmara region of Türkiye
Scientific Programme

The utilization of the National Dermatology Radiation Oncology Registry: A human research registry to collect information from patients referred to radiation oncologists for the management of melanoma and non-melanoma skin cancer through radiotherapy.

Measured anthropometric factors and cutaneous melanoma risk: Data from the population-based Janus cohort

Measurement error in Breslow thickness and misclassification of T-stage: terminal digit preference in a national melanoma register 2008-2015

Associations of statins and diabetes with diagnosis of ulcerated cutaneous melanoma

Impact of associated naevus on survival for nodular and superficial spreading melanomas

Melanoma excisions by specialty in Australia

Poster
08:00 - 18:30

P13, Epigenetics and Metabolism

The Mitochondrial Pyruvate Carrier 1 regulates differentiation and proliferation in melanoma

A-to-I miR-378a-3p editing prevents melanoma progression via regulation of PARVA expression

Epigenome-wide association scan in healthy human skin tissue in relation to naevus counts

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells

Genome-wide base-resolution DNA methylation analysis of invasive and non-invasive melanoma cell lines

Distinct histone remodelling defines early stress-induced drug tolerance in melanoma

Crosstalk between metabolism and epigenetics

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma

PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival

Elevated miR-146a-5p levels in melanoma versus melanoma microenvironment in NRAS-negative tumors

Histone Acetyltransferase p300 critically controls proliferation and survival of melanoma cells by transcriptionally regulating MITF

Targeting metabolic reprogramming in BRAFV600E melanoma

Untargeted Metabolomics of Melanoma and Adjacent Skin

Epigenetic silencing of anti-tumour immunity in melanoma.

Targeting the CoREST Complex as a Novel Therapeutic Strategy for Melanoma
Scientific Programme

Poster  
08:00 - 18:30  
Poster Exhibition

P04, Genetics & Genomics

Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and secondary cutaneous melanomas  
Hugdahl, Emilia

Genotypic frequency of EGF+61 A>G polymorphism associated with risk of cutaneous melanoma in a mixed population

Pilot study to evaluate the intratumor heterogeneity in melanoma by next generation sequencing

Efficient protocol for melanin purification: impact on melanoma molecular diagnosis of highly pigmented lesions

Genetic ancestry in Brazilian melanoma patients

Whole exome sequencing reveals that nail apparatus melanoma and acral melanoma are distinct entities

Gene expression profiling test is useful to predict the risk of relapses. A multicenter retrospective cohort study

Candidate BAP1 phenocopy variants in a cohort of high case density Queensland melanoma families

Novel segregating variants in a cohort of high case density Queensland melanoma families

Polygenic landscape and possible pleiotropy in individuals with melanoma and other cancers

Gene interactions and influence of age & sex with melanoma risk

Characteristics of mesenchymal transition of melanoma

P14, Genetics and Genomics

The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients

Melanoma cases demonstrate double the expected carrier frequency of phenylketonuria/hyperphenylalanemia mutations

Melanoma mutational burden and copy number alteration levels do not differ between adolescent and young adult and older patients

Genome-wide association study in 185,000 Europeans elucidates the genetic architecture of skin sensitivity to sun

Association between gut microbiome and naevus count in the TwinsUK registry

Low-Pass Whole Genome Sequencing of Single Uveal Melanoma Cells

Prognostic value of non-sentinel lymph node (non-SLN) status and a prognostic 31-gene expression profile (GEP) in stage III cutaneous melanoma patients
Scientific Programme

Actionable kinase fusions are frequent in pan-negative melanomas

The association between polygenic score and melanoma risk by biological pathways and examination of effect modification of sun exposure-melanoma risk associations

Incremental contribution of common genomic variants to melanoma risk, and overlap with phenotypic risk in Australia and the UK

NRAS mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy and clinical outcome

Molecular profiling of resected melanoma and its role in predicting patient outcome

Genomic characterisation of lethal melanoma from thin primaries

First-Line Immunotherapy in BRAF V600R Mutant Melanoma

The Cancer Survival Transcriptome Links Annotated Gene Signatures to Melanoma Patient Survival

TERT promoter mutations in melanoma
Kumar, Rajiv (Heidelberg, Germany)

TERT promoter mutations, telomere length and melanoma risk
Kumar, Rajiv (Heidelberg, Germany)

Characterising melanoma risk genetics through gene-based tests

Performance of a 31-gene expression profile test for melanoma prognosis in a combined validation cohort of 690 patients

Clinical impact of a 31-gene expression profile test on physician recommendations for management of melanoma patients in a prospectively tested cohort
Monzon, Frederico (Friendswood, United States)

Mutational and transcriptional profiling of clinical specimens of melanoma brain metastases: investigation of alterations and molecular signatures of potential clinical significance

A case-control analysis of POT1 variants in melanoma

Clinical use of targeted DNA, RNA, and protein analysis in cutaneous and unknown primary melanomas identifies treatment targets and frequent Co-Occurring driver alterations

Cell Free DNA BRAF (cfBRAF) Mutation V600 Plasma Detection in Melanoma: NCCTG N0879 (Alliance)

Family History of Cancer in Patients Diagnosed with Melanoma

The prevalence of somatic BRAF and NRAS mutations in dermoscopic subtypes of acquired naevi

Prediction of malignant potential of naevi using miRNA biomarkers

Whole-Genome Sequencing in Dutch Melanoma Families

BAP1 mutations prevalence and associated tumour spectrum in a cohort of Australian uveal melanoma cases

The landscape of driver mutations in over 1,000 melanoma exomes

Somatic and Germline TERT Events are Frequent in Acral Melanoma
**P05, Immunology**

- Enhancing Immunotherapy with radiotherapy and topical treatments - Case report
- Regulation of the cytotoxic immune response by the presence of normal and melanoma-associated fibroblasts
- Understanding the impact of immunotherapy side effects on quality of life of patients with stage IV melanoma not on clinical trial: 'Real world' data to inform supportive care interventions
- Inhibition of melanoma cell derived prostaglandin E2 amplifies T cell receptor signaling and shows clinical efficacy in combination with anti-PD1 therapy
- Successful reinstitution of nivolumab in combination with corticosteroids for metastatic malignant melanoma with diverse immune-related adverse events including severe hemolytic anemia

**P15, Immunotherapy**

- Preliminary results of a Phase 1b/2 study of PV-10 and pembrolizumab in Stage IV melanoma
- Response of melanoma cells to immune activity
- The oncolytic effect of ECHO-7 virus on cell viability in vitro
- Does time to switch in immunotherapy sequential strategy impact immunotherapy efficacy: results from the French cohort MelBase
- Biodistribution and Shedding of Talimogene Laherparepvec (T-VEC) in Patients (Pts) With Unresectable Stage IIIB/IV Melanoma
- Anti PD-1 therapy induced pancreatic atrophy and its clinical significance
- Older age may predict a higher response rate to anti PD-1 therapy in metastatic melanoma patients
- Dissecting and deactivating immunosuppressive signals at metastatic lymphovascular sites
- Phase Ic Trial of Intralesional OrienX010 Oncolytic Viral Therapy Into Liver Metastases Among Melanoma Patients
- Antibody profiling of melanoma patients undergoing immunotherapy with checkpoint inhibitors
- Generic strategy to model tumour antigens and T-cell based immunotherapies in melanoma
- Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma
- Quantitative analysis of immune profiles of metastatic melanoma patients reveals biomarkers of response and resistance to combined anti-CTLA-4 and anti-PD-1 immunotherapy
c-MET dependent neutrophil responses limit ACT immunotherapy of melanoma

Monitoring patient response to Pembrolizumab with peripheral blood immune profiles

Effective Immuno Gene Therapy via the Delivery of Plasmids Encoding Cytokines as a Potential Treatment of Melanoma

DNA pattern recognition receptor activation after plasmid gene therapy in melanoma and other tumor cell types

Using Mass Cytometry to assess CD8 T cell phenotype during melanoma relapse on anti-PD1 treatment

Identification of Gene Signatures Predicting Response to PD1 Immunotherapy in 54 Metastatic Melanoma Patients

Inhibitors of the renin-angiotensin system could negatively impact survival benefit from ipilimumab/nivolumab combination but not from ipilimumab monotherapy

Clinical activity and safety of ipilimumab for metastatic uveal melanoma: the St Bartholomew's Hospital experience

Real life outcome of patients with advanced melanoma after discontinuation of a PD-1 inhibitor in the absence of disease progression or treatment limiting toxicity

The efficacy of concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): Protocol for a multicenter phase II open label study

Distinct genomic alterations in patients with advanced melanoma treated with anti-PD-1 therapy

A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV Melanoma: Trial in Progress

Immune phenotypic analysis of NK cells in predicting anti-PD-1 therapy

Pembrolizumab (PEM) utilization and overall survival (OS) for patients with advanced melanoma: the real world US experience

Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis

BRAF ± MEK inhibition following pembrolizumab (pembro) in KEYNOTE-006

Pre-clinical evaluation of vectorized therapies combined with an anti-CTLA4 antibody in murine xenografted-models in melanoma

Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia.

Widely Metastatic Uveal Melanoma Responding to Combination Immune Therapy and Focal Radiotherapy after Pembrolizumab Failure

SALVO: Single Arm Phase II Study of IpiLimumab and NiVOLUMab as Adjuvant Therapy for Management of Rheumatological Immune Related Adverse Events in Melanoma Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies

An immunogenic personalized neoantigen vaccine in patients with high risk melanoma

Exploring Lenalidomide in both inhibiting proliferation and blocking PDL1 signals in melanoma cells: a preclinical study
A Time and Motion Study of Patients Treated with Pembrolizumab and Nivolumab in Australia.

Real World data on the Safety and Efficacy of anti-PD-1 antibodies in the Elderly Population with Metastatic Melanoma

Real world Efficacy and Toxicity of Combined Nivolumab and Ipilimumab in patients with Metastatic Melanoma

Autophagy Drives Resistance to PD-1 Blockade in Melanoma

Combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in melanoma pts

The peripheral blood TCR repertoire might facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma

A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic melanoma

A case of anti-PD1 induced hepatitis associated with corticosteroid resistant T cells

Inhibition of melanoma cell derived prostaglandin E2 amplifies T cell receptor signaling and shows clinical efficacy in combination with anti-PD1 therapy

A Phase II study of JS001, a Humanized IgG4 mAb Against Programmed Death-1 (PD-1) in Patients with Advanced Acral and Mucosal Melanoma

Quantifying the treatment-free interval after first-line immuno-oncology (IO) treatment of advanced melanoma

Benefit of the Nivolumab and Ipilimumab combination in pretreated advanced melanoma

Paradoxical reduced response to combined PD-1/CTLA-4 blockade in low tumor burden melanoma

Access to immunotherapy for treatment of metastatic melanoma in the Netherland and Australia: a tale of two countries

High-dose corticosteroids do not prevent lymphocyte proliferation or IL-2 production after stimulation with pembrolizumab

The role of chemotherapy after immunotherapy resistance in melanoma

Durable complete responses after cessation of anti-PD-1 monotherapy are associated with undetectable circulating tumour DNA

PD-L1 expression and density of CD8+ T cells in matched brain and extracerebral metastases are highly concordant

Profound inflammation-mediated change to the immunopeptidome of melanoma

The incidence of basal cell carcinoma is reduced in patients on anti-Programmed cell death-1 therapy for metastatic melanoma

Poster
08:00 - 18:30
Poster Exhibition

P06, Keratinocyte Cancers & Merkel Cell Carcinoma

Squamous cell carcinoma in the caruncle during Vemurafenib treatment - case report
Proposal for randomised controlled trial (RCT) of immunotherapy combined with wide field radiotherapy versus wide field radiotherapy alone in stage IA-IIC Merkel Cell Carcinoma (MCC)

Recurrence rates of lesions treated with curettage and cautery in a busy multi-practitioner dermatology practice in Brisbane, Australia.

Sentinel lymph node biopsy in clinically node negative Merkel cell carcinoma - Westmead Hospital, Sydney experience

Primary Merkel cell carcinoma of the earlobe in a young, healthy adult male

Solitary nodule on the face

Basal Cell Carcinoma detection through transfer learning in dermoscopy images using a convolutional neural network

Squamous cell carcinoma of the nail unit: A retrospective review of 14 cases and our proposal for surgical management

Omega-3 fatty acid intake and cutaneous squamous cell carcinoma in organ transplant recipients

A retrospective analysis of wide local excision for Merkel cell carcinoma: a single-center series of 11 patients

Epidermal clonal proliferative response upon UVB irradiation is bimodal

Case report of a patient with metastatic basal cell carcinoma: mixed response to vismodegib therapy

Comparison of primary Merkel cell carcinoma (MCC) and melanoma T-cell immuno-profile and PD-L1 expression by multi-spectral immunohistochemistry (mIHC)

Performance comparison of PD-L1 antibody clones 28-8 and 22C3 in stage III and IV metastatic melanoma samples: A tissue microarray study

Genetic variation in IRF4 expression modulates growth characteristics, pigmentation and interferon-gamma response in melanocytic cells

Frequency of BRAF V600 mutation in 354 locally advanced or metastatic melanoma patients from an academic center in Argentina. The apple does not fall very far from the tree.

Cinat, Gabriela (Buenos Aires, Argentina)

MiR-149 Function as a Tumor Suppressor in Mucosal Melanoma

Focal perinuclear cytoplasmic BAP1 is associated with high impact mutations in uveal melanoma

Natural genetic variation controlling propensity for an individual’s melanocytes to transform after UVR exposure

Detection, molecular profiling and culture of CSF-CTCs in leptomeningeal disease (LMDz) in melanoma
The ATM Ser49Cys variant is defective for DNA damage and senescence signalling

COMBI-i: A phase 3 study of the anti-PD1 antibody PDR001 in combination with dabrafenib (D) and trametinib (T) in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma

A novel signalling pathway ACTN4-RIPK1-NF-κB in regulating melanoma cell proliferation

Dissecting molecular and genetic determinants of UV response using iPSC based melanocyte models

Site-specific phosphorylation of the EMT-inducing molecule Y-box binding protein 1 regulates tumourigenicity and invasiveness of human melanoma cells

Pigment-producing melanocytes as the cells of origin of cutaneous melanoma

Identification of TERT, BRAF and NRAS hotspot mutations from formalin fixed and circulating tumour DNA of melanoma samples through highly sensitive ddPCR assay in melanoma

Growth factor activation of melanoma cell signalling pathways

In-depth Proteomic Profiling of Uveal Melanoma Exosomes

Evaluation of the transcriptome of large/giant congenital melanocytic nevi

Notch signaling in mouse melanoma tumor development and drug resistance of human metastatic melanoma cells

Wnt-dependent regulation of Sox10 expression in melanoma development

Functional testing of MTAP haplotypes demonstrates differential expression, signalling and pigmentation effects in primary melanocytic cells

RPS3 fucosylation in melanoma cell biology

Subcutaneous Cellular Nodule and Pigmented Epithelioid Melanocytoma on the Ipsilateral Upper Arm associated with Plaque-type Blue Nevus on the Hand

Roles of Wnt signaling in melanoma pathogenesis

---

**P07, Oncology**

Real world data on intensive follow-up for stage IV metastatic melanoma patients receiving combination ipilimumab and nivolumab: a safer model of care?

Case report: vemurafenib-induced facial edema

Effective in vivo targeting of neo-antigens to Clec9A+ cross-presenting dendritic cells to improve personalized immunotherapy of melanoma

Ipilimumab is not active in Japanese patients with nivolumab-refractory melanoma

Topical diphencyprone for the treatment of in transit melanoma metastases of the skin: Long-term outcomes & management suggestions

Incidence of hypophysitis in patients with melanoma undergoing adjuvant ipilimumab 10mg/kg - a single center experience
**Scientific Programme**

If you are going to pay for it, do it on time

Real world PD-1 immunotherapy related side effects in metastatic melanoma, an Australian regional cancer centre experience

Outcomes on Central Nervous System irradiation for melanoma brain metastasis: 10-year experience in a developing country institution

The combination of BRAFi and MEKi: a treatment option for BRAF WT patients?


Toxic epidermal necrolysis associated with combination immunotherapy with nivolumab and Ipilimumab for advanced metastatic melanoma

Patient derived organotypic slice cultures for preclinical profiling of human BRAF wildtype melanomas

Two cases of trametinib-induced rhabdomyolysis of Japanese melanoma patients treated by dabrafenib and trametinib combination therapy

Successful neoadjuvant therapy of BRAF and MEK inhibition for inoperable stage 3 metastatic Melanoma (Withdrawn)

**Poster**

08:00 - 18:30

**Poster Exhibition**

**P20, Others**

An 18-year study of Paediatric Malignant Melanoma at Morriston Hospital

Detailed FACS, migration, and invasion assay analyses of MeLiM melanoma model

Phenotypic and molecular characterisation of Circulating Tumour Cells isolated from metastatic melanoma patients using a microfluidic device

Epidemiological profile of cutaneous malignant melanoma in Tlemcen (west Algeria): January 2011 to December 2015

Malignant melanoma and psoriasis association: about a case

Metastatic malignant melanoma and vitiligo

Malignant melanoma and psoriasis acrolentigineux

Malignant Melanoma, is dominant at the ends: about a new observation acral

Concordance of Mutations in Circulating Tumour DNA (ctDNA) and Tissue Biopsy in Melanoma

Teledermatology and teledermoscopy as tools to help general practitioners in effective e-triage of suspicious skin lesions prior to dermatology evaluation

Generation and characterization of 90 melanoma patient-derived xenograft models

Preferences for advanced melanoma Immuno-Oncology treatments

Evaluation of commercial kits for extraction of circulating free DNA
Targeted therapy or immunotherapy..."this is the question" in frontline approach to BRAF-mutant melanoma: the challenge of combination immunotherapy.

Precision medicine for melanoma patients: Development of a Melanoma-specific gene panel for integrative molecular tumor boards

Electric field mediated drug and gene delivery provides effective treatment protocols for melanoma

Refining risk models for distant and CNS metastasis in Stage III melanoma

Preclinical validation of a new anti-melanoma compound in B-Raf inhibitors sensitive and resistant cells.

Randomized Phase (ph) II study of Paclitaxel (P), Carboplatin (C), Bevacizumab (B) +/- Everolimus (E) in Metastatic Melanoma (MM): Secondary analysis of outcomes in patients (pts) who harbor NRAS mutation NCCTG NO879 (Alliance).

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

Lee, Rebecca (Manchester, United Kingdom)

A preclinical platform for evaluating targeted therapy and immunotherapy combinations in BRAFV600E melanoma

Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China

Clinical application of various flaps in repair of soft tissue defect in weight-bearing region of foot caused by wide excision of melanoma: our experience after 31 cases

Multifactorial Analysis of Prognostic Factors And Survival Rates Among 706 Mucosal Melanoma Patients

Evolution of treatment patterns for advanced melanoma in US oncology clinical practices: an observational study

A significant interaction between sex and UV index in melanoma risk

Long-term survival outcome of patients with thin (T1) cutaneous melanomas: a naturally-occurring, biologically-relevant Breslow thickness cutpoint of 0.8mm separates higher risk from lower risk tumors

Optimization of spiral microfluidics for melanoma cell isolation

Clinical and molecular associations of body mass index (BMI) in regional melanoma metastases

Fortune Cookie Flap: New option to cover the defect

The burden of Non-Melanoma skin cancers in Auckland, New Zealand

Psychosocial outcome, neurocognitive functioning (NCF) and quality of life (QoL) in advanced melanoma survivor

US guided wire localization of malignant melanoma subcutaneous metastases

Sentinel node biopsy status is strongly predictive of survival in cutaneous melanoma: Extended follow-up of 1,527 Oxford patients from 1998-2014.

Predicting the development and timing of subsequent primary melanomas in a population-based Australian cohort
Iris freckling as a marker of cutaneous melanoma risk: a case-control study

Classifying dermoscopic patterns of naevi in a case-control study of melanoma

Dermoscopic features of Vulvar Intraepithelial Neoplasia

Modelling terahertz radiation absorption and reflection with computational phantoms of skin to aid melanoma diagnosis and management

The neutrophil-lymphocyte and platelet-lymphocyte ratios for surveillance in cutaneous melanoma

Acral melanoma (AM) demonstrates distinct clinical pattern and worse prognosis compared with non-acral cutaneous melanoma (NACM): a prospective analysis of 1461 cases

Poster
08:00 - 18:30
Poster Exhibition

P08, Pathology

Anorectal melanoma, a case series of patients from the Melanoma Institute of Australia (MIA)

Review article: Role of beta catenin in melanoma

A case of Spitz nevus: differential diagnosis from melanoma

Poster
08:00 - 18:30
Poster Exhibition

P09, Prevention & Health Economics

How does skin cancer risk perception influence sun-exposure behaviours in Australian adults?

At a glance: The role of vitamin D in melanoma

Connecting design and health professionals for skin cancer prevention: a novel, sustainable approach in Queensland, Australia

Photoaging smartphone apps for skin cancer prevention in German adolescents: the Sunface randomized trial

The sunscreen and young children (SAY) pilot study

New technologies in skin cancer prevention

Teledermoscopy for skin cancer - what do dermatologists want to be paid to perform a simple consultation?

Utility-based quality of life in melanoma patients: Preliminary findings from the Whole Brain Radiotherapy (WBRT) trial
Scientific Programme

Poster
08:00 - 18:30
Poster Exhibition

P10, Surgical Issues

- Total lymph node yield as a marker of quality assurance in axillary lymphadenectomy for metastatic melanoma
- Interval sentinel node drainage as a predictor factor in melanoma patients
- Clinical behavior and prognostic in patients with head and neck cutaneous melanoma who underwent sentinel node biopsy
- Invasive melanoma with preoperative diagnosis of melanoma in situ
- Subungual Melanoma of the Hand
  - A protocol for the safe use of patent blue V dye in sentinel node biopsy
- Management of primary cutaneous melanoma: A retrospective audit of 887 cases and review of current clinical guidelines
- Sentinel lymph node biopsy for cutaneous melanoma in elderly patients: the Cambridge experience
- Initial experience in the UK with use of (99mTc) Tilmanocept (a novel radiopharmaceutical) for sentinel lymph node biopsy (SLNB) for malignant melanoma
- Patterns of care for regional biopsies and nodal surgery for melanoma treatment in Queensland
- Mini-invasive subcutaneous lymphangiectomy in patients with skin melanoma
- Sentinel lymph node biopsy for cutaneous versus mucosal melanoma in the anorectal region: two case reports
- Giant melanoma of the scalp without metastases: a case report
- Augmentation of venous drainage of the paramedian forehead flap by inclusion of a superficial vein: an anatomical and radiological study
- Shave versus elliptical biopsy for melanoma substantially increases re-excision area and scar length
- Importance of ulceration and mitoses in the selection of patients for sentinel lymph node biopsy in thin cutaneous melanoma? A study based on the Swedish Melanoma Register and the Melanoma Institute Australia Research Database
- Venous free flap reconstruction of fingers and toes in subungual melanoma
- A safe way to reduce length of hospital stay following lymph node dissection for cutaneous malignancy nodal metastasis
- Treatment of melanoma in situ with erbium: YAG laser
- Results of sentinel lymph node biopsy in thin (Breslow < 1mm) cutaneous melanoma of trunk and extremities
- Video-assisted inguinal lymphadenectomy in melanoma
- The Circumferential Aligned Lateral Advancement with Fasciectomy (CALS) flap: A straightforward reconstruction technique for melanoma of the leg following wide local excision
- Surgical treatment of acral melanoma
Surgical management of cutaneous malignant melanoma - current status
Lymph node dissection guided by indocyanine green fluorescence for cutaneous melanoma
Adherence to surgical melanoma guidelines in New South Wales of all newly diagnosed melanomas over a one-year period
Management of dysplastic vaevi: An international perspective (withdrawn)
The keystone perforator island flap in the management of large melanoma defects including groin dissections

**Poster**
08:00 - 18:30
Poster Exhibition

**P17, Targeted Therapy**

- Incidental Perineural Invasion in Keratinocyte cancer (KC): A prospective analysis of the incidental Perineural Invasion (PNI) registry with a five year follow up in Queensland

- Real life targeted therapies alone or in combination in brain metastases patients: French experience within MelBase

- Possible immune adverse-events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma

- Preclinical efficacy of the DLL3-targeted antibody drug conjugate Rovalpituzumab tessirine in metastatic melanoma
  Williams, Sam (San Francisco, United States)

- Role of miR-193a as therapeutic agent and biomarker in cutaneous melanoma

- Identification of Molecular Signatures Associated with Response to MAPK Inhibitors in Metastatic Melanoma
  Stagni, Camilla (Padova, Italy)

- A Prospective Observational Safety Study of Patients (pts) With BRAFV600-Mutated Unresectable or Metastatic Melanoma (mM) Treated With Vemurafenib (VEM) (Zelboraf Safety Study [ZeSS]): Final Results
  Colburn, Dawn

- Induction of ER stress augments apoptotic and immunogenic responses in melanoma cells

- Combination of EGFRi and METi - a new targeted therapeutic strategy for melanoma

- Extended follow-up results of a phase 1b study (BRIM7) of cobimetinib (C) combined with vemurafenib (V) in BRAFV600-mutated melanoma
  McArthur, Grant (Melbourne, Australia)

- Combination BRAF/MEK inhibitors for melanoma with active brain metastases: A real-world multi-center experience

- HDAC inhibition reverses adaptation to MEK inhibitor therapy in uveal melanoma: a systems level proteomic study

- Investigating the sensitivity of RAC1 mutated melanomas to PI3K pathway inhibition

- V600EBRAF melanoma cell response to vemurafenib and trametinib is not affected by exogenous growth factors bFGF, EGF and HGF in vitro
Scientific Programme

A phase I/II study of pembrolizumab and imatinib in patients with locally advanced/metastatic melanoma with c-KIT mutation or amplification

BRAF inhibitor treatment in the oldest old metastatic melanoma patients

Deciphering the role of PREX and PI3K signalling in melanoma

Differential effects on immune activity after Neoadjuvant MAPK pathway inhibition in stage III melanoma patients

Efficacy and Safety Analysis of Imatinib in 78 Advanced Melanoma Patients Harboring KIT Aberrations

CDK4 inhibition synergizes with BRAF and MEK inhibition in treatment naïve melanoma cells but not after the development of BRAF inhibitor resistance

Clinical and biologic associations of body mass index (BMI) with survival in patients (pts) with BRAFV600-mutated metastatic melanoma (MM) treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib + vemurafenib (C+V)

Identification of actionable survival pathways in BRAF/NRAS wild type melanomas

Rose Bengal melanoma therapy - phototoxicity versus intrinsic cytotoxicity

Real-world data in a new-era of targeted and immuno-oncology treatment (Tx) of Metastatic Melanoma (MM) patients (pts)

Cobimetinib + atezolizumab versus pembrolizumab in patients with previously untreated, advanced, BRAFV600 wild-type melanoma: phase 3 IMspire 170 study

Gogas, Helen

ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment.

A Phase Ib study of AEB071, a PKC inhibitor, and BYL719, a PI3Kα inhibitor, in Patients with Metastatic Uveal Melanoma (UM)

Activity of the ERK1/2 inhibitor Ulixertinib in patients with BRAF and NRAS mutant melanoma

BRAF mutant metastatic melanoma - stopping treatment after complete response?

Elevated BRAFV600 mutant circulating tumor DNA (ctDNA) and circulating hepatocyte growth factor (cHGF) are associated with poor prognosis in patients with metastatic melanoma

A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma

In vitro study in exploring the critical mediator involved in Vemurafenib resistance

Inhibition of mitochondrial oxidative phosphorylation overcomes de novo and acquired resistance to MAPK pathway inhibitors

Poster
08:00 - 18:30

P11, Treatment & Follow-up

Poster Exhibition
Scientific Programme

Pregnancy associated multiple melanoma: A case study of nine primary melanomas in a young female patient

Sweet's syndrome associated with ipilimumab in a patient with metastatic melanoma

Clinical trial recruitment and management of melanoma patients who live a long-distance from a tertiary referral centre

A case of malignant melanoma histologically similar to lentigo maligna melanoma of the back, BRAF wild-type, developed on thermal burn

Kissing naevus of the penis: report of two cases

The prognosis of malignant melanoma in the lower extremities and mechanical stress point on the plantar surface of the foot

Neutrophilus - lymphocytes reason in the survey prognosis in patients with maligno cutaneo melanomanational institute of neoplastic diseases 2005-2012

Primary melanoma of lacrimal sac-- Report of a rare case

Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti PD-1

Laser treated agminated melanocytic nevi and the potential for malignant transformation

Poster
08:00 - 18:30

P18, Tumour Heterogeneity and Plasticity

Highly multiplexed single-cell protein analysis of melanoma FFPE samples

Convergent evolution in therapy naive human melanoma.

In-depth molecular and immune characterization of melanoma with heterogeneous PTEN expression

Role of JARID1B expression in radiation resistance in melanoma cells

Metastatic growth after melanoma dissemination requires MITF and BRN2

BRN2 co-ordinates switching of melanoma cells to an invasive phenotype to promote metastasis and metabolic adaptation to micro-environmental cues

MITF regulates dynamic heterogeneity and structural integrity in melanoma

Melanin pigment and melanoma heterogeneity

Poster
08:00 - 18:30

P19, Tumour Microenvironment

Paracrine Activin-A signaling promotes melanoma growth and mediates tumour immune evasion
Composition or lack of exogenous growth factors do not influence viability and phenotype of drug naive V600EBRAF melanoma cells but it might be crucial for drug-resistant cells

Combined loss of epidermal AMBRA1 and Loricrin is a prognostic biomarker for AJCC stage I melanoma and a companion biomarker for novel targeted therapy

Diversity of fibroblastic populations in the microenvironment of human melanomas

Multiplex immunohistochemistry and flow cytometry provide divergent but complementary insights into the immune context in metastatic melanoma

Immune Cell Profiles in Neoadjuvant Therapy of Advanced Stage III Melanoma

Fucosylation and Immune Surveillance in Melanoma

Tumour-derived exosomes promote the bone tropism of melanoma cells by CXCR7 upregulation

Development of a 3D human metastatic melanoma model for in vitro evaluation of targeted therapy efficiency

Origin of vascular progenitors driving melanoma angiogenesis in vivo


Nanoparticle-based immunotherapy in a humanized mouse melanoma model targeting macrophages in the tumor microenvironment

Metastatic melanoma cells commandeer p53 activity to promote the survival of a therapy resistant subpopulation.

GARP expressing platelets are capable of regulatory T cell induction

**Symposium**
09:40 - 10:40
Great Hall

**SY11, Clinical Diagnosis: Leveraging Technology to Assist in Melanoma Detection**

**Chairs:**
Marghoob, Ashfaq (New York, United States)
Hofmann-Wellenhof, Rainer (Graz, Austria)

- **Why do we need technology to assist in melanoma detection?**
  09:40 - 09:55
  Marghoob, Ashfaq (New York, United States)

- **Computer vision to detect new and changing lesions**
  09:55 - 10:10
  Malvehy, Josep (Barcelona, Spain)

- **Artificial Intelligence to augment cognition: can it lead to automated diagnosis?**
  10:10 - 10:25
  Marchetti, Michael (New York, United States)

- **Beyond the visual: the science and data behind electrical impedance spectroscopy**
  10:25 - 10:40
  Hofmann-Wellenhof, Rainer (Graz, Austria)
**SMR Session**  
09:40 - 10:40  
**Room M4**

**SMR03, Tumour Heterogeneity, Plasticity and Drug Resistance**

*Chairs:*
Haass, Nikolas K. (Brisbane, Australia)

- **Enforced Polarization Towards the JARID1B-high Phenotype and its Effects on Melanoma Cell Growth**  
Roesch, Alexander (Essen, Germany)  
09:40 - 10:00

- **The canonical Wnt Pathway Drives Dynamic Heterogeneity in a 3D Melanoma Model**  
Ahmed, Farzana (Brisbane, Australia)  
10:00 - 10:15

- **Portraying Drug-tolerant State Dynamics and Heterogeneity by Single-cell RNAseq**  
Rambow, Florian (Leuven, Belgium)  
10:15 - 10:30

- **Discussion**  
10:30 - 10:40

---

**Symposium**  
09:40 - 10:40  
**Room M3**

**SY12, Actinic Keratosis: Novel Treatments**

*Chairs:*
Peris, Ketty (Rome, Italy)  
Stockfleth, Eggert (Bochum, Germany)

- **Field-directed treatments in the context of therapeutic algorithms**  
Peris, Ketty (Rome, Italy)  
09:40 - 09:55

- **New insights into photodynamic therapy**  
Fargnoli, Maria Concetta (L'Aquila, Italy)  
09:55 - 10:10

- **The role of nicotinamide**  
Damian, Diona (Sydney, Australia)  
10:10 - 10:25

- **Field directed treatment: what’s new**  
Stockfleth, Eggert (Bochum, Germany)  
10:25 - 10:40

---

**Symposium**  
09:40 - 10:40  
**Room M2**

**SY13, Tackling the Inequalities of Access to New Drugs**

*Chairs:*
Kandolf-Sekulovic, Lidija (Belgrade, Serbia)  
Lorigan, Paul (Manchester, United Kingdom)

- **Inequalities of access to innovative medicines for metastatic melanoma: a global overview**  
Kandolf-Sekulovic, Lidija (Belgrade, Serbia)  
09:40 - 09:50
A patients’ perspective 09:50 - 10:00
Van Gorp, Karen (Adelaide, Australia)

The real price of access issues - a view from both sides 10:00 - 10:10
Andersen, Hayley (Melbourne, Australia)

Pharma industry initiatives for improved access to innovative Medicine 10:10 - 10:20
Spiteri, Carmel (Sydney, Australia)

Panel discussion 10:20 - 10:40

Symposium
09:40 - 10:40
Room M1

SY14, Controversies in Radiotherapy in Melanoma

Chairs:
Bastholt, Lars (Odense, Denmark)
Fogarty, Gerald (Sydney, Australia)

Part 1 - Radiotherapy interactions with new effective systemic therapies in melanoma

Radiotherapy and immunotherapy 09:40 - 09:52
Hong, Angela (Sydney, Australia)

Discussion 09:52 - 09:59
Bastholt, Lars (Odense, Denmark)

An open-label, single-arm, phase I/II, multicentre study to evaluate the safety and efficacy of the combination of dabrafenib, trametinib and palliative radiotherapy in patients with unresectable (stage IIIc) and metastatic (stage IV) BRAF V600E/K mutation-positive cutaneous Melanoma (ANZMTG 02.14 ) 09:59 - 10:09
Wang, Tim (Sydney, Australia)

Discussion 10:09 - 10:16
Fogarty, Gerald (Sydney, Australia)

Part 2 - Currently accruing radiation trials in melanoma

Update on ANZMTG 02.12 RADICAL trial 10:16 - 10:26
Guitera, Pascale (Sydney, Australia)

An international randomised trial of post-operative radiation therapy following wide excision of Neurotropic Melanoma of the head and neck (ANZMTG 01.09 RTN2) 10:26 - 10:33
Foote, Matthew (Brisbane, Australia)

Future international radiotherapy trial collaborations 10:33 - 10:40
Fogarty, Gerald (Sydney, Australia)
Scientific Programme

Plenary Lecture
11:10 - 12:40

Great Hall

PL02, Society for Melanoma Research - Plenary and Award Lectures

Chairs:
Long, Georgina (Sydney, Australia)
McMahon, Martin (Salt Lake City, United States)

Lessons from melanoma genomics for precision oncology
Garraway, Levi (Boston, United States)
11:10 - 11:45

Seeing is believing: imaging and targeting melanoma metastasis
Soengas, Marisol (Madrid, Spain)
11:45 - 12:30

Estela Medrano Award Presentation
12:30 - 12:35

SMR Award Presentations by Keith T. Flaherty
12:35 - 12:40

Satellite Symposium
12:50 - 13:50

Great Hall

SAT03, MSD: Have we Improved Survival in Advanced Melanoma?

Chairs:
Kefford, Rick (Sydney, Australia)

How we improved survival?
Agarwala, Sanjiv (Easton, United States)
12:50 - 13:10

What is on the horizon?
Luke, Jason (Chicago, United States)
13:10 - 13:30

What can we currently offer each of our patients?
Hauschild, Axel (Kiel, Germany)
13:30 - 13:50

Symposium
14:00 - 15:00

Great Hall

SY15, Clinical Diagnosis: Challenging Frontiers in the Clinical Diagnosis of Melanoma

Chairs:
Kelly, John (Melbourne, Australia)
Zalaudek, Iris (Graz, Austria)

The clinical distinction of early lentigo maligna from its precursors and simulatores in sun damaged skin
Zalaudek, Iris (Graz, Austria)
14:00 - 14:15

Post surgical recurrence of pigmented lesions: clinical signs of melanoma versus recurrent naevus
Marghoob, Ashfaq (New York, United States)
14:15 - 14:25
Scientific Programme

Hypomelanotic melanomas - how not to be tricked by the major source of melanoma misdiagnosis
Arzenzano, Giuseppe (Caserta, Italy)

Nodular melanoma - the aggressive melanoma that evades early diagnosis
Kelly, John (Melbourne, Australia)

Discussion

SMR Session
14:00 - 15:00

SMR04, Immune Therapy II

Chairs:
Dummer, Reinhard (Zurich, Switzerland)
Menzies, Alexander (Sydney, Australia)

TGF-β dominant negative receptor (TGF-DNRII) and NGFR-transduced tumour infiltrating lymphocytes (TIL) and high dose interleukin-2 (IL-2) in patients (pts) with metastatic melanoma (MM)
Amaria, Rodabe (Houston, United States)

A phase II multicentre trial of HF10, oncolytic virus immunotherapy, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma
Andtbacka, Robert (Salt Lake City, United States)

Talimogene Laherparepvec (T-VEC) and Intratumoral CD8+ Density in Patients (Pts) with Unresectable Stage IIIB-IVM1c Melanoma: Interim Efficacy, Safety and Biomarker Results of a Phase 2 Study
Malvehy, Josep (Barcelona, Spain)

Low Tumour Heterogeneity but not Mutational Burden Correlates with Response to Anti-PD-1 Treatment in a Mouse Model of Melanoma
Galvani, Elena (Manchester, United Kingdom)

Symposium
14:00 - 15:00

SY16, Treatment of Basal Cell Carcinoma – Successes and Opportunities

Chairs:
Hoeller, Christoph (Vienna, Austria)
Sekulic, Aleksandar (Scottsdale, United States)

Molecular landscape of basal cell carcinoma
Khosrotehrani, Kiarash (Brisbane, Australia)

Topical treatment of basal cell carcinoma
Stockfleth, Eggert (Bochum, Germany)
Scientific Programme

Hedgehog pathway inhibitors 14:16 - 14:29
Sekulic, Aleksandar (Scottsdale, United States)

Management of side effects of hedgehog inhibitors 14:29 - 14:37
Puig, Susana (Barcelona, Spain)

Beyond hedgehog pathway inhibitors 14:37 - 14:50
Hoeller, Christoph (Vienna, Austria)

Discussion 14:50 - 15:00

Satellite Symposium
14:00 - 15:00 Room M2

SAT04, Roche: Meet the Expert: Optimising Treatment with Targeted Treatment in the Evolving Melanoma Landscape

Chairs:
Atkinson, Victoria (Brisbane, Australia)
McArthur, Grant (Melbourne, Australia)

Science of targeted and immunotherapies: sequencing and combination 14:00 - 14:15
Flaherty, Keith T. (Boston, United States)

Case presentation 14:15 - 14:30
Mason, Robert (Nambour, Australia)

Patient case and debate 14:30 - 14:45
Robert, Caroline (Villejuif, France)

Patient case and debate 14:45 - 15:00
Daud, Adil (San Francisco, United States)

Free Communication
14:00 - 15:00 Room M1

FC04, Genetics and Genomics

Chairs:
Stark, Mitchell (Brisbane, Australia)

System biology approach of molecular landscape and identification of theranostic epigenetic drivers of melanoma brain metastasis 14:00 - 14:10
Hoon, Dave (Santa Monica, United States)

ICGC Brazilian melanoma genoma project 14:10 - 14:20
Vazquez, Vinicius (Barretos, Brazil)

Phenotypic and genotypic analysis of multiple primary melanoma patients 14:20 - 14:30
McMeniman, Erin (Brisbane, Australia)
Characteristics of melanoma patients from Brisbane, Australia and Tübingen, Germany: phenotypic and genotypic comparisons of two melanoma cohorts  
14:30 - 14:40  
Pflugfelder, Annette (Brisbane, Australia)

Point mutation in p14ARF-specific exon 1β of CDKN2A causing familial melanoma and astrocytoma  
14:40 - 14:50  
McInerney-Leo, Aideen (Brisbane, Australia)

Molecular characterisation of large or giant congenital melanocytic naevi  
14:50 - 15:00  
Puig-Butillé, Joan Anton (Barcelona, Spain)

SMR Session  
15:10 - 16:10  
Room M4

SMR05, Targeted Therapies

Targeted therapy in melanoma: response and resistance  
15:10 - 15:30  
Rizos, Helen (Sydney, Australia)

PACMEL: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in Advanced BRAF wild type melanoma  
15:30 - 15:45  
Coupe, Nicholas (Oxford, United Kingdom)

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms  
15:45 - 16:00  
Teh, Jessica (Philadelphia, United States)

Discussion  
16:00 - 16:10

Symposium  
15:10 - 16:10  
Room M3

SY17, Advances in Merkel Cell Carcinoma

Welcome and introduction  
15:10 - 15:12  
Ngheim, Paul (Seattle, United States)

Early studies of Merkel cell carcinoma: challenges and progress  
15:12 - 15:20  
Leonard, Helen (Brisbane, Australia)

Genetic basis of virus-positive and virus-negative MCC: both can be immunogenic  
15:20 - 15:30  
Tothill, Richard (Melbourne, Australia)

Immune escape mechanisms in Merkel cell carcinoma  
15:30 - 15:40  
Becker, Jürgen (Essen, Germany)
**Scientific Programme**

**Immunotherapy for MCC: progress and problems**  
Nghiem, Paul (Seattle, United States)  
15:40 - 15:50

**Discussion**  
15:50 - 16:10

**Symposium**  
15:10 - 16:10  
Room M2

**SY18, Brain Metastases**

**Chairs:**  
Foote, Matthew (Brisbane, Australia)  
Meier, Friedegund (Dresden, Germany)

- **Optimising surgical resection in melanoma brain metastases**  
  Olson, Sarah (Brisbane, Australia)  
  15:10 - 15:25

- **Radiosurgery and radiotherapy for melanoma brain metastases in the targeted era**  
  Foote, Matthew (Brisbane, Australia)  
  15:25 - 15:40

- **Targeted therapy and immunotherapy**  
  Meier, Friedegund (Dresden, Germany)  
  15:40 - 15:55

- **Managing leptomeningeal metastases in the era of BRAF/MEK inhibitors and immune checkpoint inhibitors**  
  Giltza Oliva, Isabella Claudia (Houston, United States)  
  15:55 - 16:10

**Free Communication**  
15:10 - 16:10  
Room M1

**FC05, Biology and Biomarkers**

**Chairs:**  
Gabrielli, Brian (Brisbane, Australia)  
Schaider, Helmut (Brisbane, Australia)

- **Rab27a promotes melanoma invasion via regulation of exosomes**  
  Beaumont, Kimberley (Sydney, Australia)  
  15:10 - 15:20

- **Growing or going? - The role of WNT signalling in melanoma**  
  Falschlunger, Julia (Zurich, Switzerland)  
  15:20 - 15:30

- **Clinical immune monitoring and biomarker data of pIL-12 monotherapy compared to pIL-12 with pembrolizumab in metastatic melanoma supports the rationale for combination therapy**  
  Algazi, Alain (San Francisco, United States)  
  15:30 - 15:40

- **Melanoma antigens are biomarkers for immunotherapy response**  
  Arenbergerova, Monika (Praha, Czech Republic)  
  15:40 - 15:50
Utility of monitoring cell-free DNA and circulating tumour cells in melanoma patients receiving checkpoint inhibitor immunotherapy and surgery
Hoon, Dave (Santa Monica, United States)

Identification of thin fatal melanomas, at first diagnosis, by a gene-signature based risk score
Brunner, Georg (Bönen, Germany)

Symposium
16:40 - 18:10
Great Hall

SY19, Public Health, Prevention and Epidemiology: Debate - Detection of Melanoma: the Earlier the Better!

Chairs:
Kelly, John (Melbourne, Australia)
Whiteman, David (Brisbane, Australia)

The case for and against "Detection of melanoma; the earlier the better!" will be presented by the following speakers:
Bell, Katy (Sydney, Australia)
Halpern, Allan C. (New York, United States)
Soyer, H. Peter (Brisbane, Australia)
Weyers, Wolfgang (Freiburg, Germany)

Challenging scenarios and clinical situations will be presented to the speakers plus questions from the audience
Kelly, John (Melbourne, Australia)
Whiteman, David (Brisbane, Australia)

SMR Session
16:40 - 18:10
Room M4

SMR06, Genetics and Genomics

Chairs:
Hayward, Nick (Brisbane, Australia)

Genomics and transcriptomics of youth melanoma
Wilmott, James (Sydney, Australia)

Comprehensive single-cell RNA-seq Analysis of immunotherapy-resistant melanoma patients
Izar, Benjamin (Boston, United States)

Whole exome sequence analysis of melanoma patients and unaffected controls with low and high naevus count
Sturm, Richard (Brisbane, Australia)

Integrative Genomic and Transcriptomic Analysis of Melanomas and their Precursor Lesions
Shain, Alan (San Francisco, United States)
Actionable kinase fusions are frequent in pan-negative melanoma  
Couts, Kasey (Aurora, United States)  
17:45 - 18:00

Discussion  
18:00 - 18:10

Satellite Symposium  
16:40 - 17:40  
Room M3

SAT05, Novartis: Translating Data into Clinical Practice in BRAF V600-Mutant Melanoma: A Case-Based Discussion  
Chairs:  
McArthur, Grant (Melbourne, Australia)

Welcome and close  
McArthur, Grant (Melbourne, Australia)

Case-based discussion  
Neyns, Bart (Brussels, Belgium)  
Saw, Robyn (Sydney, Australia)

Symposium  
16:40 - 18:10  
Room M2

SY20, Australia and New Zealand Melanoma Trials Group  
Chairs:  
Burmeister, Bryan (Brisbane, Australia)  
Shackleton, Mark (Melbourne, Australia)

ANZMTG - the need for investigator initiated research in melanoma  
Shackleton, Mark (Melbourne, Australia)  
White, Paul (Melbourne, Australia)  
16:40 - 16:50

A phase II study of nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases with a presentation of the interim analysis and trial results (ANZMTG 01.14 ABC)  
Long, Georgina (Sydney, Australia)  
16:50 - 17:05

Psycho-educational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma: results of a randomised controlled trial  
Cust, Anne (Sydney, Australia)  
Dieng, Mbathio (Sydney, Australia)  
17:05 - 17:20

Update on randomised trial of whole brain radiotherapy in melanoma brain metastases (ANZMTG 01.07/TROG 08.05)  
Fogarty, Gerald (Sydney, Australia)  
17:20 - 17:35

A randomised trial of excision margins for melanoma (ANZMTG 03.12 MelMarT)  
Moncrieff, Marc (Norwich, United Kingdom)  
17:35 - 17:50
Scientific Programme

**High dose vitamin D following primary treatment of melanoma at high risk of recurrence: A pilot placebo controlled randomised phase II trial assessing feasibility, safety and toxicity (ANZMTG 02.09 MEL-D)**
Saw, Robyn (Sydney, Australia)

**Discussion**

Symposium
16:40 - 18:10  Room M1

**SY21, Surgical Oncology: Management of Stage III Metastatic Melanoma**

**Chairs:**
Coit, Daniel (New York, United States)
Ross, Merrick (Houston, United States)

- **Update of the results from the Multicentre Selective Lymphadenectomy Trial II**
  Faries, Mark (Santa Monica, United States)

- **The German Dermatologic Cooperative Oncology Group study of completion lymphadenectomy compared with observation**
  Stadler, Rudolf (Minden, Germany)

- **Natural history of patients with a positive sentinel node followed with active surveillance**
  Coit, Daniel (New York, United States)

- **Experience with neoadjuvant therapy for patients with advanced nodal metastases**
  Ross, Merrick (Houston, United States)

- **Who, if anyone, with a positive sentinel node should get an immediate completion lymph node dissection?**
  Ross, Merrick (Houston, United States)
SY22, Medical Oncology: What’s New in Targeted Therapies

Chairs:  
Ascierto, Paolo (Napoli, Italy)  
Flaherty, Keith T. (Boston, United States)

- **New targets beyond MAP kinase pathway signalling** 08:00 - 08:15  
  Flaherty, Keith T. (Boston, United States)
- **Immunological effects of BRAF and MEK inhibition** 08:15 - 08:30  
  Ascierto, Paolo (Napoli, Italy)
- **Immunological effects of CDK4i** 08:30 - 08:45  
  McArthur, Grant (Melbourne, Australia)
- **Discussion** 08:45 - 09:00

SMR07, Epigenetics and Metabolism

Chairs:  
Holmen, Sheri (Salt Lake City, United States)

- **A ’Welcome Stranger’ to cancer immunology** 08:00 - 08:20  
  Dawson, Mark (Melbourne, Australia)
- **Redox imbalance mediates MAPKi-Resistance via UPR-Induced autophagy in metastatic melanoma** 08:20 - 08:35  
  Kapoor, Somya (Iowa City, United States)
- **Epigenetic Regulator SATB2 Leads to Metastatic Behaviour in Melanoma** 08:35 - 08:50  
  Fazio, Maurizio (Boston, United States)
- **Discussion** 08:50 - 09:00

SY23, International Guidelines Development

Chairs:  
Garbe, Claus (Tuebingen, Germany)  
Thompson, John (Sydney, Australia)

- **The case for strictly evidence-based guidelines - the German example** 08:00 - 08:07  
  Garbe, Claus (Tuebingen, Germany)
Scientific Programme

**The case for consensus-based guidelines - the NCCN guidelines in the US**
Coit, Daniel (New York, United States) 08:07 - 08:14

**The UK (NICE) Guidelines**
Peach, Howard (West Yorkshire, United Kingdom) 08:14 - 08:21

**Decisional forces charts**
Grob, Jean-Jacques (Marseille, France) 08:21 - 08:28

**New Australian Wiki-based guidelines**
Thompson, John (Sydney, Australia) 08:28 - 08:35

**Establishment of an international data resource for melanoma guideline development**
Garbe, Claus (Tuebingen, Germany) 08:35 - 08:42

**Discussion** 08:42 - 09:00

**Symposium**
08:00 - 09:00  Room M2

**SY24, Treatment of Advanced Squamous Cell Carcinoma**

**Chairs:**
Guminski, Alexander (Sydney, Australia)
Stratigos, Alexandros (Athens, Greece)

**Risk classification of cutaneous SCC**
Stratigos, Alexandros (Athens, Greece) 08:00 - 08:15

**Clinical implications of translational research and mutation analysis in SCC**
Proby, Charlotte (Dundee, United Kingdom) 08:15 - 08:30

**Systemic therapy of advanced SCC**
Guminski, Alexander (Sydney, Australia) 08:30 - 08:40

**New approaches in the treatment of advanced SCC (immunotherapy)**
Hauschild, Axel (Kiel, Germany) 08:40 - 08:50

**Discussion** 08:50 - 09:00

**Free Communication**
08:00 - 09:00  Room M1

**FC06, Prevention and Health Economics**

**Chairs:**
Morton, Rachael (Sydney, Australia)
Gordon, Louisa (Brisbane, Australia)
Scientific Programme

08:00 - 08:10
The melanoma genomics Managing Your Risk Study: a randomised controlled trial of an innovative behaviour change intervention to improve melanoma prevention in the Australian general population
Cust, Anne (Sydney, Australia)

08:10 - 08:20
Personalised melanoma risk assessments and tailored prevention advice on sun protection behaviours: a randomised controlled trial in Australian general practice
Cust, Anne (Sydney, Australia)

08:20 - 08:30
Photoaging smartphone apps: a novel opportunity for melanoma prevention?
Brinker, Titus (Essen, Germany)

08:30 - 08:40
Multiplicity of skin cancers in Queensland and their cost burden to government and patients
Elliott, Thomas (Brisbane, Australia)

08:40 - 08:50
A systematic review and meta-analysis of preference-based (utility) estimates in melanoma
Tran, Anh (Sydney, Australia)

08:50 - 09:00
Clinical and economic evaluation of ipilimumab for metastatic melanoma in Brazil: a public health system perspective
Conceicao, Vinicius Correa (Campinas, Brazil)

Miscellaneous
08:00 - 18:00
Mezzanine Foyer

Industry Exhibition

Poster
08:00 - 18:00
Poster Exhibition

P01, Biology & Biomarkers

Nortriptyline can induce cytotoxic effect and autophagy on human melanoma cells (A2058)
The role of neuronal nitric oxide synthase (nNOS) in interferon-gamma-induced melanoma progression
A gene-signature based risk score significantly improves melanoma relapse prediction in synergy with sentinel lymph node status
Targeting cell cycle phase-specific drug sensitivity for melanoma therapy
Serum doublecortin like kinase 1 (DCLK1) levels measured by ELISA correlate with disease status, and pre-treatment levels predict for therapeutic response in patients with malignant melanoma
Cooperativity of HOXA5 and STAT3 is essential for transcriptional activation of PD-L1
Analysis of the statistic data of melanogenesis disregulation
Diversity of circulating melanoma cells; detection of heterogenous BRAF mutations by single-cell analysis
MAPK inhibitor resistant melanoma cells can be effectively targeted by inhibition of the p90 ribosomal S6 kinase

Immune profiles of responders and non-responders to topical imiquimod for the treatment of lentigo maligna

Peripheral blood Th9 cells can be an efficacy biomarker of anti-PD-1 antibody treatment in metastatic melanoma patients

Melanoma - What’s hair got to do with it?

Isolation of cytotoxic compounds against melanoma cells from Epicoccum nigrum, an endophyte isolated from Ferula sumbul plant

Establishment of a clinical resource to evaluate biomarkers to systemic therapies in melanoma patients

Body-Mass-Index as a predictive marker for response in patients with metastatic melanoma treated with ipilimumab

Acetylsalicylic acid governs the effect of Sorafenib in NRAS- mutant melanoma

The serial measurements of S100B protein serum concentrations predict independently disease outcome in advanced melanoma stage

The baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios as biomarkers of survival in cutaneous melanoma

The baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios are associated with microscopic metastases of cutaneous melanoma to the sentinel lymph node

The co-evolution of tumour and host immunity in metastatic melanoma through BRAF inhibition and checkpoint blockade

2-Deoxy-D-glucose can abolish the cisplatin-induced melanoma giant cell formation and enhance the cytotoxic effect of cisplatin on melanoma cells

**P12, Drug Resistance**

Mechanisms of Resistance in anti-PD1 Treated Patients with Metastatic Melanoma

Targeting TOP1 gene in melanoma as a novel mechanism of resistance and combinational therapies

Repurposing chemotherapy to target methylation and induce DNA repair to overcome treatment resistance in melanoma.

Uncovering novel resistance mechanisms to BRAF and MEK inhibition by integrative RNAseq and targeted panel sequencing

Targeting the JNK-JUN pathway to reduce phenotypic plasticity and overcome therapy resistance in metastatic melanoma

Detection of BRAF splicing variants in plasma of patients developing resistance to combined BRAF/MEK inhibition
Scientific Programme

Amino acid transporter ASCT2 as a potential therapeutic target for BRAF inhibitor resistant melanoma

OGT and TET1 mediated H3K4me3 remodelling drives acquired BRAF inhibitor resistance in melanoma

Targeting Apoptosis to Enhance BRAF/MEK Directed Therapy

A Phase Ib/II randomised study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib in patients with advanced melanoma

ABCB5 Transporter: Mediator of Intrinsic Resistance to Vemurafenib in Melanoma

SETDB2-mediated drug tolerance in melanoma

Preclinical efficacy and sensitivity determinants of statins in molecularly-defined models of melanoma

Use of primary melanoma cells for testing novel combination therapies

Response and Resistance of MEKi Treated Melanomas with BRAF Fusions

Resistance to BRAF inhibition in a somatic mouse model of melanoma

Poster
08:00 - 18:00

P02, Early Diagnosis & Dermoscopy

Diagnostic melanoma smartphone applications - what are the legal implications for dermatologists, patients and regulators?

An unusual onset of agminated Spitz naevi in an adult patient

The unregulated use of Melanotan-II may induce change and obscure the assessment of melanocytic lesions

Relationship between melanocytic naevi (MN) acquired during childhood and adult MN count and melanoma risk

Confocal features of Sutton nevi can simulate melanoma: A reminder of the role of clinical-dermoscopic and confocal correlation to avoid overestimation of confocal features

A case report of Lentigo Maligna of the nose treated with topical Imiquimod & followed-up with reflective confocal microscopy

Teledermatology: an effective aid in diagnosing melanoma

Cancer systems biology of therapy-resistant melanoma

Photometric spectral analysis of digital images can improves telediagnostics of skin melanoma

Head and neck sentinel lymph node biopsy for cutaneous melanoma at a tertiary referral centre

A guideline for the assessment of adult patients with suspected melanoma of unknown primary (MUP)

Frequency and clinical features of synchronous multiple primary melanomas at an Australian tertiary referral centre
Self-assessed sunbed use is not associated with melanoma diagnosis in patients attending a teledermatoscopy clinic in New Zealand

Referrals of skin lesions from primary care do not meet quality standards for teledermatology

Case report: Upstaging of melanoma in-situ following shave biopsy

Naevi in chronic graft versus host disease patients, a clinical challenge for dermatologist. Dermoscopic evaluation

Melanoma in a cohort of organ transplant recipients: Experience from a dedicated transplant dermatology clinic in Victoria

The role of teledermoscopy in prompt diagnosis of melanoma

Dermoscopy in Asian Skin

Fluorescent and reflective spectroscopy at diagnosis of melanoma malignum and dysplastic nevi

Dermoscopic “Chaos and Clues” in the diagnosis of melanoma in situ

Digital imaging in melanoma diagnosis

Triple assessment of early melanoma - a new gold standard?

Mapping the unexpected: Delineating the margins of complex Lentigo Maligna with In vivo reflectance confocal microscopy

Surveillance of patients with high-risk resected melanoma: What are we doing with these patients?

Development of a low-cost, liquid-biopsy microRNA assay for melanoma diagnosis, staging and treatment response monitoring

Identification and validation of a diagnostic autoantibody signature for primary cutaneous melanoma

Poster
08:00 - 18:00
Poster Exhibition

**P03, Epidemiology**

Survival of cutaneous melanoma patients with MC1R and CDKN2A mutations in Southern Brazil

1,848 Brazilian melanoma patient characteristics: From Demographic to clinical and related to treatment and survival from a single institution from Brazil

Endogenous and exogenous hormonal factors associated with the presence and number of naevi in women

Recent trends in cutaneous melanoma incidence and mortality: a 10-year nationwide cohort study

Diverging in situ and invasive melanoma incidences - Trends from Victoria, Australia, 1985-2015

Incidence of invasive cutaneous melanoma in the island of Gran Canaria (Spain) in the period 2011 - 2015
Descriptive epidemiology of malignant skin melanoma in Morocco

Hydrochlorothiazide use and risk of malignant melanoma

Acral lentiginous melanoma - Does it confer a poorer prognosis? An analysis of cases from 2009 to 2017 at University College Hospital Galway

Melanoma skin cancer : epidemiology study about 85 cases in Casablanca morocco

Heterogeneous spectrum of acral melanoma: A clinicoprognostic study of 213 acral melanomas according to tumor site

Acral lentiginous melanoma - is chronic microtrauma the missing link?

Increased incidence of cutaneous melanoma in organ transplant recipients in a single-center longitudinal study in Rome, Italy

Prevalence of common melanocytic naevi in the general population in South East Queensland and a systematic review of the evidence

The natural history of common melanocytic naevi in the general population: systematic review and pilot results from the Mind Your Moles study

High mortality of cutaneous melanoma in Norway: a population-based study of prognostic factors

Melanoma and sunscreen use - A systematic review and meta-analysis

Is vitamin D status at time of melanoma diagnosis associated with stage of tumour? Study protocol and recruitment

Exposure in early adulthood and subsequent risk of malignant melanoma: a review

Comparation of histopathological features and clinical outcomes of primary invasive amelanotic and pigmented melanomas

Primary cutaneous melanoma: clinical characteristics and demographic features of 200 cases: A single center experience from the south east marmara region of Türkiye

The utilization of the National Dermatology Radiation Oncology Registry: A human research registry to collect information from patients referred to radiation oncologists for the management of melanoma and non-melanoma skin cancer through radiotherapy.

Measured anthropometric factors and cutaneous melanoma risk: Data from the population-based Janus cohort

Measurement error in Breslow thickness and misclassification of T-stage: terminal digit preference in a national melanoma register 2008-2015

Associations of statins and diabetes with diagnosis of ulcerated cutaneous melanoma

Impact of associated naevus on survival for nodular and superficial spreading melanomas

Melanoma excisions by specialty in Australia

---

Poster

08:00 - 18:00

P13, Epigenetics and Metabolism

---

Page 75 / 122
Scientific Programme

The Mitochondrial Pyruvate Carrier 1 regulates differentiation and proliferation in melanoma

A-to-I miR-378a-3p editing prevents melanoma progression via regulation of PARVA expression

Epigenome-wide association scan in healthy human skin tissue in relation to naevus counts

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells

Genome-wide base-resolution DNA methylation analysis of invasive and non-invasive melanoma cell lines

Distinct histone remodelling defines early stress-induced drug tolerance in melanoma

Crosstalk between metabolism and epigenetics

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma

PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival

Elevated miR-146a-5p levels in melanoma versus melanoma microenvironment in NRAS-negative tumors

Histone Acetyltransferase p300 critically controls proliferation and survival of melanoma cells by transcriptionally regulating MITF

Targeting metabolic reprogramming in BRAFV600E melanoma

Untargeted Metabolomics of Melanoma and Adjacent Skin

Epigenetic silencing of anti-tumour immunity in melanoma.

Targeting the CoREST Complex as a Novel Therapeutic Strategy for Melanoma

Poster

08:00 - 18:00

Poster Exhibition

P04, Genetics & Genomics

Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and secondary cutaneous melanomas

Hugdahl, Emilia

Genotypic frequency of EGF+61 A>G polymorphism associated with risk of cutaneous melanoma in a mixed population

Pilot study to evaluate the intratumor heterogeneity in melanoma by next generation sequencing

Efficient protocol for melanin purification: impact on melanoma molecular diagnosis of highly pigmented lesions

Genetic ancestry in Brazilian melanoma patients

Whole exome sequencing reveals that nail apparatus melanoma and acral melanoma are distinct entities
**Scientific Programme**

Gene expression profiling test is useful to predict the risk of relapses. A multicenter retrospective cohort study

Candidate BAP1 phenocopy variants in a cohort of high case density Queensland melanoma families

Novel segregating variants in a cohort of high case density Queensland melanoma families

Polygenic landscape and possible pleiotropy in individuals with melanoma and other cancers

Gene interactions and influence of age & sex with melanoma risk

Characteristics of mesenchymal transition of melanoma

**Poster**

08:00 - 18:00

**Poster Exhibition**

**P14, Genetics and Genomics**

The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients

Melanoma cases demonstrate double the expected carrier frequency of phenylketonuria/hyperphenylalanemia mutations

Melanoma mutational burden and copy number alteration levels do not differ between adolescent and young adult and older patients

Genome-wide association study in 185,000 Europeans elucidates the genetic architecture of skin sensitivity to sun

Association between gut microbiome and naevus count in the TwinsUK registry

Low-Pass Whole Genome Sequencing of Single Uveal Melanoma Cells

Prognostic value of non-sentinel lymph node (non-SLN) status and a prognostic 31-gene expression profile (GEP) in stage III cutaneous melanoma patients

Actionable kinase fusions are frequent in pan-negative melanomas

The association between polygenic score and melanoma risk by biological pathways and examination of effect modification of sun exposure-melanoma risk associations

Incremental contribution of common genomic variants to melanoma risk, and overlap with phenotypic risk in Australia and the UK

NRAS mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy and clinical outcome

Molecular profiling of resected melanoma and its role in predicting patient outcome

Genomic characterisation of lethal melanoma from thin primaries

First-Line Immunotherapy in BRAF V600R Mutant Melanoma

The Cancer Survival Transcriptome Links Annotated Gene Signatures to Melanoma Patient Survival

TERT promoter mutations in melanoma

Kumar, Rajiv (Heidelberg, Germany)
Scientific Programme

TERT promoter mutations, telomere length and melanoma risk
Kumar, Rajiv (Heidelberg, Germany)

Characterising melanoma risk genetics through gene-based tests

Performance of a 31-gene expression profile test for melanoma prognosis in a combined validation cohort of 690 patients

Clinical impact of a 31-gene expression profile test on physician recommendations for management of melanoma patients in a prospectively tested cohort
Monzon, Frederico (Friendswood, United States)

Mutational and transcriptional profiling of clinical specimens of melanoma brain metastases: investigation of alterations and molecular signatures of potential clinical significance

A case-control analysis of POT1 variants in melanoma

Clinical use of targeted DNA, RNA, and protein analysis in cutaneous and unknown primary melanomas identifies treatment targets and frequent Co-Occurring driver alterations

Cell Free DNA BRAF (cfBRAF) Mutation V600 Plasma Detection in Melanoma: NCCTG N0879 (Alliance)

Family History of Cancer in Patients Diagnosed with Melanoma

The prevalence of somatic BRAF and NRAS mutations in dermoscopic subtypes of acquired naevi

Prediction of malignant potential of naevi using miRNA biomarkers

Whole-Genome Sequencing in Dutch Melanoma Families

BAP1 mutations prevalence and associated tumour spectrum in a cohort of Australian uveal melanoma cases

The landscape of driver mutations in over 1,000 melanoma exomes

Somatic and Germline TERT Events are Frequent in Acral Melanoma

P05, Immunology

Enhancing Immunotherapy with radiotherapy and topical treatments - Case report

Regulation of the cytotoxic immune response by the presence of normal and melanoma-associated fibroblasts

Understanding the impact of immunotherapy side effects on quality of life of patients with stage IV melanoma not on clinical trial: 'Real world' data to inform supportive care interventions

Inhibition of melanoma cell derived prostaglandin E2 amplifies T cell receptor signaling and shows clinical efficacy in combination with anti-PD1 therapy

Successful reinstitution of nivolumab in combination with corticosteroids for metastatic malignant melanoma with diverse immune-related adverse events including severe hemolytic anemia
P15, Immunotherapy

Preliminary results of a Phase 1b/2 study of PV-10 and pembrolizumab in Stage IV melanoma

Response of melanoma cells to immune activity

The oncolytic effect of ECHO-7 virus on cell viability in vitro

Does time to switch in immunotherapy sequential strategy impact immunotherapy efficacy: results from the French cohort MelBase

Biodistribution and Shedding of Talmogene Laherparepvec (T-VEC) in Patients (Pts) With Unresectable Stage IIIB/IV Melanoma

Anti PD-1 therapy induced pancreatic atrophy and its clinical significance

Older age may predict a higher response rate to anti PD-1 therapy in metastatic melanoma patients

Improving adoptive T cell therapy by selection of 4-1BB expressing TIL

Dissecting and deactivating immunosuppressive signals at metastatic lymphovascular sites

Phase Ic Trial of Intralesionial OrienX010 Oncolytic Viral Therapy Into Liver Metastases Among Melanoma Patients

Antibody profiling of melanoma patients undergoing immunotherapy with checkpoint inhibitors

Generic strategy to model tumour antigens and T-cell based immunotherapies in melanoma

Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma

Quantitative analysis of immune profiles of metastatic melanoma patients reveals biomarkers of response and resistance to combined anti-CTLA-4 and anti-PD-1 immunotherapy

c-MET dependent neutrophil responses limit ACT immunotherapy of melanoma

Monitoring patient response to Pembrolizumab with peripheral blood immune profiles

Effective Immuno Gene Therapy via the Delivery of Plasmids Encoding Cytokines as a Potential Treatment of Melanoma

DNA pattern recognition receptor activation after plasmid gene therapy in melanoma and other tumor cell types

Using Mass Cytometry to assess CD8 T cell phenotype during melanoma relapse on anti-PD1 treatment

Identification of Gene Signatures Predicting Response to PD1 Immunotherapy in 54 Metastatic Melanoma Patients

Inhibitors of the renin-angiotensin system could negatively impact survival benefit from ipilimumab/nivolumab combination but not from ipilimumab monotherapy

Clinical activity and safety of ipilimumab for metastatic uveal melanoma: the St Bartholomew's Hospital experience
Real life outcome of patients with advanced melanoma after discontinuation of a PD-1 inhibitor in the absence of disease progression or treatment limiting toxicity

The efficacy of concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDCAC study): Protocol for a multicenter phase II open label study

Distinct genomic alterations in patients with advanced melanoma treated with anti-PD-1 therapy

A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV Melanoma: Trial in Progress

Immune phenotypic analysis of NK cells in predicting anti-PD-1 therapy

Pembrolizumab (PEM) utilization and overall survival (OS) for patients with advanced melanoma: the real world US experience

Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis

BRAF ± MEK inhibition following pembrolizumab (pembro) in KEYNOTE-006

Pre-clinical evaluation of vectorized therapies combined with an anti-CTLA4 antibody in murine xenografted-models in melanoma

Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis

BRAF ± MEK inhibition following pembrolizumab (pembro) in KEYNOTE-006

Pre-clinical evaluation of vectorized therapies combined with an anti-CTLA4 antibody in murine xenografted-models in melanoma

Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia.

Widely Metastatic Uveal Melanoma Responding to Combination Immune Therapy and Focal Radiotherapy after Pembrolizumab Failure

SALVO: Single Arm Phase II Study of Ipilimumab and NIVOlimab as Adjuvant Therapy for Management of Rheumatological Immune Related Adverse Events in Melanoma Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies

An immunogenic personalized neoantigen vaccine in patients with high risk melanoma

Exploring Lenalidomide in both inhibiting proliferation and blocking PDL1 signals in melanoma cells: a preclinical study

A Time and Motion Study of Patients Treated with Pembrolizumab and Nivolumab in Australia.

Real World data on the Safety and Efficacy of anti-PD-1 antibodies in the Elderly Population with Metastatic Melanoma

Real world Efficacy and Toxicity of Combined Nivolumab and Ipilimumab in patients with Metastatic Melanoma

Autophagy Drives Resistance to PD-1 Blockade in Melanoma

Combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in melanoma pts

The peripheral blood TCR repertoire might facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma

A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic melanoma

A case of anti-PD1 induced hepatitis associated with corticosteroid resistant T cells
Inhibition of melanoma cell derived prostaglandin E2 amplifies T cell receptor signaling and shows clinical efficacy in combination with anti-PD1 therapy

A Phase II study of JS001, a Humanized IgG4 mAb Against Programmed Death-1 (PD-1) in Patients with Advanced Acral and Mucosal Melanoma

Quantifying the treatment-free interval after first-line immuno-oncology (IO) treatment of advanced melanoma

Benefit of the Nivolumab and Ipilimumab combination in pretreated advanced melanoma

Paradoxical reduced response to combined PD-1/CTLA-4 blockade in low tumor burden melanoma

Access to immunotherapy for treatment of metastatic melanoma in the Netherland and Australia: a tale of two countries

High-dose corticosteroids do not prevent lymphocyte proliferation or IL-2 production after stimulation with pembrolizumab

The role of chemotherapy after immunotherapy resistance in melanoma

Durable complete responses after cessation of anti-PD-1 monotherapy are associated with undetectable circulating tumour DNA

PD-L1 expression and density of CD8+ T cells in matched brain and extracerebral metastases are highly concordant

Profound inflammation-mediated change to the immunopeptidome of melanoma

The incidence of basal cell carcinoma is reduced in patients on anti-Programmed cell death-1 therapy for metastatic melanoma

P06, Keratinocyte Cancers & Merkel Cell Carcinoma

Squamous cell carcinoma in the caruncle during Vemurafenib treatment - case report

Proposal for randomised controlled trial (RCT) of immunotherapy combined with wide field radiotherapy versus wide field radiotherapy alone in stage IA-IIIC Merkel Cell Carcinoma (MCC)

Recurrence rates of lesions treated with curettage and cautery in a busy multi-practitioner dermatology practice in Brisbane, Australia.

Sentinel lymph node biopsy in clinically node negative Merkel cell carcinoma - Westmead Hospital, Sydney experience

Primary Merkel cell carcinoma of the earlobe in a young, healthy adult male

Solitary nodule on the face

Basal Cell Carcinoma detection through transfer learning in dermoscopy images using a convolutional neural network

Squamous cell carcinoma of the nail unit: A retrospective review of 14 cases and our proposal for surgical management
Scientific Programme

Omega-3 fatty acid intake and cutaneous squamous cell carcinoma in organ transplant recipients

A retrospective analysis of wide local excision for Merkel cell carcinoma: a single-center series of 11 patients

Epidermal clonal proliferative response upon UVB irradiation is bimodal

Case report of a patient with metastatic basal cell carcinoma: mixed response to vismodegib therapy

Comparison of primary Merkel cell carcinoma (MCC) and melanoma T-cell immuno-profile and PD-L1 expression by multi-spectral immunohistochemistry (mIHC)

P16, Melanoma and Melanocyte Biology

Performance comparison of PD-L1 antibody clones 28-8 and 22C3 in stage III and IV metastatic melanoma samples: A tissue microarray study

Genetic variation in IRF4 expression modulates growth characteristics, pigmentation and interferon-gamma response in melanocytic cells

Frequency of BRAF V600 mutation in 354 locally advanced or metastatic melanoma patients from an academic center in Argentina. The apple does not fall very far from the tree.

Cinat, Gabriela (Buenos Aires, Argentina)

MiR-149 Function as a Tumor Suppressor in Mucosal Melanoma

Focal perinuclear cytoplasmic BAP1 is associated with high impact mutations in uveal melanoma

Natural genetic variation controlling propensity for an individual’s melanocytes to transform after UVR exposure

Detection, molecular profiling and culture of CSF-CTCs in leptomeningeal disease (LMDz) in melanoma

The ATM Ser49Cys variant is defective for DNA damage and senescence signalling

COMBI-i: A phase 3 study of the anti-PD1 antibody PDR001 in combination with dabrafenib (D) and trametinib (T) in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma

A novel signalling pathway ACTN4-RIPK1-NF-κB in regulating melanoma cell proliferation

Dissecting molecular and genetic determinants of UV response using iPSC based melanocyte models

Site-specific phosphorylation of the EMT-inducing molecule Y-box binding protein 1 regulates tumourigenicity and invasiveness of human melanoma cells

BRIM8: a randomized, double-blind, placebo-controlled phase 3 study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600 mutation-positive melanoma at high risk for recurrence

Pigment-producing melanocytes as the cells of origin of cutaneous melanoma
Scientific Programme

Identification of TERT, BRAF and NRAS hotspot mutations from formalin fixed and circulating tumour DNA of melanoma samples through highly sensitive ddPCR assay in melanoma

Growth factor activation of melanoma cell signalling pathways

In-depth Proteomic Profiling of Uveal Melanoma Exosomes

Evaluation of the transcriptome of large/giant congenital melanocytic nevi

Notch signaling in mouse melanoma tumor development and drug resistance of human metastatic melanoma cells

Wnt-dependent regulation of Sox10 expression in melanoma development

Functional testing of MTAP haplotypes demonstrates differential expression, signalling and pigmentation effects in primary melanocytic cells

RPS3 fucosylation in melanoma cell biology

Subcutaneous Cellular Nodule and Pigmented Epithelioid Melanocytoma on the Ipsilateral Upper Arm associated with Plaque-type Blue Nevus on the Hand

Roles of Wnt signaling in melanoma pathogenesis

Poster
08:00 - 18:00

P07, Oncology

Real world data on intensive follow-up for stage IV metastatic melanoma patients receiving combination ipilimumab and nivolumab: a safer model of care?

Case report: vemurafenib-induced facial edema

Effective in vivo targeting of neo-antigens to Clec9A+ cross-presenting dendritic cells to improve personalized immunotherapy of melanoma

Ipilimumab is not active in Japanese patients with nivolumab-refractory melanoma

Topical diphencyprone for the treatment of in transit melanoma metastases of the skin: Long-term outcomes & management suggestions

Incidence of hypophysitis in patients with melanoma undergoing adjuvant ipilimumab 10mg/kg - a single center experience

High-dose rate radiation therapy and radionuclide diagnosis in the treatment of localized cutaneous melanoma more than 1 mm thick

If you are going to pay for it, do it on time

Real world PD-1 immunotherapy related side effects in metastatic melanoma, an Australian regional cancer centre experience

Outcomes on Central Nervous System irradiation for melanoma brain metastasis: 10-year experience in a developing country institution

Improved survival without increased toxicity in Melanoma brain metastases patients treated with stereotactic radiosurgery and ipilimumab versus stereotactic radiosurgery alone
The combination of BRAFi and MEKi: a treatment option for BRAF WT patients?


Toxic epidermal necrolysis associated with combination immunotherapy with nivolumab and Ipilimumab for advanced metastatic melanoma

Patient derived organotypic slice cultures for preclinical profiling of human BRAF wildtype melanomas

Two cases of trametinib-induced rhabdomyolysis of Japanese melanoma patients treated by dabrafenib and trametinib combination therapy

Successful neoadjuvant therapy of BRAF and MEK inhibition for inoperable stage 3 metastatic Melanoma (Withdrawn)

Poster Exhibition: 08:00 - 18:00

P20, Others

An 18-year study of Paediatric Malignant Melanoma at Morriston Hospital

Detailed FACS, migration, and invasion assay analyses of MeLiM melanoma model

Phenotypic and molecular characterisation of Circulating Tumour Cells isolated from metastatic melanoma patients using a microfluidic device

Epidemiological profile of cutaneous malignant melanoma in Tlemcen (west Algeria): January 2011 to December 2015

Malignant melanoma and psoriasis association: about a case

Metastatic malignant melanoma and vitiligo

Malignant melanoma and psoriasis acrolentigineux

Malignant Melanoma, is dominant at the ends: about a new observation acral

Concordance of Mutations in Circulating Tumour DNA (ctDNA) and Tissue Biopsy in Melanoma

Teledermatology and teledermoscopy as tools to help general practitioners in effective e-triage of suspicious skin lesions prior to dermatology evaluation

Generation and characterization of 90 melanoma patient-derived xenograft models

Preferences for advanced melanoma Immuno-Oncology treatments

Evaluation of commercial kits for extraction of circulating free DNA

Targeted therapy or immunotherapy..."this is the question" in frontline approach to BRAF-mutant melanoma: the challenge of combination immunotherapy.

Precision medicine for melanoma patients: Development of a Melanoma-specific gene panel for integrative molecular tumor boards

Electric field mediated drug and gene delivery provides effective treatment protocols for melanoma
Refining risk models for distant and CNS metastasis in Stage III melanoma

Preclinical validation of a new anti-melanoma compound in B-Raf inhibitors sensitive and resistant cells.

Randomized Phase (ph) II study of Paclitaxel (P), Carboplatin (C), Bevacizumab (B) +/- Everolimus (E) in Metastatic Melanoma (MM): Secondary analysis of outcomes in patients (pts) who harbor NRAS mutation NCCTG N0879 (Alliance).

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
Lee, Rebecca (Manchester, United Kingdom)

A preclinical platform for evaluating targeted therapy and immunotherapy combinations in BRAFV600E melanoma

Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China

Clinical application of various flaps in repair of soft tissue defect in weight-bearing region of foot caused by wide excision of melanoma: our experience after 31 cases

Multifactorial Analysis of Prognostic Factors And Survival Rates Among 706 Mucosal Melanoma Patients

Evolution of treatment patterns for advanced melanoma in US oncology clinical practices: an observational study

A significant interaction between sex and UV index in melanoma risk

Long-term survival outcome of patients with thin (T1) cutaneous melanomas: a naturally-occurring, biologically-relevant Breslow thickness cutpoint of 0.8mm separates higher risk from lower risk tumors

Optimization of spiral microfluidics for melanoma cell isolation

Clinical and molecular associations of body mass index (BMI) in regional melanoma metastases

Fortune Cookie Flap: New option to cover the defect

The burden of Non-Melanoma skin cancers in Auckland, New Zealand

Psychosocial outcome, neurocognitive functioning (NCF) and quality of life (QoL) in advanced melanoma survivor

US guided wire localization of malignant melanoma subcutaneous metastases

Sentinel node biopsy status is strongly predictive of survival in cutaneous melanoma: Extended follow-up of 1,527 Oxford patients from 1998-2014.

Predicting the development and timing of subsequent primary melanomas in a population-based Australian cohort

Iris freckling as a marker of cutaneous melanoma risk: a case-control study

Classifying dermoscopic patterns of naevi in a case-control study of melanoma

Dermoscopic features of Vulvar Intraepithelial Neoplasia

Modelling terahertz radiation absorption and reflection with computational phantoms of skin to aid melanoma diagnosis and management
Scientific Programme

The neutrophil-lymphocyte and platelet-lymphocyte ratios for surveillance in cutaneous melanoma

Acral melanoma (AM) demonstrates distinct clinical pattern and worse prognosis compared with non-acral cutaneous melanoma (NACM): a prospective analysis of 1461 cases

Poster
08:00 - 18:00
Poster Exhibition

P08, Pathology

Anorectal melanoma, a case series of patients from the Melanoma Institute of Australia (MIA)

Review article: Role of beta catenin in melanoma

A case of Spitz nevus: differential diagnosis from melanoma

Poster
08:00 - 18:00
Poster Exhibition

P09, Prevention & Health Economics

How does skin cancer risk perception influence sun-exposure behaviours in Australian adults?

At a glance: The role of vitamin D in melanoma

Connecting design and health professionals for skin cancer prevention: a novel, sustainable approach in Queensland, Australia

Photoaging smartphone apps for skin cancer prevention in German adolescents: the Sunface randomized trial

The sunscreen and young children (SAY) pilot study

New technologies in skin cancer prevention

Teledermoscopy for skin cancer - what do dermatologists want to be paid to perform a simple consultation?

Utility-based quality of life in melanoma patients: Preliminary findings from the Whole Brain Radiotherapy (WBRT) trial

Poster
08:00 - 18:00
Poster Exhibition

P10, Surgical Issues

Total lymph node yield as a marker of quality assurance in axillary lymphadenectomy for metastatic melanoma

Interval sentinel node drainage as a predictor factor in melanoma patients
Scientific Programme

- Clinical behavior and prognostic in patients with head and neck cutaneous melanoma who underwent sentinel node biopsy
- Invasive melanoma with preoperative diagnosis of melanoma in situ
- Subungal Melanoma of the Hand
- A protocol for the safe use of patent blue V dye in sentinel node biopsy
- Management of primary cutaneous melanoma: A retrospective audit of 887 cases and review of current clinical guidelines
- Sentinel lymph node biopsy for cutaneous melanoma in elderly patients: the Cambridge experience
- Initial experience in the UK with use of (99mTc) Tilmanocept (a novel radiopharmaceutical) for sentinel lymph node biopsy (SLNB) for malignant melanoma
- Patterns of care for regional biopsies and nodal surgery for melanoma treatment in Queensland
- Mini-invasive subcutaneous lymphangiecytomy in patients with skin melanoma
- Sentinel lymph node biopsy for cutaneous versus mucosal melanoma in the anorectal region: two case reports
- Giant melanoma of the scalp without metastases: a case report
- Augmentation of venous drainage of the paramedian forehead flap by inclusion of a superficial vein: an anatomical and radiological study
- Shave versus elliptical biopsy for melanoma substantially increases re-excision area and scar length
- Importance of ulceration and mitoses in the selection of patients for sentinel lymph node biopsy in thin cutaneous melanoma? A study based on the Swedish Melanoma Register and the Melanoma Institute Australia Research Database
- Venous free flap reconstruction of fingers and toes in subungual melanoma
- A safe way to reduce length of hospital stay following lymph node dissection for cutaneous malignancy nodal metastasis
- Treatment of melanoma in situ with erbium: YAG laser
- Results of sentinel lymph node biopsy in thin (Breslow < 1mm) cutaneous melanoma of trunk and extremities
- Video-assisted inguinal lymphadenectomy in melanoma
- The Circumferential Aligned Lateral Advancement with Fasciotomy (CALF) flap: A straightforward reconstruction technique for melanoma of the leg following wide local excision
- Surgical treatment of acral melanoma
- Surgical management of cutaneous malignant melanoma - current status
- Lymph node dissection guided by indocyanine green fluorescence for cutaneous melanoma
- Adherence to surgical melanoma guidelines in New South Wales of all newly diagnosed melanomas over a one-year period
- Management of dysplastic vaevi: An international perspective (withdrawn)
The keystone perforator island flap in the management of large melanoma defects including groin dissections

P17, Targeted Therapy

Incidental Perineural Invasion in Keratinocyte cancer (KC): A prospective analysis of the incidental Perineural Invasion (PNI) registry with a five year follow up in Queensland

Real life targeted therapies alone or in combination in brain metastases patients: French experience within MelBase

Possible immune adverse-events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma

Preclinical efficacy of the DLL3-targeted antibody drug conjugate Rovalpituzumab tessirine in metastatic melanoma

Williams, Sam (San Francisco, United States)

Role of miR-193a as therapeutic agent and biomarker in cutaneous melanoma

Identification of Molecular Signatures Associated with Response to MAPK Inhibitors in Metastatic Melanoma

Stagni, Camilla (Padova, Italy)

A Prospective Observational Safety Study of Patients (pts) With BRAFV600-Mutated Unresectable or Metastatic Melanoma (mM) Treated With Vemurafenib (VEM) (Zelboraf Safety Study [ZeSS]): Final Results

Colburn, Dawn

Induction of ER stress augments apoptotic and immunogenic responses in melanoma cells

Combination of EGFRi and METi - a new targeted therapeutic strategy for melanoma

Extended follow-up results of a phase 1b study (BRIM7) of cobimetinib (C) combined with vemurafenib (V) in BRAFV600-mutated melanoma

McArthur, Grant (Melbourne, Australia)

Combination BRAF/MEK inhibitors for melanoma with active brain metastases: A real-world multi-center experience

HDAC inhibition reverses adaptation to MEK inhibitor therapy in uveal melanoma: a systems level proteomic study

Investigating the sensitivity of RAC1 mutated melanomas to PI3K pathway inhibition

V600EBRAF melanoma cell response to vemurafenib and trametinib is not affected by exogenous growth factors bFGF, EGF and HGF in vitro

A phase I/II study of pembrolizumab and imatinib in patients with locally advanced/metastatic melanoma with c-KIT mutation or amplification

BRAF inhibitor treatment in the oldest old metastatic melanoma patients

Deciphering the role of PREX and PI3K signalling in melanoma
Scientific Programme

Differential effects on immune activity after Neoadjuvant MAPK pathway inhibition in stage III melanoma patients

Efficacy and Safety Analysis of Imatinib in 78 Advanced Melanoma Patients Harboring KIT Aberrations

CDK4 inhibition synergizes with BRAF and MEK inhibition in treatment naive melanoma cells but not after the development of BRAF inhibitor resistance

Clinical and biologic associations of body mass index (BMI) with survival in patients (pts) with BRAFV600-mutated metastatic melanoma (MM) treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib + vemurafenib (C+V)

Identification of actionable survival pathways in BRAF/NRAS wild type melanomas

Rose Bengal melanoma therapy - phototoxicity versus intrinsic cytotoxicity

Real-world data in a new-era of targeted and immuno-oncology treatment (Tx) of Metastatic Melanoma (MM) patients (pts)

Cobimetinib + atezolizumab versus pembrolizumab in patients with previously untreated, advanced, BRAFV600 wild-type melanoma: phase 3 IMspire 170 study

Gogas, Helen

ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment.

A Phase Ib study of AEB071, a PKC inhibitor, and BYL719, a PI3Kα inhibitor, in Patients with Metastatic Uveal Melanoma (UM)

Activity of the ERK1/2 inhibitor Ulixertinib in patients with BRAF and NRAS mutant melanoma

BRAF mutant metastatic melanoma - stopping treatment after complete response?

Elevated BRAFV600 mutant circulating tumor DNA (ctDNA) and circulating hepatocyte growth factor (cHGF) are associated with poor prognosis in patients with metastatic melanoma

A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma

In vitro study in exploring the critical mediator involved in Vemurafenib resistance

Inhibition of mitochondrial oxidative phosphorylation overcomes de novo and acquired resistance to MAPK pathway inhibitors

P11, Treatment & Follow-up

Pregnancy associated multiple melanoma: A case study of nine primary melanomas in a young female patient

Sweet's syndrome associated with ipilimumab in a patient with metastatic melanoma

Clinical trial recruitment and management of melanoma patients who live a long-distance from a tertiary referral centre
A case of malignant melanoma histologically similar to lentigo maligna melanoma of the back, BRAF wild-type, developed on thermal burn

Kissing naevus of the penis: report of two cases

The prognosis of malignant melanoma in the lower extremities and mechanical stress point on the plantar surface of the foot

Neutrophilus - lymphocytes reason in the survey prognosis in patients with maligno cutaneo melanomanational institute of neoplastic diseases 2005-2012

Primary melanoma of lacrimal sac-- Report of a rare case

Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti PD-1

Laser treated agminated melanocytic nevi and the potential for malignant transformation

P18, Tumour Heterogeneity and Plasticity

Spatial analysis of gene expression in Stage III cutaneous malignant melanoma

Highly multiplexed single-cell protein analysis of melanoma FFPE samples

Convergent evolution in therapy naïve human melanoma.

In-depth molecular and immune characterization of melanoma with heterogeneous PTEN expression

Role of JARID1B expression in radiation resistance in melanoma cells

Metastatic growth after melanoma dissemination requires MITF and BRN2

BRN2 co-ordinates switching of melanoma cells to an invasive phenotype to promote metastasis and metabolic adaptation to micro-environmental cues

MITF regulates dynamic heterogeneity and structural integrity in melanoma

Melanin pigment and melanoma heterogeneity

P19, Tumour Microenvironment

Paracrine Activin-A signaling promotes melanoma growth and mediates tumour immune evasion

Composition or lack of exogenous growth factors do not influence viability and phenotype of drug naïve V600EBRAF melanoma cells but it might be crucial for drug-resistant cells

Combined loss of epidermal AMBRA1 and Loricrin is a prognostic biomarker for AJCC stage I melanoma and a companion biomarker for novel targeted therapy

Diversity of fibroblastic populations in the microenvironment of human melanomas
Scientific Programme

**Multiplex immunohistochemistry and flow cytometry provide divergent but complementary insights into the immune context in metastatic melanoma**

**Immune Cell Profiles in Neoadjuvant Therapy of Advanced Stage III Melanoma**

**Fucosylation and Immune Surveillance in Melanoma**

**Tumour-derived exosomes promote the bone tropism of melanoma cells by CXCR7 upregulation**

**Development of a 3D human metastatic melanoma model for in vitro evaluation of targeted therapy efficiency**

**Origin of vascular progenitors driving melanoma angiogenesis in vivo**

**A αvβ3 integrin-linked 'stromal response' expression signature to identify high-risk melanoma: Report on a 330 patient multi-center validation cohort.**

**Nanoparticle-based immunotherapy in a humanized mouse melanoma model targeting macrophages in the tumor microenvironment**

**Metastatic melanoma cells commandeer p53 activity to promote the survival of a therapy resistant subpopulation.**

**GARP expressing platelets are capable of regulatory T cell induction**

---

**Plenary Lecture**

09:10 - 10:40

**Great Hall**

**PL03, Staging, Surgery and Targeted Therapies for Melanoma**

**Chairs:**

Sondak, Vernon (Tampa, United States)

Stretch, Jonathan (Sydney, Australia)

---

**The new AJCC melanoma classification**

Gershenwald, Jeffrey (Houston, United States) 09:10 - 09:30

**Controversies on lymph node management**

van Akkooi, Alexander (Amsterdam, Netherlands) 09:30 - 09:50

**Surgery for stage 4 melanoma patients: is it still worthwhile?**

Thompson, John (Sydney, Australia) 09:50 - 10:10

**Keynote Address: targeted therapies and combination approaches in metastatic melanoma**

Hauschild, Axel (Kiel, Germany) 10:10 - 10:40

---

**Symposium**

11:10 - 12:40

**Great Hall**

**SY25, Surgical Oncology: The Role of Surgery for Stage IV Disease**

**Chairs:**

Gershenwald, Jeffrey (Houston, United States)

Faries, Mark (Santa Monica, United States)
Scientific Programme

**Satellite Symposium**

**Room M4**

SAT06, Elsevier Office of Continuing Medical Education and In Vivo Academy: How Immune Checkpoint Inhibitors are Changing the Treatment Landscape for Metastatic Melanoma

**Chairs:**
Sullivan, Lisa (Sydney, Australia)

The biology and evidence for treating patients with metastatic melanoma with immune checkpoint inhibitors  
McArthur, Grant (Melbourne, Australia)

Practical management of patients treated with immune checkpoint inhibitors  
Carlino, Matteo (Sydney, Australia)

**Symposium**

**Room M3**

SY26, Clinical Diagnosis: Sequential Digital Dermoscopy Imaging

**Chairs:**
Menzies, Scott (Sydney, Australia)  
Scope, Alon (Tel Aviv, Israel)
**Scientific Programme**

**11:10 - 11:20**
**How to manage you patients with multiple naevi if you do NOT have a digital system**
Zalaudek, Iris (Graz, Austria)

**11:20 - 11:30**
**2017 Australian Guidelines for digital dermoscopy monitoring: evidence and recommendations**
Menzies, Scott (Sydney, Australia)

**11:30 - 11:40**
**What's new in the literature of digital monitoring**
Scope, Alon (Tel Aviv, Israel)

**11:40 - 11:50**
**Surveillance programme for patients at high risk of melanoma: the Vienna experience**
Kittler, Harald (Vienna, Austria)

**11:50 - 12:00**
**Total body photography and its value for melanoma screening**
Curiel-Lewandrowski, Clara (Tuscon, United States)

**12:00 - 12:10**
**Integrating dermoscopic monitoring with RCM imaging**
Longo, Caterina (Reggio Emilia, Italy)

**12:10 - 12:20**
**Sequential digital dermoscopy imaging: economic considerations**
Tromme, Isabelle (Brussels, Belgium)

**12:20 - 12:40**
**Discussion**

**Symposium**
**11:10 - 12:40**
Room M2

**SY27, Pathology: New Developments and Hot Topics in Melanoma Pathology**

**Chairs:**
Busam, Klaus J. (New York, United States)
Cerroni, Lorenzo (Graz, Austria)
Scolyer, Richard (Sydney, Australia)

**11:10 - 11:28**
**Unusual variants of melanoma**
Cerroni, Lorenzo (Graz, Austria)

**11:28 - 11:46**
**Lentiginous melanocytic proliferations in the setting of confocal monitoring of difficult patients at Melanoma Institute Australia**
Jackett, Louise (Sydney, Australia)

**11:46 - 12:04**
**Spitzoid melanocytic lesions: an update**
Barnhill, Ray (Paris, France)

**12:04 - 12:22**
**2018 WHO classification of melanomas and naevi**
Elder, David (Philadelphia, United States)

**12:22 - 12:40**
**Clinicopathologic findings in cutaneous adverse effects of melanoma systemic therapy**
Lezcano, Cecilia (Boston, United States)
Scientific Programme

Symposium
11:10 - 12:40
Room M1

SY28, Sunscreen: Bioavailability and Toxicity

Chairs:
Prow, Tarl (Adelaide, Australia)
Kimlin, Michael (Brisbane, Australia)

Introduction - Sunscreens: current issues and controversies
11:10 - 11:20
Kimlin, Michael (Brisbane, Australia)

Public health implications of sunscreen use
11:20 - 11:35
Sinclair, Craig (Melbourne, Australia)

Sunscreen testing in Australia
11:35 - 11:50
Gies, Peter (Melbourne, Australia)

Should nanoparticles be used in sunscreens?
11:50 - 12:05
Gulson, Brian (Sydney, Australia)

Toxicity of zinc oxide particles in sunscreens: myth or fact?
12:05 - 12:20
Prow, Tarl (Adelaide, Australia)

Discussion
12:20 - 12:40

Satellite Symposium
12:50 - 13:50
Great Hall

SAT07, Bristol-Myers Squibb: Moving Forward in Melanoma: Exploring Opportunities in Early Therapy

Chairs:
Schadendorf, Dirk (Essen, Germany)

Welcome and introduction
12:50 - 12:55
Schadendorf, Dirk (Essen, Germany)

Advancing early treatment in melanoma
12:55 - 13:15
Postow, Michael (United States)

New horizons in advanced melanoma
13:15 - 13:35
Atkinson, Victoria (Brisbane, Australia)

Discussion: what does the future hold?
13:35 - 13:50
Atkinson, Victoria (Brisbane, Australia)
Schadendorf, Dirk (Essen, Germany)
Postow, Michael (United States)

Close
Schadendorf, Dirk (Essen, Germany)
Symposium
14:00 - 15:30

SY29, Medical Oncology: Combination Systemic Therapy for Advanced Melanoma

Chairs:
Menzies, Alexander (Sydney, Australia)
Schadendorf, Dirk (Essen, Germany)

Combining targeted therapy and checkpoint blockade 14:00 - 14:20
Schadendorf, Dirk (Essen, Germany)

Combining radiotherapy with immunotherapy 14:20 - 14:40
Hong, Angela (Sydney, Australia)

Combining chemotherapy and immunotherapy 14:40 - 15:00
Coupe, Nicholas (Oxford, United Kingdom)

Designing trials and selecting endpoints in the era of combination systemic treatment of melanoma 15:00 - 15:20
Menzies, Alexander (Sydney, Australia)

Discussion 15:20 - 15:30

SMR Session
14:00 - 15:30

SMR08, Melanoma and Melanocyte Biology

Chairs:
Sturm, Richard (Brisbane, Australia)

Targeting the Developmental Melanocyte Lineage in Melanoma 14:00 - 14:20
Patton, Elizabeth (Edinburgh, United Kingdom)

Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via RB-BRN2 Axis 14:20 - 14:35
Judson, Robert (San Francisco, United States)

In Vivo Modeling of Molecular Mechanisms in Uveal Melanoma 14:35 - 14:50
Hagen, Hannah (Cambridge, United States)

Tumor Cell Intrinsic TLR4 Signaling Promotes Melanoma Progression and Metastatic Dissemination 14:50 - 15:05
Rogava, Meri (Bonn, Germany)

Transcriptional regulation by MITF in melanocytes and melanoma 15:05 - 15:20
Lo, Jennifer (Boston, United States)

Discussion 15:20 - 15:30
### Scientific Programme

#### SY30, Melanoma Centres

**Chairs:**
Hauschild, Axel (Kiel, Germany)
Malvehy, Josep (Barcelona, Spain)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Chair(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:15</td>
<td>The role of specialised melanoma/skin cancer centres in 2017</td>
<td>Malvehy, Josep (Barcelona, Spain)</td>
</tr>
<tr>
<td>14:15 - 14:30</td>
<td>Accreditation of melanoma/skin cancer centres. Should it be mandatory for all patients with melanoma to be managed at an accredited centre?</td>
<td>Moncrieff, Marc (Norwich, United Kingdom)</td>
</tr>
<tr>
<td>14:30 - 14:45</td>
<td>The role of a melanoma/skin cancer centre in physician teaching and training</td>
<td>Carrera, Cristina (Barcelona, Spain)</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>Conducting an efficient and effective melanoma tumour board/multi-disciplinary meeting</td>
<td>Long, Georgina (Sydney, Australia)</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>Bio specimen banking and translational research at melanoma/skin cancer centres</td>
<td>Messina, Jane (Tampa, United States)</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>Current neoadjuvant and adjuvant therapy trials for melanoma: how does the centre keep patients from slipping through the cracks?</td>
<td>Hauschild, Axel (Kiel, Germany)</td>
</tr>
</tbody>
</table>

#### SY31, Pathology: Melanoma Pathology - Bridging Genomics and Morphology

**Chairs:**
Busam, Klaus J. (New York, United States)
Cerroni, Lorenzo (Graz, Austria)
Scolyer, Richard (Sydney, Australia)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Chair(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:18</td>
<td>Desmoplastic melanoma</td>
<td>Messina, Jane (Tampa, United States)</td>
</tr>
<tr>
<td>14:18 - 14:36</td>
<td>Mutation analysis for the diagnosis of melanoma</td>
<td>Busam, Klaus J. (New York, United States)</td>
</tr>
<tr>
<td>14:36 - 15:12</td>
<td>Combined cutaneous tumours with a melanoma component - conceptual and practical issues</td>
<td>Emanuel, Patrick (Auckland, New Zealand)</td>
</tr>
<tr>
<td></td>
<td>Clinical implications of genomic aberrations in spitzoid melanocytic tumours</td>
<td>Wiesner, Thomas (New York, United States)</td>
</tr>
</tbody>
</table>
Scientific Programme

**Pathological aspects of melanoma staging: a guide to the AJCC 8th edition**
Scolyer, Richard (Sydney, Australia)  
15:12 - 15:30

Free Communication
14:00 - 15:30  
Room M1

**FC07, Epidemiology**

**Chairs:**
Neale, Rachel (Brisbane, Australia)  
Cust, Anne (Sydney, Australia)

**Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral centre**
Tsoutsos, Dimosthenis (Athens, Greece)  
14:00 - 14:10

**Epidemiology of malignant melanoma in Japan**
Fujisawa, Yasuhiro (Tsukuba, Japan)  
14:10 - 14:20

**Lifetime sunburns and melanoma risk**
Rueegg, Corina S. (Oslo, Norway)  
14:20 - 14:30

**Host characteristics, sun exposure, and site-specific risk of melanoma: a large prospective cohort study in Norway**
Ghiasvand, Reza (Oslo, Norway)  
14:30 - 14:40

**Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure**
Cust, Anne (Sydney, Australia)  
14:40 - 14:50

**Number of naevi and cancer risk: a prospective cohort study in French women**
Cervenka, Iris (Villejuif, France)  
14:50 - 15:00

**Postmenopausal hormone use and cutaneous melanoma risk: a French prospective cohort study**
Cervenka, Iris (Villejuif, France)  
15:00 - 15:10

**Prognosis of patients diagnosed with a second primary Stage I or II melanoma**
Youlden, Danny R (Brisbane, Australia)  
15:10 - 15:20

**Sex and survival in cutaneous melanoma: analysis of latest SEER data using AJCC 8th edition staging**
Hieken, Tina (Rochester, United States)  
15:20 - 15:30

15:30 - 16:15  
Poster Exhibition

**WCM Poster Viewing**
Plenary Lecture
16:15 - 17:45
Great Hall

**PL04, Immuno-Oncology in Melanoma**

Chairs:
Cebon, Jonathan (Melbourne, Australia)
Hersey, Peter (Sydney, Australia)

Keynote Address: Rationale for immunotherapy in melanoma
Ribas, Antoni (Los Angeles, United States)

Latest results of immunotherapy in melanoma
Robert, Caroline (Villejuif, France)

Adaptive T-cell transfer in the era of checkpoint inhibition
Schachter, Jacob (Ramat Gan, Israel)

Checkpoint inhibition beyond PD-1 and CTLA-4 inhibition
Dummer, Reinhard (Zurich, Switzerland)

Miscellaneous
18:00 - 20:20
Room M1

**Workshop: Confocal Microscopy and Dermoscopy (ticket required)**

Technique and semiology: how to learn and pitfalls of the beginner
Churchin, Claudia (Brisbane, Australia)

Tips to integrate RCM in practice flow and when it is worth the time: melanocytic lesions and non-melanocyte
Longo, Caterina (Reggio Emilia, Italy)
Hofmann-Wellenhof, Rainer (Graz, Austria)

Didactic cases and discussion
Bosari, Stefania (Sydney, Australia)
Guitera, Pascale (Sydney, Australia)
Star, Phoebe (Sydney, Australia)
Waddell, Andréanne (Québec, Canada)

Ex vivo confocal microscopy
Puig, Susana (Barcelona, Spain)

RCM place in the world landscape and technology landscape: now and the future
Pellacani, Giovanni (Modena, Italy)
Scientific Programme

Saturday, 21 October 2017

Miscellaneous
08:00 - 12:30
Mezzanine Foyer

Industry Exhibition

Poster
08:00 - 12:00
Poster Exhibition

P01, Biology & Biomarkers

Nortriptyline can induce cytotoxic effect and autophagy on human melanoma cells (A2058)

The role of neuronal nitric oxide synthase (nNOS) in interferon-gamma-induced melanoma progression

A gene-signature based risk score significantly improves melanoma relapse prediction in synergy with sentinel lymph node status

Targeting cell cycle phase-specific drug sensitivity for melanoma therapy

Serum doublecortin like kinase 1 (DCLK1) levels measured by ELISA correlate with disease status, and pre-treatment levels predict for therapeutic response in patients with malignant melanoma

Cooperativity of HOXA5 and STAT3 is essential for transcriptional activation of PD-L1

Analysis of the statistic data of melanogenesis disregulation

Diversity of circulating melanoma cells; detection of heterogenetic BRAF mutations by single-cell analysis

MAPK inhibitor resistant melanoma cells can be effectively targeted by inhibition of the p90 ribosomal S6 kinase

Immune profiles of responders and non-responders to topical imiquimod for the treatment of lentigo maligna

Peripheral blood Th9 cells can be an efficacy biomarker of anti-PD-1 antibody treatment in metastatic melanoma patients

Melanoma - What’s hair got to do with it?

Isolation of cytotoxic compounds against melanoma cells from Epicoccum nigrum, an endophyte isolated from Ferula sambuli plant

Establishment of a clinical resource to evaluate biomarkers to systemic therapies in melanoma patients

Body-Mass-Index as a predictive marker for response in patients with metastatic melanoma treated with ipilimumab

Acetylsalicylic acid governs the effect of Sorafenib in NRAS- mutant melanoma

The serial measurements of S100B protein serum concentrations predict independently disease outcome in advanced melanoma stage
Scientific Programme

The baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios as biomarkers of survival in cutaneous melanoma

The baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios are associated with microscopic metastases of cutaneous melanoma to the sentinel lymph node

The co-evolution of tumour and host immunity in metastatic melanoma through BRAF inhibition and checkpoint blockade

2-Deoxy-D-glucose can abolish the cisplatin-induced melanoma giant cell formation and enhance the cytotoxic effect of cisplatin on melanoma cells

Poster
08:00 - 12:00

P12, Drug Resistance

Mechanisms of Resistance in anti-PD1 Treated Patients with Metastatic Melanoma

Targeting TOP1 gene in melanoma as a novel mechanism of resistance and combinational therapies

Repurposing chemotherapy to target methylation and induce DNA repair to overcome treatment resistance in melanoma.

Uncovering novel resistance mechanisms to BRAF and MEK inhibition by integrative RNAseq and targeted panel sequencing

Targeting the JNK-JUN pathway to reduce phenotypic plasticity and overcome therapy resistance in metastatic melanoma

Detection of BRAF splicing variants in plasma of patients developing resistance to combined BRAF/MEK inhibition

Amino acid transporter ASCT2 as a potential therapeutic target for BRAF inhibitor resistant melanoma

OGT and TET1 mediated H3K4me3 remodelling drives acquired BRAF inhibitor resistance in melanoma

Targeting Apoptosis to Enhance BRAF/MEK Directed Therapy

A Phase Ib/II randomised study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib in patients with advanced melanoma

ABCBS Transporter: Mediator of Intrinsic Resistance to Vemurafenib in Melanoma

SETDB2-mediated drug tolerance in melanoma

Preclinical efficacy and sensitivity determinants of statins in molecularly-defined models of melanoma

Use of primary melanoma cells for testing novel combination therapies

Response and Resistance of MEKi Treated Melanomas with BRAF Fusions

Resistance to BRAF inhibition in a somatic mouse model of melanoma
9th World Congress of Melanoma – a Joint Meeting with the Society for Melanoma Research

Scientific Programme

Poster
08:00 - 12:00
Poster Exhibition

**P02, Early Diagnosis & Dermoscopy**

- Diagnostic melanoma smartphone applications - what are the legal implications for dermatologists, patients and regulators?
- An unusual onset of agminated Spitz naevi in an adult patient
- The unregulated use of Melanotan-II may induce change and obscure the assessment of melanocytic lesions
- Relationship between melanocytic naevi (MN) acquired during childhood and adult MN count and melanoma risk
- Confocal features of Sutton nevi can simulate melanoma: A reminder of the role of clinical-dermoscopic and confocal correlation to avoid overestimation of confocal features
- A case report of Lentigo Maligna of the nose treated with topical Imiquimod & followed-up with reflective confocal microscopy
- Teledermatology: an effective aid in diagnosing melanoma
- Cancer systems biology of therapy-resistant melanoma
- Photometric spectral analysis of digital images can improves telediagnostics of skin melanoma
- Head and neck sentinel lymph node biopsy for cutaneous melanoma at a tertiary referral centre
- A guideline for the assessment of adult patients with suspected melanoma of unknown primary (MUP)
- Frequency and clinical features of synchronous multiple primary melanomas at an Australian tertiary referral centre
- Self-assessed sunbed use is not associated with melanoma diagnosis in patients attending a teledermatoscopy clinic in New Zealand
- Referrals of skin lesions from primary care do not meet quality standards for teledermatology
- Case report: Upstaging of melanoma in-situ following shave biopsy
- Naevi in chronic graft versus host disease patients, a clinical challenge for dermatologist. Dermoscopic evaluation
- Melanoma in a cohort of organ transplant recipients: Experience from a dedicated transplant dermatology clinic in Victoria
- The role of teledermoscopy in prompt diagnosis of melanoma
- Dermoscopy in Asian Skin
- Fluorescent and reflective spectroscopy at diagnosis of melanoma malignum and dysplastic nevi
- Dermatoscopic “Chaos and Clues” in the diagnosis of melanoma in situ
- Digital imaging in melanoma diagnosis
- Triple assessment of early melanoma - a new gold standard?
Scientific Programme

Mapping the unexpected: Delineating the margins of complex Lentigo Maligna with In vivo reflectance confocal microscopy

Surveillance of patients with high-risk resected melanoma: What are we doing with these patients?

Development of a low-cost, liquid-biopsy microRNA assay for melanoma diagnosis, staging and treatment response monitoring

Identification and validation of a diagnostic autoantibody signature for primary cutaneous melanoma

Poster

08:00 - 12:00

P03, Epidemiology

Survival of cutaneous melanoma patients with MC1R and CDKN2A mutations in Southern Brazil

1,848 Brazilian melanoma patient characteristics: From Demographic to clinical and related to treatment and survival from a single institution from Brazil

Endogenous and exogenous hormonal factors associated with the presence and number of naevi in women

Recent trends in cutaneous melanoma incidence and mortality: a 10-year nationwide cohort study

Diverging in situ and invasive melanoma incidences - Trends from Victoria, Australia, 1985-2015

Incidence of invasive cutaneous melanoma in the island of Gran Canaria (Spain) in the period 2011 - 2015

Descriptive epidemiology of malignant skin melanoma in Morocco

Hydrochlorothiazide use and risk of malignant melanoma

Acral lentiginous melanoma - Does it confer a poorer prognosis? An analysis of cases from 2009 to 2017 at University College Hospital Galway

Melanoma skin cancer: epidemiology study about 85 cases in Casablanca morocco

Heterogeneous spectrum of acral melanoma: A clinicoprognostic study of 213 acral melanomas according to tumor site

Acral lentiginous melanoma - is chronic microtrauma the missing link?

Increased incidence of cutaneous melanoma in organ transplant recipients in a single-center longitudinal study in Rome, Italy

Prevalence of common melanocytic naevi in the general population in South East Queensland and a systematic review of the evidence

The natural history of common melanocytic naevi in the general population: systematic review and pilot results from the Mind Your Moles study

High mortality of cutaneous melanoma in Norway: a population-based study of prognostic factors
Melanoma and sunscreen use - A systematic review and meta-analysis

Is vitamin D status at time of melanoma diagnosis associated with stage of tumour? Study protocol and recruitment

Exposure in early adulthood and subsequent risk of malignant melanoma: a review

Comparison of histopathological features and clinical outcomes of primary invasive amelanotic and pigmented melanomas

Primary cutaneous melanoma: clinical characteristics and demographic features of 200 cases: A single center experience from the south east marmara region of Türkiye

The utilization of the National Dermatology Radiation Oncology Registry: A human research registry to collect information from patients referred to radiation oncologists for the management of melanoma and non-melanoma skin cancer through radiotherapy.

Measured anthropometric factors and cutaneous melanoma risk: Data from the population-based Janus cohort

Measurement error in Breslow thickness and misclassification of T-stage: terminal digit preference in a national melanoma register 2008-2015

Associations of statins and diabetes with diagnosis of ulcerated cutaneous melanoma

Impact of associated naevus on survival for nodular and superficial spreading melanomas

Melanoma excisions by specialty in Australia

P13, Epigenetics and Metabolism

The Mitochondrial Pyruvate Carrier 1 regulates differentiation and proliferation in melanoma

A-to-I miR-378a-3p editing prevents melanoma progression via regulation of PARVA expression

Epigenome-wide association scan in healthy human skin tissue in relation to naevus counts

ROS production induced by BRAF inhibitor treatment rewire metabolic processes affecting cell growth of melanoma cells

Genome-wide base-resolution DNA methylation analysis of invasive and non-invasive melanoma cell lines

Distinct histone remodelling defines early stress-induced drug tolerance in melanoma

Crosstalk between metabolism and epigenetics

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma

PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival

Elevated miR-146a-5p levels in melanoma versus melanoma microenvironment in NRAS-negative tumors
**Scientific Programme**

Histone Acetyltransferase p300 critically controls proliferation and survival of melanoma cells by transcriptionally regulating MITF

Targeting metabolic reprogramming in BRAFV600E melanoma

Untargeted Metabolomics of Melanoma and Adjacent Skin

Epigenetic silencing of anti-tumour immunity in melanoma.

Targeting the CoREST Complex as a Novel Therapeutic Strategy for Melanoma

---

**P04, Genetics & Genomics**

Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and secondary cutaneous melanomas  
Hugdahl, Emilia

Genotypic frequency of EGF+61 A>G polymorphism associated with risk of cutaneous melanoma in a mixed population

Pilot study to evaluate the intratumor heterogeneity in melanoma by next generation sequencing

Efficient protocol for melanin purification: impact on melanoma molecular diagnosis of highly pigmented lesions

Genetic ancestry in Brazilian melanoma patients

Whole exome sequencing reveals that nail apparatus melanoma and acral melanoma are distinct entities

Gene expression profiling test is useful to predict the risk of relapses. A multicenter retrospective cohort study

Candidate BAP1 phenocopy variants in a cohort of high case density Queensland melanoma families

Novel segregating variants in a cohort of high case density Queensland melanoma families

Polygenic landscape and possible pleiotropy in individuals with melanoma and other cancers

Gene interactions and influence of age & sex with melanoma risk

Characteristics of mesenchymal transition of melanoma

---

**P14, Genetics and Genomics**

The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
Melanoma cases demonstrate double the expected carrier frequency of phenylketonuria/hyperphenylalanemia mutations

Melanoma mutational burden and copy number alteration levels do not differ between adolescent and young adult and older patients

Genome-wide association study in 185,000 Europeans elucidates the genetic architecture of skin sensitivity to sun

Association between gut microbiome and naevus count in the TwinsUK registry

Low-Pass Whole Genome Sequencing of Single Uveal Melanoma Cells

Prognostic value of non-sentinel lymph node (non-SLN) status and a prognostic 31-gene expression profile (GEP) in stage III cutaneous melanoma patients

Actionable kinase fusions are frequent in pan-negative melanomas

The association between polygenic score and melanoma risk by biological pathways and examination of effect modification of sun exposure-melanoma risk associations

Incremental contribution of common genomic variants to melanoma risk, and overlap with phenotypic risk in Australia and the UK

NRAS mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy and clinical outcome

Molecular profiling of resected melanoma and its role in predicting patient outcome

Genomic characterisation of lethal melanoma from thin primaries

First-Line Immunotherapy in BRAF V600R Mutant Melanoma

The Cancer Survival Transcriptome Links Annotated Gene Signatures to Melanoma Patient Survival

TERT promoter mutations in melanoma
Kumar, Rajiv (Heidelberg, Germany)

TERT promoter mutations, telomere length and melanoma risk
Kumar, Rajiv (Heidelberg, Germany)

Characterising melanoma risk genetics through gene-based tests

Performance of a 31-gene expression profile test for melanoma prognosis in a combined validation cohort of 690 patients

Clinical impact of a 31-gene expression profile test on physician recommendations for management of melanoma patients in a prospectively tested cohort
Monzon, Frederico (Friendswood, United States)

Mutational and transcriptional profiling of clinical specimens of melanoma brain metastases: investigation of alterations and molecular signatures of potential clinical significance

A case-control analysis of POT1 variants in melanoma

Clinical use of targeted DNA, RNA, and protein analysis in cutaneous and unknown primary melanomas identifies treatment targets and frequent Co-Occurring driver alterations

Cell Free DNA BRAF (cfBRAF) Mutation V600 Plasma Detection in Melanoma: NCCTG N0879 (Alliance)
**Scientific Programme**

**Family History of Cancer in Patients Diagnosed with Melanoma**

**The prevalence of somatic BRAF and NRAS mutations in dermoscopic subtypes of acquired naevi**

**Prediction of malignant potential of naevi using miRNA biomarkers**

**Whole-Genome Sequencing in Dutch Melanoma Families**

**BAP1 mutations prevalence and associated tumour spectrum in a cohort of Australian uveal melanoma cases**

**The landscape of driver mutations in over 1,000 melanoma exomes**

**Somatic and Germline TERT Events are Frequent in Acral Melanoma**

---

**Poster 08:00 - 12:00**

**Poster Exhibition**

**P05, Immunology**

**Enhancing Immunotherapy with radiotherapy and topical treatments - Case report**

**Regulation of the cytotoxic immune response by the presence of normal and melanoma-associated fibroblasts**

**Understanding the impact of immunotherapy side effects on quality of life of patients with stage IV melanoma not on clinical trial: 'Real world' data to inform supportive care interventions**

**Inhibition of melanoma cell derived prostaglandin E2 amplifies T cell receptor signaling and shows clinical efficacy in combination with anti-PD1 therapy**

**Successful reinstitution of nivolumab in combination with corticosteroids for metastatic malignant melanoma with diverse immune-related adverse events including severe hemolytic anemia**

---

**Poster 08:00 - 12:00**

**Poster Exhibition**

**P15, Immunotherapy**

**Preliminary results of a Phase 1b/2 study of PV-10 and pembrolizumab in Stage IV melanoma**

**Response of melanoma cells to immune activity**

**The oncolytic effect of ECHO-7 virus on cell viability in vitro**

**Does time to switch in immunotherapy sequential strategy impact immunotherapy efficacy: results from the French cohort MelBase**

**Biodistribution and Shedding of Talimogene Laherparepvec (T-VEC) in Patients (Pts) With Unresectable Stage IIIB/IV Melanoma**

**Anti PD-1 therapy induced pancreatic atrophy and its clinical significance**
Older age may predict a higher response rate to anti PD-1 therapy in metastatic melanoma patients

Improving adoptive T cell therapy by selection of 4-1BB expressing TIL

Dissecting and deactivating immunosuppressive signals at metastatic lymphovascular sites

Phase Ic Trial of Intralresional OrienX010 Oncolytic Viral Therapy into Liver Metastases Among Melanoma Patients

Antibody profiling of melanoma patients undergoing immunotherapy with checkpoint inhibitors

Generic strategy to model tumour antigens and T-cell based immunotherapies in melanoma

Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma

Quantitative analysis of immune profiles of metastatic melanoma patients reveals biomarkers of response and resistance to combined anti-CTLA-4 and anti-PD-1 immunotherapy

c-MET dependent neutrophil responses limit ACT immunotherapy of melanoma

Monitoring patient response to Pembrolizumab with peripheral blood immune profiles

Effective Immuno Gene Therapy via the Delivery of Plasmids Encoding Cytokines as a Potential Treatment of Melanoma

DNA pattern recognition receptor activation after plasmid gene therapy in melanoma and other tumor cell types

Using Mass Cytometry to assess CD8 T cell phenotype during melanoma relapse on anti-PD1 treatment

Identification of Gene Signatures Predicting Response to PD1 Immunotherapy in 54 Metastatic Melanoma Patients

Inhibitors of the renin-angiotensin system could negatively impact survival benefit from ipilimumab/nivolumab combination but not from ipilimumab monotherapy

Clinical activity and safety of ipilimumab for metastatic uveal melanoma: the St Bartholomew’s Hospital experience

Real life outcome of patients with advanced melanoma after discontinuation of a PD-1 inhibitor in the absence of disease progression or treatment limiting toxicity

The efficacy of concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): Protocol for a multicenter phase II open label study

Distinct genomic alterations in patients with advanced melanoma treated with anti-PD-1 therapy

A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV Melanoma: Trial in Progress

Immune phenotypic analysis of NK cells in predicting anti-PD-1 therapy

Pembrolizumab (PEM) utilization and overall survival (OS) for patients with advanced melanoma: the real world US experience

Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis
BRAF ± MEK inhibition following pembrolizumab (pembro) in KEYNOTE-006
Pre-clinical evaluation of vectorized therapies combined with an anti-CTLA4 antibody in murine xenografted-models in melanoma
Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia.
Widely Metastatic Uveal Melanoma Responding to Combination Immune Therapy and Focal Radiotherapy after Pembrolizumab Failure
SALVO: Single Arm Phase II Study of IpiLimumab and NiVOlumab as Adjuvant Therapy for Management of Rheumatological Immune Related Adverse Events in Melanoma Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies
An immunogenic personalized neoantigen vaccine in patients with high risk melanoma
Exploring Lenalidomide in both inhibiting proliferation and blocking PDL1 signals in melanoma cells: a preclinical study
A Time and Motion Study of Patients Treated with Pembrolizumab and Nivolumab in Australia.
Real World data on the Safety and Efficacy of anti-PD-1 antibodies in the Elderly Population with Metastatic Melanoma
Real world Efficacy and Toxicity of Combined Nivolumab and Ipilimumab in patients with Metastatic Melanoma
Autophagy Drives Resistance to PD-1 Blockade in Melanoma
Combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in melanoma pts
The peripheral blood TCR repertoire might facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma
A phase lb study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic melanoma
A case of anti-PD1 induced hepatitis associated with corticosteroid resistant T cells
Inhibition of melanoma cell derived prostaglandin E2 amplifies T cell receptor signaling and shows clinical efficacy in combination with anti-PD1 therapy
A Phase II study of JS001, a Humanized IgG4 mAb Against Programmed Death-1 (PD-1) in Patients with Advanced Acral and Mucosal Melanoma
Quantifying the treatment-free interval after first-line immuno-oncology (IO) treatment of advanced melanoma
Benefit of the Nivolumab and Ipilimumab combination in pretreated advanced melanoma
Paradoxical reduced response to combined PD-1/CTLA-4 blockade in low tumor burden melanoma
Access to immunotherapy for treatment of metastatic melanoma in the Netherland and Australia: a tale of two countries
High-dose corticosteroids do not prevent lymphocyte proliferation or IL-2 production after stimulation with pembrolizumab
The role of chemotherapy after immunotherapy resistance in melanoma
Durable complete responses after cessation of anti-PD-1 monotherapy are associated with undetectable circulating tumour DNA

PD-L1 expression and density of CD8+ T cells in matched brain and extracerebral metastases are highly concordant

Profound inflammation-mediated change to the immunopeptidome of melanoma

The incidence of basal cell carcinoma is reduced in patients on anti-Programmed cell death-1 therapy for metastatic melanoma

**P06, Keratinocyte Cancers & Merkel Cell Carcinoma**

Squamous cell carcinoma in the caruncle during Vemurafenib treatment - case report

Proposal for randomised controlled trial (RCT) of immunotherapy combined with wide field radiotherapy versus wide field radiotherapy alone in stage IA-IIC Merkel Cell Carcinoma (MCC)

Recurrence rates of lesions treated with curettage and cautery in a busy multi-practitioner dermatology practice in Brisbane, Australia.

Sentinel lymph node biopsy in clinically node negative Merkel cell carcinoma - Westmead Hospital, Sydney experience

Primary Merkel cell carcinoma of the earlobe in a young, healthy adult male

Solitary nodule on the face

Basal Cell Carcinoma detection through transfer learning in dermoscopy images using a convolutional neural network

Squamous cell carcinoma of the nail unit: A retrospective review of 14 cases and our proposal for surgical management

Omega-3 fatty acid intake and cutaneous squamous cell carcinoma in organ transplant recipients

A retrospective analysis of wide local excision for Merkel cell carcinoma: a single-center series of 11 patients

Epidermal clonal proliferative response upon UVB irradiation is bimodal

Case report of a patient with metastatic basal cell carcinoma: mixed response to vismodegib therapy

Comparison of primary Merkel cell carcinoma (MCC) and melanoma T-cell immuno-profile and PD-L1 expression by multi-spectral immunohistochemistry (miHC)
Performance comparison of PD-L1 antibody clones 28-8 and 22C3 in stage III and IV metastatic melanoma samples: A tissue microarray study

Genetic variation in IRF4 expression modulates growth characteristics, pigmentation and interferon-gamma response in melanocytic cells

Frequency of BRAF V600 mutation in 354 locally advanced or metastatic melanoma patients from an academic center in Argentina. The apple does not fall very far from the tree.
Cinat, Gabriela (Buenos Aires, Argentina)

MiR-149 Function as a Tumor Suppressor in Mucosal Melanoma

Focal perinuclear cytoplasmic BAP1 is associated with high impact mutations in uveal melanoma

Natural genetic variation controlling propensity for an individual’s melanocytes to transform after UVR exposure

Detection, molecular profiling and culture of CSF-CTCs in leptomeningeal disease (LMDz) in melanoma

The ATM Ser49Cys variant is defective for DNA damage and senescence signalling

COMBI-i: A phase 3 study of the anti-PD1 antibody PDR001 in combination with dabrafenib (D) and trametinib (T) in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma

A novel signalling pathway ACTN4-RIPK1-NF-κB in regulating melanoma cell proliferation

Dissecting molecular and genetic determinants of UV response using iPSC based melanocyte models

Site-specific phosphorylation of the EMT-inducing molecule Y-box binding protein 1 regulates tumourigenicity and invasiveness of human melanoma cells

BRIM8: a randomized, double-blind, placebo-controlled phase 3 study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600 mutation-positive melanoma at high risk for recurrence

Pigment-producing melanocytes as the cells of origin of cutaneous melanoma

Identification of TERT, BRAF and NRAS hotspot mutations from formalin fixed and circulating tumour DNA of melanoma samples through highly sensitive ddPCR assay in melanoma

Growth factor activation of melanoma cell signalling pathways

In-depth Proteomic Profiling of Uveal Melanoma Exosomes

Evaluation of the transcriptome of large/giant congenital melanocytic nevi

Notch signaling in mouse melanoma tumor development and drug resistance of human metastatic melanoma cells

Wnt-dependent regulation of Sox10 expression in melanoma development

Functional testing of MTAP haplotypes demonstrates differential expression, signalling and pigmentation effects in primary melanocytic cells

RPS3 fucosylation in melanoma cell biology

Subcutaneous Cellular Nodule and Pigmented Epithelioid Melanocytoma on the Ipsilateral Upper Arm associated with Plaque-type Blue Nevus on the Hand
Roles of Wnt signaling in melanoma pathogenesis

Poster
08:00 - 12:00
Poster Exhibition

P07, Oncology

Real world data on intensive follow-up for stage IV metastatic melanoma patients receiving combination ipilimumab and nivolumab: a safer model of care?

Case report: vemurafenib-induced facial edema

Effective in vivo targeting of neo-antigens to Clec9A+ cross-presenting dendritic cells to improve personalized immunotherapy of melanoma

Ipilimumab is not active in Japanese patients with nivolumab-refractory melanoma

Topical diphencyprone for the treatment of in transit melanoma metastases of the skin: Long-term outcomes & management suggestions

Incidence of hypophysisis in patients with melanoma undergoing adjuvant ipilimumab 10mg/kg - a single center experience

High-dose rate radiation therapy and radionuclide diagnosis in the treatment of localized cutaneous melanoma more than 1 mm thick

If you are going to pay for it, do it on time

Real world PD-1 immunotherapy related side effects in metastatic melanoma, an Australian regional cancer centre experience

Outcomes on Central Nervous System irradiation for melanoma brain metastasis: 10-year experience in a developing country institution

Improved survival without increased toxicity in Melanoma brain metastases patients treated with stereotactic radiosurgery and ipilimumab versus stereotactic radiosurgery alone

The combination of BRAFi and MEKi: a treatment option for BRAF WT patients?


Toxic epidermal necrolysis associated with combination immunotherapy with nivolumab and Ipilimumab for advanced metastatic melanoma

Patient derived organotypic slice cultures for preclinical profiling of human BRAF wildtype melanomas

Two cases of trametinib-induced rhabdomyolysis of Japanese melanoma patients treated by dabrafenib and trametinib combination therapy

Successful neoadjuvant therapy of BRAF and MEK inhibition for inoperable stage 3 metastatic Melanoma (Withdrawn)
Scientific Programme

P20, Others

An 18-year study of Paediatric Malignant Melanoma at Morriston Hospital

Detailed FACS, migration, and invasion assay analyses of MeLiM melanoma model

Phenotypic and molecular characterisation of Circulating Tumour Cells isolated from metastatic melanoma patients using a microfluidic device

Epidemiological profile of cutaneous malignant melanoma in Tlemcen (west Algeria): January 2011 to December 2015

Malignant melanoma and psoriasis association: about a case

Metastatic malignant melanoma and vitiligo

Malignant melanoma and psoriasis acrolentigineux

Malignant Melanoma, is dominant at the ends: about a new observation acral

Concordance of Mutations in Circulating Tumour DNA (ctDNA) and Tissue Biopsy in Melanoma

Teledermatology and teledermoscopy as tools to help general practitioners in effective e-triage of suspicious skin lesions prior to dermatology evaluation

Generation and characterization of 90 melanoma patient-derived xenograft models

Preferences for advanced melanoma Immuno-Oncology treatments

Evaluation of commercial kits for extraction of circulating free DNA

Targeted therapy or immunotherapy..."this is the question" in frontline approach to BRAF-mutant melanoma: the challenge of combination immunotherapy.

Precision medicine for melanoma patients: Development of a Melanoma-specific gene panel for integrative molecular tumor boards

Electric field mediated drug and gene delivery provides effective treatment protocols for melanoma

Refining risk models for distant and CNS metastasis in Stage III melanoma

Preclinical validation of a new anti-melanoma compound in B-Raf inhibitors sensitive and resistant cells.

Randomized Phase (ph) II study of Paclitaxel (P), Carboplatin (C), Bevacizumab (B) +/- Everolimus (E) in Metastatic Melanoma (MM): Secondary analysis of outcomes in patients (pts) who harbor NRAS mutation NCCTG N0879 (Alliance).

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

Lee, Rebecca (Manchester, United Kingdom)

A preclinical platform for evaluating targeted therapy and immunotherapy combinations in BRAFV600E melanoma

Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China
Clinical application of various flaps in repair of soft tissue defect in weight-bearing region of foot caused by wide excision of melanoma: our experience after 31 cases

Multifactorial Analysis of Prognostic Factors And Survival Rates Among 706 Mucosal Melanoma Patients

Evolution of treatment patterns for advanced melanoma in US oncology clinical practices: an observational study

A significant interaction between sex and UV index in melanoma risk

Long-term survival outcome of patients with thin (T1) cutaneous melanomas: a naturally-occurring, biologically-relevant Breslow thickness cutpoint of 0.8mm separates higher risk from lower risk tumors

Optimization of spiral microfluidics for melanoma cell isolation

Clinical and molecular associations of body mass index (BMI) in regional melanoma metastases

Fortune Cookie Flap: New option to cover the defect

The burden of Non-Melanoma skin cancers in Auckland, New Zealand

Psychosocial outcome, neurocognitive functioning (NCF) and quality of life (QoL) in advanced melanoma survivor

US guided wire localization of malignant melanoma subcutaneous metastases

Sentinel node biopsy status is strongly predictive of survival in cutaneous melanoma: Extended follow-up of 1,527 Oxford patients from 1998-2014.

Predicting the development and timing of subsequent primary melanomas in a population-based Australian cohort

Iris freckling as a marker of cutaneous melanoma risk: a case-control study

Classifying dermoscopic patterns of naevi in a case-control study of melanoma

Dermoscopic features of Vulvar Intraepithelial Neoplasia

Modelling terahertz radiation absorption and reflection with computational phantoms of skin to aid melanoma diagnosis and management

The neutrophil-lymphocyte and platelet-lymphocyte ratios for surveillance in cutaneous melanoma

Acral melanoma (AM) demonstrates distinct clinical pattern and worse prognosis compared with non-acral cutaneous melanoma (NACM): a prospective analysis of 1461 cases

Poster
08:00 - 12:00

P08, Pathology

Anorectal melanoma, a case series of patients from the Melanoma Institute of Australia (MIA)

Review article: Role of beta catenin in melanoma

A case of Spitz nevus: differential diagnosis from melanoma
Scientific Programme

Poster
08:00 - 12:00
Poster Exhibition

P09, Prevention & Health Economics

How does skin cancer risk perception influence sun-exposure behaviours in Australian adults?

At a glance: The role of vitamin D in melanoma

Connecting design and health professionals for skin cancer prevention: a novel, sustainable approach in Queensland, Australia

Photoaging smartphone apps for skin cancer prevention in German adolescents: the Sunface randomized trial

The sunscreen and young children (SAY) pilot study

New technologies in skin cancer prevention

Teledermoscopy for skin cancer - what do dermatologists want to be paid to perform a simple consultation?

Utility-based quality of life in melanoma patients: Preliminary findings from the Whole Brain Radiotherapy (WBRT) trial

P10, Surgical Issues

Total lymph node yield as a marker of quality assurance in axillary lymphadenectomy for metastatic melanoma

Interval sentinel node drainage as a predictor factor in melanoma patients

Clinical behavior and prognostic in patients with head and neck cutaneous melanoma who underwent sentinel node biopsy

Invasive melanoma with preoperative diagnosis of melanoma in situ

Subungual Melanoma of the Hand

A protocol for the safe use of patent blue V dye in sentinel node biopsy

Management of primary cutaneous melanoma: A retrospective audit of 887 cases and review of current clinical guidelines

Sentinel lymph node biopsy for cutaneous melanoma in elderly patients: the Cambridge experience

Initial experience in the UK with use of (99mTc) Tilmanocept (a novel radiopharmaceutical) for sentinel lymph node biopsy (SLNB) for malignant melanoma

Patterns of care for regional biopsies and nodal surgery for melanoma treatment in Queensland

Mini-invasive subcutaneous lymphangiectomy in patients with skin melanoma

Sentinel lymph node biopsy for cutaneous versus mucosal melanoma in the anorectal region: two case reports
Scientific Programme

Giant melanoma of the scalp without metastases: a case report
Augmentation of venous drainage of the paramedian forehead flap by inclusion of a superficial vein: an anatomical and radiological study
Shave versus elliptical biopsy for melanoma substantially increases re-excision area and scar length
Importance of ulceration and mitoses in the selection of patients for sentinel lymph node biopsy in thin cutaneous melanoma? A study based on the Swedish Melanoma Register and the Melanoma Institute Australia Research Database
Venous free flap reconstruction of fingers and toes in subungual melanoma
A safe way to reduce length of hospital stay following lymph node dissection for cutaneous malignancy nodal metastasis
Treatment of melanoma in situ with erbium: YAG laser
Results of sentinel lymph node biopsy in thin (Breslow < 1mm) cutaneous melanoma of trunk and extremities
Video-assisted inguinal lymphadenectomy in melanoma
The Circumferential Aligned Lateral Advancement with Fasciotomy (CALF) flap: A straightforward reconstruction technique for melanoma of the leg following wide local excision
Surgical treatment of acral melanoma
Surgical management of cutaneous malignant melanoma - current status
Lymph node dissection guided by indocyanine green fluorescence for cutaneous melanoma
Adherence to surgical melanoma guidelines in New South Wales of all newly diagnosed melanomas over a one-year period
Management of dysplastic vaevi: An international perspective (withdrawn)
The keystone perforator island flap in the management of large melanoma defects including groin dissections

Poster
08:00 - 12:00
Poster Exhibition

P17, Targeted Therapy

Incidental Perineural Invasion in Keratinocyte cancer (KC): A prospective analysis of the incidental Perineural Invasion (PNI) registry with a five year follow up in Queensland
Real life targeted therapies alone or in combination in brain metastases patients: French experience within MelBase
Possible immune adverse-events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma
Preclinical efficacy of the DLL3-targeted antibody drug conjugate Rovalpituzumab tessirine in metastatic melanoma
Williams, Sam (San Francisco, United States)

Role of miR-193a as therapeutic agent and biomarker in cutaneous melanoma
Scientific Programme

Identification of Molecular Signatures Associated with Response to MAPK Inhibitors in Metastatic Melanoma
Stagni, Camilla (Padova, Italy)

A Prospective Observational Safety Study of Patients (pts) With BRAFV600-Mutated Unresectable or Metastatic Melanoma (mM) Treated With Vemurafenib (VEM) (Zelboraf Safety Study [ZeSS]): Final Results
Colburn, Dawn

Induction of ER stress augments apoptotic and immunogenic responses in melanoma cells

Combination of EGFRi and METi - a new targeted therapeutic strategy for melanoma

Extended follow-up results of a phase 1b study (BRIM7) of cobimetinib (C) combined with vemurafenib (V) in BRAFV600-mutated melanoma
McArthur, Grant (Melbourne, Australia)

Combination BRAF/MEK inhibitors for melanoma with active brain metastases: A real-world multi-center experience

HDAC inhibition reverses adaptation to MEK inhibitor therapy in uveal melanoma: a systems level proteomic study

Investigating the sensitivity of RAC1 mutated melanomas to PI3K pathway inhibition

V600EBRAF melanoma cell response to vemurafenib and trametinib is not affected by exogenous growth factors bFGF, EGF and HGF in vitro

A phase I/II study of pembrolizumab and imatinib in patients with locally advanced/metastatic melanoma with c-KIT mutation or amplification

BRAF inhibitor treatment in the oldest old metastatic melanoma patients

Deciphering the role of PREX and PI3K signalling in melanoma

Differential effects on immune activity after Neoadjuvant MAPK pathway inhibition in stage III melanoma patients

Efficacy and Safety Analysis of Imatinib in 78 Advanced Melanoma Patients Harboring KIT Aberrations

CDK4 inhibition synergizes with BRAF and MEK inhibition in treatment naive melanoma cells but not after the development of BRAF inhibitor resistance

Clinical and biologic associations of body mass index (BMI) with survival in patients (pts) with BRAFV600-mutated metastatic melanoma (MM) treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib + vemurafenib (C+V)

Identification of actionable survival pathways in BRAF/NRAS wild type melanomas

Rose Bengal melanoma therapy - phototoxicity versus intrinsic cytotoxicity

Real-world data in a new-era of targeted and immuno-oncology treatment (Tx) of Metastatic Melanoma (MM) patients (pts)

Cobimetinib + atezolizumab versus pembrolizumab in patients with previously untreated, advanced, BRAFV600 wild-type melanoma: phase 3 IMspire 170 study
Gogas, Helen

ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment.
A Phase Ib study of AEB071, a PKC inhibitor, and BYL719, a PI3Kα inhibitor, in Patients with Metastatic Uveal Melanoma (UM)

Activity of the ERK1/2 inhibitor Ulixertinib in patients with BRAF and NRAS mutant melanoma

BRAF mutant metastatic melanoma - stopping treatment after complete response?

Elevated BRAFV600 mutant circulating tumor DNA (ctDNA) and circulating hepatocyte growth factor (cHGF) are associated with poor prognosis in patients with metastatic melanoma

A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma

In vitro study in exploring the critical mediator involved in Vemurafenib resistance

Inhibition of mitochondrial oxidative phosphorylation overcomes de novo and acquired resistance to MAPK pathway inhibitors

---

Poster
08:00 - 12:00

**P11, Treatment & Follow-up**

Pregnancy associated multiple melanoma: A case study of nine primary melanomas in a young female patient

Sweet's syndrome associated with ipilimumab in a patient with metastatic melanoma

Clinical trial recruitment and management of melanoma patients who live a long-distance from a tertiary referral centre

A case of malignant melanoma histologically similar to lentigo maligna melanoma of the back, BRAF wild-type, developed on thermal burn

Kissing naevus of the penis: report of two cases

The prognostic of malignant melanoma in the lower extremities and mechanical stress point on the plantar surface of the foot


Primary melanoma of lacrimal sac-- Report of a rare case

Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti PD-1

Laser treated agminated melanocytic nevi and the potential for malignant transformation

---

Poster
08:00 - 12:00

**P18, Tumour Heterogeneity and Plasticity**

Spatial analysis of gene expression in Stage III cutaneous malignant melanoma
Highly multiplexed single-cell protein analysis of melanoma FFPE samples
Convergent evolution in therapy naive human melanoma.
In-depth molecular and immune characterization of melanoma with heterogeneous PTEN expression
Role of JARID1B expression in radiation resistance in melanoma cells
Metastatic growth after melanoma dissemination requires MITF and BRN2
BRN2 co-ordinates switching of melanoma cells to an invasive phenotype to promote metastasis and metabolic adaptation to micro-environmental cues
MITF regulates dynamic heterogeneity and structural integrity in melanoma
Melanin pigment and melanoma heterogeneity

Poster
08:00 - 12:00
Poster Exhibition

P19, Tumour Microenvironment

Paracrine Activin-A signaling promotes melanoma growth and mediates tumour immune evasion
Composition or lack of exogenous growth factors do not influence viability and phenotype of drug naive V600EBRAF melanoma cells but it might be crucial for drug-resistant cells
Combined loss of epidermal AMBRA1 and Loricrin is a prognostic biomarker for AJCC stage I melanoma and a companion biomarker for novel targeted therapy
Diversity of fibroblastic populations in the microenvironment of human melanomas
Multiplex immunohistochemistry and flow cytometry provide divergent but complementary insights into the immune context in metastatic melanoma
Immune Cell Profiles in Neoadjuvant Therapy of Advanced Stage III Melanoma
Fucosylation and Immune Surveillance in Melanoma
Tumour-derived exosomes promote the bone tropism of melanoma cells by CXCR7 upregulation
Development of a 3D human metastatic melanoma model for in vitro evaluation of targeted therapy efficiency
Origin of vascular progenitors driving melanoma angiogenesis in vivo
Nanoparticle-based immunotherapy in a humanized mouse melanoma model targeting macrophages in the tumor microenvironment
Metastatic melanoma cells commandeer p53 activity to promote the survival of a therapy resistant subpopulation.
GARP expressing platelets are capable of regulatory T cell induction
Scientific Programme

SMR Session
08:30 - 10:00

SMR09, Late Breaking Clinical Updates

Chairs:
Long, Georgina (Sydney, Australia)

- Efficacy outcomes in the phase 3 COMBI-AD study of adjuvant dabrafenib (D) plus trametinib (T) vs placebo (PBO) in patients (pts) with stage III BRAF V600E/K-mutant melanoma
  08:30 - 08:45
  Long, Georgina (Sydney, Australia)

- A phase I trial of LXS196, a PKC inhibitor for uveal melanoma
  08:45 - 09:00
  Piperno-Neumann, Sophie (Paris, France)

- Outcomes and characteristics of patients (pts) who achieved a complete response (CR) with combination dabrafenib and trametinib (D+T)
  09:00 - 09:15
  Robert, Caroline (Villejuif, France)

- Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 Brain Collaboration (ABC)
  09:15 - 09:30
  Menzies, Alexander (Sydney, Australia)

- A phase II study of glembatumumab vedotin for metastatic uveal melanoma
  09:30 - 09:45
  Patel, Sapna (Houston, United States)

- Mature results of combination nivolumab (NIVO) plus ipilimumab (IPI) as adjuvant therapy in stage IIIIC/IV melanoma (MEL)
  09:45 - 10:00
  Eroglu, Zeynep (Tampa, United States)

Symposium
08:30 - 10:00

SY32, Clinical Diagnosis: Practical Teledermoscopy

Chairs:
Martin, Richard (Auckland, New Zealand)
Oakley, Amanda (Hamilton, New Zealand)

- Teledermoscopy: pathways to referral
  08:30 - 08:45
  Oakley, Amanda (Hamilton, New Zealand)

- E-referrals and teledermatology: a successful model of care
  08:45 - 09:00
  Martin, Richard (Auckland, New Zealand)

- The future of artificial intelligence in the telediagnosis of melanoma
  09:00 - 09:15
  Bowling, Adrian (Auckland, New Zealand)

- Dermatoscopy: a must for teledermatology-based skin cancer programs
  09:15 - 09:30
  Moreno-Ramirez, David (Sevilla, Spain)

- Consumer views and perceptions of mobile teledermoscopy
  09:30 - 09:45
  Janda, Monika (Brisbane, Australia)

- Discussion
  09:45 - 10:00
Symposium
08:30 - 10:00
Room M3

SY33, How to Organise an Interdisciplinary Skin Cancer Centre

Chairs:
Sondak, Vernon (Tampa, United States)
Kelly, John (Melbourne, Australia)

Quality Assurance at melanoma/skin cancer centres
Moreno-Ramirez, David (Seville, Spain) 08:30 - 08:45

Should paediatric patients be managed at an adult-orientated melanoma centre?
Sondak, Vernon (Tampa, United States) 08:45 - 09:00

Database design and maintenance at a melanoma/skin cancer centre
Haydu, Lauren (Houston, United States) 09:00 - 09:15

The role of the melanoma/skin cancer centre in public education, primary and secondary prevention and follow-up of high risk patients
Kelly, John (Melbourne, Australia) 09:15 - 09:30

How do we manage the growing burden of follow-up for early stage melanoma patients?
Allan, Chris (Brisbane, Australia) 09:30 - 09:45

How to maintain and develop the centres structure
Garbe, Claus (Tuebingen, Germany) 09:45 - 10:00

Symposium
08:30 - 10:00
Room M2

SY34, Patient Support and Survivorship

Chairs:
Dunn, Jeff (Brisbane, Australia)
Guild, Valerie (San Francisco, United States)

Melanoma: a clinician's perspective
Robert, Caroline (Villejuif, France) 08:30 - 08:45

Melanoma: a patient perspective
Renwick, Leisa (Tauranga, New Zealand) 08:45 - 09:00

The survivorship conundrum
Bennett, Fiona (Brisbane, Australia) 09:00 - 09:10

Living with melanoma - a patient plan
Guild, Valerie (San Francisco, United States) 09:10 - 09:25
Scientific Programme

Roundtable discussion - advocates and physicians 09:25 - 10:00
Andersen, Hayley (Melbourne, Australia)
Bennett, Fiona (Brisbane, Australia)
Dummer, Reinhard (Zurich, Switzerland)
Guild, Valerie (San Francisco, United States)
McArthur, Grant (Melbourne, Australia)
Renwick, Leisa (Tauranga, New Zealand)
Robert, Caroline (Villejuif, France)

Free Communication 08:30 - 10:00 Room M1

FC08, Surgical Issues

Chairs:
Spillane, Andrew (Sydney, Australia)
Bayley, Gerard (Brisbane, Australia)

The prognostic significance of extracapsular extension in micro-metastatic and macro-metastatic lymphadenopathy for cutaneous melanoma 08:30 - 08:40
Moncrieff, Marc (Norwich, United Kingdom)

Resource usage and reconstructive burden for wide local excision of cutaneous melanoma - implications of wider margins 08:40 - 08:50
Moncrieff, Marc (Norwich, United Kingdom)

Surgical management of the clinically negative neck in metastatic melanoma to the parotid 08:50 - 09:00
Ch’ng, Sydney (Sydney, Australia)

The management of primary mucosal melanoma: a tertiary institutional experience 09:00 - 09:10
Tan, Grace (Singapore, Singapore)

Melanoma-related limb lymphoedema 09:10 - 09:20
Hölmich, Lisbet Rosenkrantz (Herlev, Denmark)

Lymph node management and outcomes for T1 cutaneous melanomas in Queensland 09:20 - 09:30
Smithers, B. Mark (Brisbane, Australia)

Prognostic value of tumour burden for melanoma patients with sentinel lymph node metastasis 09:30 - 09:40
Vuoristo, Mikko (Helsinki, Finland)

Does the interval from diagnostic excision to sentinel node biopsy influence the outcome in melanoma? 09:40 - 09:50
Rughani, Milap (Oxford, United Kingdom)

Survival outcomes and interval between lymphoscintigraphy and sentinel node biopsy in cutaneous melanoma - findings of a large prospective cohort study. 09:50 - 10:00
Moncrieff, Marc (Norwich, United Kingdom)
Scientific Programme

Plenary Lecture
10:30 - 12:00

PL05, Future Perspectives and Congress Highlights

Chairs:
Garbe, Claus (Tuebingen, Germany)
McMahon, Martin (Salt Lake City, United States)

- **Keynote Address: Unsolved questions in melanoma genesis**
  Bastian, Boris (San Francisco, United States)
  10:30 - 11:00

- **Genetic testing for skin cancer in 2017 and beyond**
  McArthur, Grant (Melbourne, Australia)
  11:00 - 11:20

- **Future perspectives of early detection of skin cancers**
  Soyer, H. Peter (Brisbane, Australia)
  11:20 - 11:40

- **Highlights in melanoma from 2017**
  Long, Georgina (Sydney, Australia)
  11:40 - 12:00

Miscellaneous
12:00 - 12:15

MIS03, Closing Remarks

Chairs:
Dunn, Jeff (Brisbane, Australia)
Smithers, B. Mark (Brisbane, Australia)
Soyer, H. Peter (Brisbane, Australia)